0001829126-23-005654.txt : 20230825 0001829126-23-005654.hdr.sgml : 20230825 20230825120008 ACCESSION NUMBER: 0001829126-23-005654 CONFORMED SUBMISSION TYPE: S-1/A PUBLIC DOCUMENT COUNT: 58 FILED AS OF DATE: 20230825 DATE AS OF CHANGE: 20230825 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMERIGUARD SECURITY SERVICES, INC. CENTRAL INDEX KEY: 0001514443 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-DETECTIVE, GUARD & ARMORED CAR SERVICES [7381] IRS NUMBER: 990363866 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: S-1/A SEC ACT: 1933 Act SEC FILE NUMBER: 333-271200 FILM NUMBER: 231204767 BUSINESS ADDRESS: STREET 1: 5470 W. SPRUCE AVENUE , SUITE 102 CITY: FRESNO STATE: CA ZIP: 93722 BUSINESS PHONE: 559-271-5984 MAIL ADDRESS: STREET 1: 5470 W. SPRUCE AVENUE , SUITE 102 CITY: FRESNO STATE: CA ZIP: 93722 FORMER COMPANY: FORMER CONFORMED NAME: HEALTH REVENUE ASSURANCE HOLDINGS, INC. DATE OF NAME CHANGE: 20120423 FORMER COMPANY: FORMER CONFORMED NAME: HEALTH REVENEUE ASSURANCE HOLDINGS, INC. DATE OF NAME CHANGE: 20120420 FORMER COMPANY: FORMER CONFORMED NAME: ANVEX INTERNATIONAL, INC. DATE OF NAME CHANGE: 20110303 S-1/A 1 ameriguardsec_s1a3.htm S-1/A
0001514443 true 0001514443 2023-01-01 2023-06-30 0001514443 dei:BusinessContactMember 2023-01-01 2023-06-30 0001514443 2022-12-31 0001514443 2021-12-31 0001514443 2022-01-01 2022-12-31 0001514443 2021-01-01 2021-12-31 0001514443 hraad:SecurityServicesMember 2022-01-01 2022-12-31 0001514443 hraad:SecurityServicesMember 2021-01-01 2021-12-31 0001514443 hraad:OtherRelatedIncomeMember 2022-01-01 2022-12-31 0001514443 hraad:OtherRelatedIncomeMember 2021-01-01 2021-12-31 0001514443 hraad:SalariesAndRelatedTaxesMember 2022-01-01 2022-12-31 0001514443 hraad:SalariesAndRelatedTaxesMember 2021-01-01 2021-12-31 0001514443 hraad:EmployeeBenefitsMember 2022-01-01 2022-12-31 0001514443 hraad:EmployeeBenefitsMember 2021-01-01 2021-12-31 0001514443 hraad:SubContractorPaymentsMember 2022-01-01 2022-12-31 0001514443 hraad:SubContractorPaymentsMember 2021-01-01 2021-12-31 0001514443 hraad:GuardTrainingMember 2022-01-01 2022-12-31 0001514443 hraad:GuardTrainingMember 2021-01-01 2021-12-31 0001514443 hraad:VehiclesAndEquipmentExpensesMember 2022-01-01 2022-12-31 0001514443 hraad:VehiclesAndEquipmentExpensesMember 2021-01-01 2021-12-31 0001514443 us-gaap:CommonStockMember 2020-12-31 0001514443 us-gaap:PreferredStockMember 2020-12-31 0001514443 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001514443 hraad:StockholdersEquityMember 2020-12-31 0001514443 2020-12-31 0001514443 us-gaap:CommonStockMember 2021-12-31 0001514443 us-gaap:PreferredStockMember 2021-12-31 0001514443 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001514443 hraad:StockholdersEquityMember 2021-12-31 0001514443 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001514443 us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001514443 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001514443 hraad:StockholdersEquityMember 2021-01-01 2021-12-31 0001514443 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001514443 us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001514443 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001514443 hraad:StockholdersEquityMember 2022-01-01 2022-12-31 0001514443 us-gaap:CommonStockMember 2022-12-31 0001514443 us-gaap:PreferredStockMember 2022-12-31 0001514443 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001514443 hraad:StockholdersEquityMember 2022-12-31 0001514443 2021-11-01 2021-11-14 0001514443 srt:ChiefExecutiveOfficerMember 2021-11-01 2021-11-14 0001514443 hraad:LillianFloresMember 2021-11-01 2021-11-14 0001514443 hraad:CustodianVenturesMember 2021-07-07 0001514443 2021-09-08 0001514443 2022-11-01 2022-11-14 0001514443 srt:ChiefExecutiveOfficerMember 2022-11-01 2022-11-14 0001514443 hraad:LillianFloresMember 2022-11-01 2022-11-14 0001514443 2023-06-30 0001514443 us-gaap:MachineryAndEquipmentMember 2022-12-31 0001514443 us-gaap:VehiclesMember 2022-12-31 0001514443 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001514443 us-gaap:VehiclesMember 2023-06-30 0001514443 us-gaap:LeaseholdImprovementsMember 2023-06-30 0001514443 2021-07-01 2021-07-07 0001514443 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001514443 us-gaap:MachineryAndEquipmentMember 2021-12-31 0001514443 us-gaap:VehiclesMember 2021-12-31 0001514443 us-gaap:MachineryAndEquipmentMember 2023-06-30 0001514443 hraad:SBALoanMember 2020-06-30 0001514443 hraad:SBALoanMember 2020-06-01 2020-06-30 0001514443 hraad:SBALoanMember 2022-01-01 2022-12-31 0001514443 hraad:SBALoanMember 2021-01-01 2021-12-31 0001514443 hraad:SBALoanMember 2022-12-31 0001514443 hraad:SBALoanMember 2021-12-31 0001514443 hraad:MasterSecurityCompanyMember 2020-01-30 0001514443 hraad:MasterSecurityCompanyMember 2020-01-01 2020-01-30 0001514443 hraad:MasterSecurityCompanyMember 2022-12-31 0001514443 hraad:MasterSecurityCompanyMember 2021-12-31 0001514443 hraad:SecureTransportationIncMember 2021-12-31 0001514443 hraad:SecureTransportationIncMember 2021-12-01 2021-12-31 0001514443 hraad:SecureTransportationIncMember 2022-12-31 0001514443 hraad:SecureTransportationIncMember 2021-12-31 0001514443 hraad:LillianFloresMember 2022-07-07 0001514443 hraad:LillianFloresMember 2020-12-01 2020-12-31 0001514443 hraad:LillianFloresMember 2022-07-01 2022-07-07 0001514443 hraad:SBALoanMember 2023-01-01 2023-06-30 0001514443 hraad:SBALoanMember 2023-06-30 0001514443 2022-06-30 0001514443 hraad:NotesAndLoansPayableMember 2022-12-31 0001514443 hraad:NotesAndLoansPayableMember 2021-12-31 0001514443 hraad:AmeriguardSecurityServicesMember 2020-01-01 2020-12-31 0001514443 hraad:GuardServiceMember 2022-01-01 2022-12-31 0001514443 hraad:GuardServiceMember 2021-01-01 2021-12-31 0001514443 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember hraad:GuardServiceMember 2022-01-01 2022-12-31 0001514443 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember hraad:GuardServiceMember 2021-01-01 2021-12-31 0001514443 hraad:GuardServiceMember 2023-01-01 2023-06-30 0001514443 hraad:GuardServiceMember 2022-01-01 2022-06-30 0001514443 us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember hraad:GuardServiceMember 2022-01-01 2022-06-30 0001514443 us-gaap:SubsequentEventMember hraad:SocialSecurityAdministrationNSCMember 2022-09-01 2027-09-30 0001514443 us-gaap:SubsequentEventMember hraad:SocialSecurityAdministrationSSCMember 2022-06-01 2027-06-30 0001514443 us-gaap:SubsequentEventMember hraad:SocialSecurityAdministrationWBDOCMember 2021-06-01 2026-07-31 0001514443 hraad:NationalInstituteOfHealthEPAMember 2020-05-01 2023-05-31 0001514443 us-gaap:SubsequentEventMember 2023-03-01 2023-03-23 0001514443 2022-01-01 2022-06-30 0001514443 hraad:SecurityServicesMember 2023-01-01 2023-06-30 0001514443 hraad:SecurityServicesMember 2022-01-01 2022-06-30 0001514443 hraad:OtherRelatedIncomeMember 2023-01-01 2023-06-30 0001514443 hraad:OtherRelatedIncomeMember 2022-01-01 2022-06-30 0001514443 hraad:SalariesAndRelatedTaxesMember 2023-01-01 2023-06-30 0001514443 hraad:SalariesAndRelatedTaxesMember 2022-01-01 2022-06-30 0001514443 hraad:EmployeeBenefitsMember 2023-01-01 2023-06-30 0001514443 hraad:EmployeeBenefitsMember 2022-01-01 2022-06-30 0001514443 hraad:SubContractorPaymentsMember 2023-01-01 2023-06-30 0001514443 hraad:SubContractorPaymentsMember 2022-01-01 2022-06-30 0001514443 hraad:GuardTrainingMember 2023-01-01 2023-06-30 0001514443 hraad:GuardTrainingMember 2022-01-01 2022-06-30 0001514443 hraad:VehiclesAndEquipmentExpensesMember 2023-01-01 2023-06-30 0001514443 hraad:VehiclesAndEquipmentExpensesMember 2022-01-01 2022-06-30 0001514443 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001514443 us-gaap:PreferredStockMember 2023-01-01 2023-06-30 0001514443 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001514443 hraad:StockholdersEquityMember 2023-01-01 2023-06-30 0001514443 us-gaap:CommonStockMember 2023-06-30 0001514443 us-gaap:PreferredStockMember 2023-06-30 0001514443 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001514443 hraad:StockholdersEquityMember 2023-06-30 0001514443 hraad:NotesAndLoansPayableMember 2023-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

 

As filed with the Securities and Exchange Commission on August 25, 2023

 

Registration No. 333-271200

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

Amendment No.3

 

FORM S-1/A

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

 

AMERIGUARD SECURITY SERVICES, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   7200   99-0363866

(State or other jurisdiction of

incorporation or organization)

 

(Primary Standard Industrial

Classification Code Number)

 

(I.R.S. Employer
Identification Number)

 

5470 W. Spruce Avenue, Suite 102

Fresno, CA

(559) 271-5984

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 

NEVADA AGENCY AND TRANSFER COMPANY

Registered Agent

50 West Liberty Street Suite 880, Reno, NV, 8950

(775) 322-0626

(Name, address, including zip code, and telephone number, including area code, of agent for service)

 

With copies to:

Matthew McMurdo

McMurdo Law Group, LLC

1185 Avenue of the Americas, 3rd Floor

New York, NY 10036

(917) 318-2865

 

Approximate date of commencement of proposed sale to the public: As soon as practicable after this Registration Statement is declared effective.

 

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box: ☒

 

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

 

Indicate by check mark whether the registrant is a large, accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large, accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

  Large accelerated filer Accelerated filer
  Non-accelerated filer Smaller reporting company
      Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

 

The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

 

 

 

 

 

 

The information in this prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and the Company is not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

 

Selling Shareholder Preliminary Prospectus

Subject to completion August 25, 2023

AMERIGUARD SECURITY SERVICES, INC.

3,585,946 Shares of Common Stock

 

This prospectus relates to the resale of up to 3,585,946 shares of common stock, $.001 par value, of Ameriguard Security Services, Inc., a Nevada corporation (the “Company” or “AGSS”), by certain shareholders, as described herein (the “Selling Shareholders”). A portion of the Selling Shareholders held their shares for approximately ten (10) years, with them currently restricted under the Securities Act of 1933, as amended. A certain Selling Shareholder was issued his shares in 2014 with a Rule 144 legend on it. Certain shareholders were issued an aggregate of 675,000 shares upon the conversion of preferred shares. The remaining Selling Shareholders were issued their shares of common stock on or about December 9, 2022, pursuant to a Definitive Share Exchange Agreement (the “AGSS Merger Agreement”) with Ameriguard Security Services, Inc., a California corporation, (“Ameriguard”) and Lawrence Garcia (“Garcia”) the majority shareholder of Ameriguard (the “Majority Shareholder”) and the minority shareholders of Ameriguard (“Minority Shareholders”). Under the AGSS Merger Agreement, One Hundred Percent (100%) of the ownership interest of Ameriguard was exchanged for an aggregate of 90,000,000 shares of common stock of AGSS issued to the Majority Shareholders and the Minority Shareholders, in accordance with the AGSS Merger Agreement (the “AGSS Merger”). The former stockholders of Ameriguard acquired a majority of the issued and outstanding common stock as a result of the share exchange transaction. Lawrence Garcia currently owns 86.26% of the issued and outstanding voting stock of the Company and will be able to exert significant influence and control over the Company for the foreseeable future.

 

We have 10,000,000 authorized and designated Series A-1 Preferred Stock which are entitled to seventy-two (72) votes per share of Series A-1 Preferred Stock on all matters on which stockholders may vote. While we currently have no such shares issued and outstanding, the voting rights afforded these Series A-1 Preferred Stock would give any future holders a disparate voting interest and allow them to potentially exert control over the actions of the Company.

 

The total amount of shares of common stock, which may be sold pursuant to this prospectus, would constitute approximately 6.22% of our issued and outstanding common stock as of August 14, 2023.

 

The Selling Shareholders are selling all the shares of common stock offered by this prospectus. It is anticipated that the Selling Shareholders will sell these shares of common stock from time to time in one or more transactions, at $1.18 per share. We will not receive any proceeds from the sale of shares by the Selling Shareholders.

 

The Selling Shareholders are each an “underwriter” within the meaning of Section 2(a)(11) of the Securities Act of 1933, as amended, or the Securities Act. In the event all shares are sold by the Selling Shareholders, each Selling Shareholder will realize net proceeds of $1.1799 per share and the aggregate net proceeds to the Selling Shareholders would be $4,231,416.28.

 

Our common stock is quoted on the OTC Markets Pink under the symbol “AGSS.” On May 17, 2023, the closing price of our common stock was $.92255 per share on the OTC Pink. These prices will fluctuate based on the demand for our common stock.

 

We may amend or supplement this prospectus from time to time by filing amendments or supplements as required. You should read the entire prospectus and any amendments or supplements carefully before you make your investment decision. The Company is not a blank check company because it has a specific business purpose and has no plans or intention to merge with an operating company. To our knowledge, none of the Company’s shareholders have plans to enter a change of control or change of management. None of our current management has previously been involved with a development stage company that did not implement its business plan, that generated no or minimal revenues or was engaged in a change of control.

 

The shares being offered. See “Risk Factors” beginning on page 5.

 

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense.

 

The date of this prospectus is subject to completion August 25, 2023.

 

 

 

 

TABLE OF CONTENTS

 

PROSPECTUS SUMMARY   1
     
RISK FACTORS   5
     
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS   12
     
USE OF PROCEEDS   13
     
DETERMINATION OF OFFERING PRICE   14
     
THE SELLING SHAREHOLDERS   15
     
PLAN OF DISTRIBUTION   17
     
BUSINESS   19
     
MANAGEMENT’S DISCUSSION AND ANALYSIS AND RESULTS OF OPERATIONS   23
     
DESCRIPTION OF PROPERTY   31
     
LEGAL PROCEEDINGS   32
     
DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS   34
     
EXECUTIVE COMPENSATION   39
     
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT   40
     
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS   41
     
DESCRIPTION OF SECURITIES   42
     
MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS   43
     
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE   44
     
DISCLOSURE OF COMMISSION POSITION OF INDEMNIFICATION FOR SECURITIES ACT LIABILITIES   45
     
EXPERTS   45
     
WHERE YOU CAN FIND MORE INFORMATION   46
     
FINANCIAL STATEMENTS   F-1

 

You may only rely on the information contained in this prospectus or that we have referred you to. We have not authorized anyone to provide you with different information. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities other than the common stock offered by this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any common stock in any circumstances in which such offer or solicitation is unlawful. Neither the delivery of this prospectus nor any sale made in connection with this prospectus shall, under any circumstances, create any implication that there has been no change in our affairs since the date of this prospectus or that the information contained by reference to this prospectus is correct as of any time after its date.

 

i

 

 

 

PROSPECTUS SUMMARY

 

This summary highlights selected information contained elsewhere in this Prospectus. This summary does not contain all the information that you should consider before investing in the common stock of Ameriguard Security Services, Inc. (referred to herein as “we,” “our,” “us,” “AGSS” or the “Company”). You should carefully read the entire Prospectus, including “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the accompanying financial statements and the related notes to the Financial Statements before making an investment decision.

 

The information presented is a brief overview of the key aspects of the offering. The prospectus summary contains a summary of information contained elsewhere in this prospectus. You should carefully read all information in the prospectus, including the financial statements and the notes to the financial statements under the Financial Statements section beginning on page F-1 prior to making an investment decision.

 

Corporate History

 

The Company was incorporated in Nevada on December 13, 2010.

 

The Company intended to become a provider of revenue cycle services to a broad range of healthcare providers. We offer our customers integrated solutions designed around their specific business needs, including revenue cycle data analysis, contract and outsourced coding, billing, coding and compliance audits, coding education, coding consulting, physician coding services and ICD-10 education and transition services.

 

On February 10, 2012, the Company entered into an Agreement and Plan of Merger and Reorganization (the “HRAA Merger Agreement”) with Health Revenue Assurance Holdings, Inc. (formerly known as Anvex International, Inc., “HRAH”), a Nevada company, and its wholly-owned subsidiary Health Revenue Acquisition Corporation (“Acquisition Sub”), which was treated for accounting purposes as a reverse recapitalization with HRAA, considered the accounting acquirer. Each share of HRAA’s common stock was exchanged for the right to receive approximately 1,271 shares of HRAH’s common stock. Before their entry into the HRAA Merger Agreement, no material relationship existed between HRAH and Acquisition Sub or HRAA. On April 27, 2012, the Company completed a 12.98 to 1 forward stock split. On May 2, 2012, the Company changed its ticker symbol from ANVX to HRAA.

 

The Company then went dormant in August 2014.

 

On July 14, 2020, as a result of a custodianship in Clark County, Nevada, Case Number: A816259, Custodian Ventures LLC (“Custodian”) was appointed Custodian of the Company.

 

On July 15, 2020 Custodian appointed David Lazar as the Company’s Chief Executive Officer, President, Secretary, Chief Financial Officer, Chief Executive Officer and Chairman of the Board of Directors.

 

On September 8, 2021, under the terms of a private stock purchase agreement, 10,000,000 shares of Series A-1 Preferred Stock, $0.001 par value per share (the “Shares”) of the Company, were transferred from Custodian Ventures, LLC to Ameriguard Security Services, Inc. California corporation (Ameriguard). As a result, Ameriguard became holder of approximately 91% of the voting rights of the issued and outstanding share capital of the Company on a fully-diluted basis of the Company, and became the controlling shareholder. The consideration paid for the 10,000,000 shares of Series A-1 Preferred Stock was $500,000. In connection with the transaction, David Lazar forgave the Company from all debts owed to him and/or Custodian Ventures, LLC.

 

On September 8, 2021, the Company accepted the resignations from David Lazar as the Company’s Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and as a Member of the Board of Directors. Effective on the same date to fill the vacancies created by Mr. Lazar’s resignations, the Company appointed Lawrence Garcia as the Company’s President, CEO, CFO, Treasurer, Secretary, and Chairman of the Board of Directors. These resignations are in connection with the consummation of the private stock purchase agreement and was not the result of any disagreement with Company on any matter relating to Company’s operations, policies or practices.

 

On March 11, 2022, the Company, amended its articles of incorporation to change its name to Ameriguard Security Services, Inc. from Health Revenue Assurance Holdings, Inc. The name was deemed effective by FINRA on March 17, 2022.

 

On December 9, 2022, the Company entered into a Definitive Share Exchange Agreement (the “AGSS Merger Agreement”) with Ameriguard Security Services, Inc., a California corporation, (“Ameriguard”) and Lawrence Garcia (“Garcia”) the majority shareholder of Ameriguard (the “Majority Shareholder”) and the minority shareholders of Ameriguard (“Minority Shareholders”). Under the AGSS Merger Agreement, One Hundred Percent (100%) of the ownership interest of Ameriguard was exchanged for an aggregate of 90,000,000 shares of common stock of AGSS issued to the Majority Shareholders and the Minority Shareholders, in accordance with the AGSS Merger Agreement (the “AGSS Merger”). Also, as part of the AGSS Merger, Ameriguard cancelled the 10,000,000 shares of Series A-1 Preferred Stock it had purchased from Custodian Ventures, LLC. The former stockholders of Ameriguard acquired a majority of the issued and outstanding common stock as a result of the share exchange transaction. Lawrence Garcia currently owned 86.26% of the issued and outstanding voting stock of the Company and will be able to exert significant influence and control over the Company for the foreseeable future.

 

 

1

 

 

 

We have 10,000,000 authorized and designated Series A-1 Preferred Stock which are entitled to seventy-two (72) votes per share of Series A-1 Preferred Stock on all matters on which stockholders may vote. While we currently have no such shares issued and outstanding, the voting rights afforded these Series A-1 Preferred Stock would give any future holders a disparate voting interest and allow them to potentially exert control over the actions of the Company.

 

Pursuant to the AGSS Merger Agreement, we acquired the business of Ameriguard and will continue the existing business of Ameriguard as our wholly owned subsidiary.

 

Ameriguard was formed on November 14, 2002. The corporation was incorporated with the issuance of 1,000 common shares formerly held by Lawrence Garcia, President and CEO with 550 shares and Lillian Flores, former VP of Operations with 450 shares. On July 12, 2022 under the terms of a Settlement Agreement, Flores exchanged her 450 shares for consideration of $3,384,950 and a promissory note in that amount secured by a stock pledge. Ameriguard provides armed guard services as a federal contractor with licenses in 7 states and provides commercial guard services in California.

 

Lawrence Garcia currently owns 86.26% of the issued and outstanding voting stock of the Company and will be able to exert significant influence and control over the Company for the foreseeable future.

 

Ameriguard principally provides guard services to governmental, quasi-governmental and commercial property management. Guard services generated $24.6 million in revenues for the fiscal year ended December 31, 2022. Guard services include, providing armed and unarmed uniformed security personnel for access control, mobile patrols, traffic control, security console/system operators, fire safety directors, communication, reception, concierge and front desk/doorman operations.

 

Corporation Information

 

Our principal executive offices are currently located at 5470 W Spruce Ave Suite 102 Fresno CA 93722.

 

Our website; www.ameriguardsecurity.com.

 

Employees

 

As of June 30, 2023, we had 253 full-time employees, 182 of these employees are represented by collective bargaining agreements and the Company considers it relations with its employees to be very good.

 

Our Industry

 

Security guard and related services in the US is comprised of over 11,000 companies and 900,000 officers. We compete with top firms, such as Allied Universal, Securitas, G4S and Prosegur Security, which control the majority of the industry. Ameriguard’s approximately $24.6 million in annual revenue places it in a strong competitive position.

 

We believe that the top 40 companies have the resources to harness technology, to expand their business into related services other than guard services. Companies with over $50 million in revenue have, over the last 10 years, experienced steady growth while those guard companies under $20 million, the remaining 9,900 firms, have experienced declining revenues. We believe that the principal reason for this is the steady diversification of security services away from the traditional guard services to areas of utilization of technology requiring capital. Along with this, we believe that the profitability challenges below $20 million annual sales are much more difficult that above $50 million is sales, largely due to the significant economies of scale achieve at the higher revenue levels.

 

The proliferation of technology while increasing efficacy in performance and inevitably lower costs in the future, the impact on the contract security industry will likely have mixed results – positive for companies who harness technology into their service delivery strategies – and negative for those companies who fail to invest in or adopt these service-enhancing capabilities. Despite the advances in the U.S. contract guarding business over recent years, there remains a question as to the industry’s viability in view of the increasing trend for integrating manned services with security systems (i.e. security video, access control and monitoring) along with the emergence of other new smart technology options and solutions (i.e. robotics, drones, cybersecurity and crowd sharing alert notification).

 

The recent merger and acquisition trend, primarily by the major national and international security organizations and fueled by investment and funding from private equity firms, is continuing. The underlying reason for this shift is less obvious and suggests an increasing number of sellers who concluded that their better option was to exit and sell rather than remain in the marketplace and try to compete and organically grow their market share.

 

 

2

 

 

 

Despite its low barriers of entry and nominal capital requirements, the security guard business has become more challenging for the smaller owner/operator. The traditionally historic advantage of the smaller operator’s ability to offer relationship-driven customized services is no longer totally sufficient for sustainable growth – especially with the increasing regulatory challenges of the Affordable Care Act, federal and state minimum wage laws, Family Medical Leave Act and state laws (i.e. meal and rest break reporting and now, predictive scheduling).

 

Even stronger local and smaller regional companies are finding it more difficult to protect their client base and grow revenues under increasing regulatory as well as competitive pressures. Larger regional and national organizations are dealing with the regulatory climate while growing market share by leveraging infrastructure, technology, economies of scale with more aggressive pricing and better service reliability. This approach appears to offer a more compelling value proposition from the client’s perspective, which seems evident by the higher client retention rates reported by the major security companies.

 

However, this consolidating trend may not be inevitable for the future as newer, more tech-savvy owner/operators enter the business and recognize how to adopt best practices with a variety of sophisticated third-party software platforms and applications to help level the playing field. These include talent management and on-boarding applications to attract, hire and maintain a more skilled and reliable workforce; integrated labor management platforms to control scheduling, compliance, operations, payroll, billing and financial reporting; and state-of-the-art social media marketing applications.

 

The contract security industry should now be able to more effectively capitalize on and penetrate opportunities in a $20 billion in-house market – especially for those companies who have invested and integrated technology into a more highly reliable ecosystem of protective services.

 

For the foreseeable future, the U.S. manned guarding business seems likely for continued sustainable growth. While the technology/manpower ratio may shift the revenue mix going forward, based on today’s currently expanding U.S. economy, the prospects for an aggregate growth rate of four percent or more seem realistic and perhaps even conservative, especially for ownership who have prudently invested in technology enhancements to their core guarding operations.

 

Providing these strategies can yield an attractive ROI, increase operating profits (EBITDA ranges of four to six percent and higher) and enterprise valuations, this industry seems not only viable but also opportune for further investment consideration.

 

(The above industry data taken from https://www.nasco.org/wp-content/uploads/2021/08/2021-Bob-Perry-Contract-Security-Industry-White-Paper-1.pdf)

 

Regulatory Matters/Compliance

 

Each State has specific licensing requirements companies must meet to perform guard services, especially armed guard services. To date, the Company holds firearm licenses in over twelve States and does not foresee any license or governmental requirements preventing us from continuing to operate in any State a contract is awarded to us. As a company with over 300 employees, we are subject to all of the standard federal and state labor laws and have consistently met those requirements to date, including ERISA.

 

Properties

 

The Company’s corporate headquarters is located at 5470 W. Spruce Avenue, Suite 102, Fresno CA. The lease is currently month to month. Landlord has not indicated a desire for a new lease. Our lease payments are a total of $55,767 for the entire term (or, $4,230 per month).

 

Legal Proceedings

 

While we have not been involved in any litigation related to the performance of our guard services, armed or otherwise, to date, as an armed guard Company with contracts with Governmental entities is a possibility of legal proceedings that could be more serious than the average business. From time to time, the Company is involved in matters relating to claims arising from the ordinary course of business, but those claims have been labor and union related and have been settled on an administrative level not in court.

 

While the results of such claims and legal actions cannot be predicted with certainty, the Company’s management does not believe that there are claims or actions, pending or threatened against the Company, the ultimate disposition of which would have a material adverse effect on our business, results of operations, financial condition or cash flows.

 

 

3

 

 

 

The Terms of the Offering

 

Securities Being Offered:   3,585,946 shares of common stock being registered on behalf of the Selling Shareholders.
     
Offering Period:   Until all shares are sold by the Shareholders or until 12 months from the date that the registration statement becomes effective, whichever comes first.
     
Offering Price   The Selling Shareholders will sell our shares at a fixed price of $1.18 per share. This price was determined by us based on the current market price.
     
Risk of Factors:   The Securities offered hereby involve a high degree of risk and should not be purchased by investors who cannot afford the loss of their entire investment. See “Risk Factors.”
     
Common Stock Issued and Outstanding Before Offering:   93,418,291 shares of our common stock are issued and outstanding as of the date of this Prospectus.
     
Common Stock Issued and Outstanding After Offering:   93,418,291 shares of common stock.
     
Use of Proceeds:   We will not receive any proceeds from the sale of the common stock by the Selling Shareholders. See “Use of Proceeds.”

 

 

4

 

 

RISK FACTORS

 

An investment in our securities is highly speculative and subject to numerous and substantial risks. These risks are set forth below. You should not invest in the Company unless you can afford to lose your entire investment. Readers are encouraged to review these risks carefully before making any investment decision.

 

Risks Related to Our Corporate Business:

 

Concentration of Revenue

 

The company receives over 87% of its total revenue from four Federal contracts. These contracts have specific terms, typically five years with the opportunity for extension, but there are no assurances they will be extended. Although we have had several extended in the past, there is no guarantee this will again happened in the future. However, there are significant direct expenses for each contract that also are removed from operations at the end of a contract. As a result, the revenue lost from a completed contract does not affect the bottom-line profits in an amount equal to the revenue lost. The actual net income impact depends on the contract. To mitigate this risk the company actively pursues additional contracts on an ongoing basis.

 

Long process in acquiring contracts

 

The process required to acquire a government contract takes several months to complete prior to delivery of the proposal to the contracting agency. Due to the time span required to prepare a proposal and wining the contract is not guaranteed, the company maintains a department of individuals who monitor and write proposals for all government contracts that fit our operating criteria that become open for bid on a continuing basis. It is important to the company that new contracts are acquired consistently to maintain and grow annual revenue

 

The growth of the Company is dependent on acquisition opportunities 

 

With our revenue materially concentrated and our timeline to organic growth very drawn out, we are dependent on closing acquisitions over the next eighteen months in order to grow. Failure to close on acquisitions, or a lack of synergy with our target companies, could stall growth and, eventually, cause a material decline in our financial situation. The Company does not currently have any agreements with potential acquisition targets.

 

Transitioning from carve out contracts to open market contracts

 

Currently the company benefits from several ownership criteria and business size contract qualifications, referred to as contract carveouts, that increases the probability of contract awards. The company meets the contracting qualifications of disabled veteran and minority owned business. Another aspect of contract opportunities is set aside for small businesses. This is defined as those who have operating revenue on average over the past five (5) years under $25.5 million. Currently the company is below this threshold, yet our strategic plan is to move past the average revenue limits within the next 24 months. This should not be seen as a negative in that we will only exceed this limit once we reach annual revenue of $40 million or more during the next 24 months, putting us in an excellent financial position to compete with the much larger companies who operate in the $50-$100 million revenue level. Another aspect of our strategy is to acquire similar guard companies who already have small business contracts with the government, which add significantly to our bottom line putting us in even a better position to win additional large government contracts.

 

Currently we have four federal contracts that approximate 87% of our total guard service revenue for the year ended December 31,2022. All federal contracts are awarded with a term of 5 years, with annual renewals. At the end of each contract year the government has the option to renew, cancel or renegotiate. Our four contracts and their respective terms are as follows:

 

  Social Security Administration, NSC   -

September 2022 through September 2027

Annual Revenue of approx. $3.145M

           
  Social security Administration, SSC    -

June 2022 through June 2027

Annual Revenue of approx. $4.932M

           
  Social Security Administration, WBDOC   -

June 2021 through July 2026

Annual Revenue of approx. $5.838M

           
  National Institute of Health- EPA   -

May 2020 through March 2023

Annual Revenue of approx. $7.514M

 

5

 

 

Staffing Shortages

 

The guard industry suffers from staffing shortages. This is an ongoing challenge and in its worst case can impact our ability to meet the requirements of the contracts awarded.

 

Impact of COVID

 

Initially the impact of the COVID pandemic was positive for the guard industry. Our industry is considered essential and with less activity at the sites we protect, we were able to meet and exceed the contract requirements with fewer staff and little to no overtime. As a result, each contract became more profitable than normal full operations. The challenges have actually come after the critical year of 2020. As the government began to require vaccinations for all employees and contractors, along with quarantine requirements, staffing became a big problem. Starting in 2021, these policies implemented by the federal government have made it very difficult for us to meet the staffing needs. COVID restriction rules on the local, state and national levels recruitment results are ending. Moving forward we anticipate any related recruitment issues to end.

 

Accelerating Inflation

 

All industries struggle when operating in times of inflation like we are experiencing in 2022. The results are increased pressure on salaries, operational costs increase due to higher fuel prices and the increased cost of all supplies. The one silver lining for the company is that federal contacts require that the salary increases that we negotiate with the labor union must be covered by increasing the monthly contracted rate. This of course is stipulated by contract that we do not exceed what is customary in the area with related contracts. This is significant in that guard salaries account for over 90% of operational costs, reducing the impact of inflation.

 

Key employees are essential to expanding our business.

 

Lawrence Garcia and other key employees are essential to our ability to continue to grow and expand our business. Mr. Garcia, as CEO and majority shareholder, allows the company to bid on the restricted contracts that we discussed, in the “Transitioning from carve out contracts to open market contract” paragraph on the previous page. Other long-term employees have significant impact on the success of operations and understanding of the industry. They have established relationships within the industry in which we operate. If Mr. Garcia or any of the long-term employees were to leave the company, our growth strategy might be hindered, which could materially affect our business and limit our ability to increase revenue. However, we are taking steps to implement process and procedure to insure no single person lost would be detrimental to our long- term success.

 

If we are unable to establish appropriate internal financial reporting controls and procedures, it could cause us to fail to meet our reporting obligations, result in the restatement of our financial statements, harm our operating results, subject us to regulatory scrutiny and sanction, cause investors to lose confidence in our reported financial information and have a negative effect on the market price for shares of our Common Stock.

 

Effective internal controls are necessary for us to provide reliable financial reports and to effectively prevent fraud. We maintain a system of internal control over financial reporting, which is defined as a process designed by, or under the supervision of, our principal executive officer and principal financial officer, or persons performing similar functions, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

 

As a public company, we have significant requirements for enhanced financial reporting and internal controls. We will be required to document and test our internal control procedures in order to satisfy the requirements of Section 404 of the Sarbanes-Oxley Act of 2002, which requires annual management assessments of the effectiveness of our internal controls over financial reporting. The process of designing and implementing effective internal controls is a continuous effort that requires us to anticipate and react to changes in our business and the economic and regulatory environments and to expend significant resources to maintain a system of internal controls that is adequate to satisfy our reporting obligations as a public company.

 

Although our management team, CEO and CFO, have not specifically managed a publicly traded company, we do have experience with the issues and requirements of Sarbanes-Oxley Act. The company CFO is a California CPA with over 30 years of experience in business operations and has been through multiple financial statement audits that required compliance with the Sarbanes-Oxley Act.

 

6

 

 

Technology innovations in the markets that we serve may create alternatives to our products and result in reduced sales.

 

Technology innovations to which our current and potential customers might have access to, could reduce or eliminate their need for our services. New or other disruptive technology that reduces or eliminates the use of one or more of our services could negatively impact the need for our services. However, our management team and board of directors are aware of this challenge and are very innovative and forward thinking. Yet, our failure to develop, introduce or enhance our services able to compete with new technologies in a timely manner could have an adverse effect on our business, results of operation and financial condition. The management team is continually focused on improvements and new technology to insure we are not left behind.

 

We may engage in a business combination that causes tax consequences to us and our shareholders.

 

Federal and state tax consequences can be a significant factor in considering any business combination that we may undertake. As a result, such transactions may be subject to significant taxation to the buyer and its shareholders under applicable federal and state tax laws. While we intend to structure any business combination so as to minimize the federal and state tax consequences to the extent practicable in accordance with our business objectives, there can be no assurance that any business combination we undertake will meet the statutory or regulatory requirements of a tax-free reorganization or similar favorable treatment or that the parties to such a transaction will obtain the tax treatment intended or expected upon a transfer of equity interests or assets. A non-qualifying reorganization, combination or similar transaction could result in the imposition of significant taxation, both at the federal and state levels, which may have an adverse effect on both parties to the transaction, including our shareholders.

 

It is unlikely that our shareholders will have any opportunity to evaluate or approve a business combination.

 

Our shareholders will not have the opportunity to evaluate and approve the business combination. In most cases, business combinations do not require shareholder approval under applicable law, and our Articles of Incorporation and Bylaws do not afford our shareholders with the right to approve such a transaction. Further, Mr. Garcia, our Chief Executive Officer and sole director, is the holder of over 86% of the voting rights of the Company on a fully diluted basis. Accordingly, our shareholders will be relying almost exclusively on the judgement of our board of directors (“Board”) and Chief Executive Officer and any persons on whom they may rely with respect to a potential business combination. To develop and implement our business plan, may in the future hire lawyers, accountants, technical experts, appraisers, or other consultants to assist with determining the Company’s direction’ and consummating any transactions contemplated thereby. We may rely on such persons in making difficult decisions in connection with the Company’s future business and prospects. The selection of any such persons will be made by our Board, and any expenses incurred, or decisions made based on any of the foregoing could prove to be averse to the Company in hindsight, the result of which could be diminished value to our shareholders.

 

Risks Related to Our Stockholders and Purchasing Shares of Common Stock

 

We have not voluntarily implemented various corporate governance measures.

 

Federal legislation, including the Sarbanes-Oxley Act of 2002, has resulted in the adoption of various corporate governance measures designed to promote the integrity of the corporate management and the securities markets. Some of these measures have been adopted in response to legal requirements. Others have been adopted by companies in response to the requirements of national securities exchanges, such as the NYSE or The NASDAQ Stock Market, on which their securities are listed. Among the corporate governance measures that are required under the rules of national securities exchanges are those that address board of directors’ independence, audit committee oversight and the adoption of a Code of Ethics. Our Board of Directors expects to adopt a Code of Ethics at its next Board meeting. The Company has not adopted exchange-mandated corporate governance measures and, since our securities are not listed on a national securities exchange, we are not required to do so. It is possible that if we were to adopt some or all these corporate governance measures, stockholders would benefit from somewhat greater assurances that internal corporate decisions were being made by disinterested directors and that policies had been implemented to define responsible conduct. For example, in the absence of audit, nominating and compensation committees comprised of at least most independent directors, decisions concerning matters such as compensation packages to our senior officers and recommendations for director nominees may be made by most directors who have an interest in the outcome of the matters being decided. Prospective investors should bear in mind our current lack of corporate governance measures in formulating their investment decisions.

 

7

 

 

We may be exposed to potential risks relating to our internal control over financial reporting.

 

As directed by Section 404 of the Sarbanes-Oxley Act of 2002 (“SOX 404”), the SEC has adopted rules requiring public companies to include a report of management on the Company’s internal control over financial reporting in its annual reports. While we expect to expend significant resources in developing the necessary documentation and testing procedures required by SOX 404, there is a risk that we will not comply with all the requirements imposed thereby. At present, there is no precedent available with which to measure compliance adequately. In the event we identify significant deficiencies or material weaknesses in our internal control over financial reporting that we cannot remediate in a timely manner, investors and others may lose confidence in the reliability of our financial statements and our ability to obtain equity or debt financing could suffer.

 

We have many authorized but unissued shares of our common stock.

 

We have many authorized but unissued shares of common stock, which our management may issue without further stockholder approval, thereby causing dilution of your holdings of our common stock. Our management will continue to have broad discretion to issue shares of our common stock in a range of transactions, including capital-raising transactions, mergers, acquisitions and other transactions, without obtaining stockholder approval, unless stockholder approval is required. If our management determines to issue shares of our common stock from the large pool of authorized but unissued shares for any purpose in the future, your ownership position would be diluted without your further ability to vote on that transaction.

 

While we have no preferred shares issued and outstanding, we have authorized and designated 10,000,000 shares as Series A-1 Preferred Shares with super-voting and conversion rights.

 

While there are no shares of Preferred stock outstanding, the Company has authorized and designated 10,000,000 shares as Series A-1 Preferred Stock, which (i) have preferred equal ratable rights to dividends from funds legally available therefore, when, as and if declared by the Board of Directors of the Company; (ii) hold distribution preferences upon liquidation, dissolution or winding up of the affairs of the Company (iii) convert into seventy-two (72) shares, for each share of Series A-1 Preferred Stock, at the discretion of the holder; and (iv) are entitled to seventy-two (72) votes per share of Series A-1 Preferred Stock on all matters on which stock holders may vote. This dual-class structure may render our shares ineligible for inclusion in certain stock market indices, and thus adversely affect share price and liquidity, and may adversely affect public sentiment. Furthermore, any future issuances of Series A-1 preferred stock may be dilutive to the voting power and value of our common stock shareholders.

 

Shares of our common stock may become illiquidity because our shares may begin to be thinly traded and may never become eligible for trading on a national securities exchange.

 

While we may at some point be able to meet the requirements necessary for our common stock to be listed on a national securities exchange, we cannot assure you that we will ever achieve a listing of our common stock on a national securities exchange. Our shares are currently only eligible for quotation on the OTC Pink, which is not an exchange. Initial listing on a national securities exchange is subject to a variety of requirements, including minimum trading price and minimum public “float” requirements, and could also be affected by the general scepticism of such markets concerning companies that are the result of mergers with inactive publicly-held companies. There are also continuing eligibility requirements for companies listed on public trading markets. If we are unable to satisfy the initial or continuing eligibility requirements of any such market, then our stock may not be listed or could be delisted. This could result in a lower trading price for our common stock and may limit your ability to sell your shares, any of which could result in you losing some or all your investments.

 

The market valuation of our business may fluctuate due to factors beyond our control and the value of your investment may fluctuate correspondingly.

 

The market valuation of smaller reporting companies, such as us, frequently fluctuate due to factors unrelated to the past or present operating performance of such companies. Our market valuation may fluctuate significantly in response to several factors, many of which are beyond our control, including:

 

  i. changes in securities analysts’ estimates of our financial performance, although there are currently no analysts covering our stock;

 

8

 

 

  ii. fluctuations in stock market prices and volumes, particularly among securities of smaller reporting companies;

 

  iii. changes in market valuations of similar companies;

 

  iv. announcements by us or our competitors of significant contracts, new technologies, acquisitions, commercial relationships, joint ventures or capital commitments;

 

  v. variations in our quarterly operating results;

 

  vi. fluctuations in related commodities prices; and

 

  vii. additions or departures of key personnel.

 

As a result, the value of your investment in us may fluctuate.

 

We have never paid dividends on our common stock.

 

We have never paid cash dividends on our common stock and do not presently intend to pay any dividends in the foreseeable future. Investors should not look to dividends as a source of income.

 

In the interest of reinvesting initial profits back into our business, we do not intend to pay cash dividends in the foreseeable future. Consequently, any economic return will initially be derived, if at all, from appreciation in the fair market value of our stock, and not because of dividend payments.

 

Future sales or perceived sales of our common stock could depress our stock price.

 

This resale prospectus covers 3,585,946 shares of common stock. If the holders of these shares were to attempt to sell a substantial amount of their holdings at once, the market price of our common stock could decline. Moreover, the perceived risk of this potential dilution could cause shareholders to attempt to sell their shares and investors to short the common stock, a practice in which an investor sells shares that he or she does not own at prevailing market prices, hoping to purchase shares later at a lower price to cover the sale. As each of these events would cause the number of shares of our common stock being offered for sale to increase, our common stock market price would likely further decline. All these events could combine to make it very difficult for us to sell equity or equity-related securities in the future at a time and price that we deem appropriate.

 

Due to factors beyond our control, our stock price may be volatile.

 

Any of the following factors could affect the market price of our common stock:

 

  The continued COVID-19 pandemic and its adverse impact upon the capital markets;

 

  The loss of one or more members of our management team;

 

  Our failure to generate material revenues;

 

  Regulatory changes including new laws and rules which adversely affect companies in our line of business;

 

  Our public disclosure of the terms of any financing which we consummate in the future;

 

  An announcement that we have affected a reverse split of our common stock;

 

  Our failure to become profitable;

 

9

 

 

  Our failure to raise working capital;

 

  Any acquisitions we may consummate;

 

  Announcements by us or our competitors of significant contracts, new services, acquisitions, commercial relationships, joint ventures or capital commitments;

 

  Cancellation of key contracts;

 

  Our failure to meet financial forecasts we publicly disclose;

 

  Short selling activities; or

 

  Changes in market valuations of similar companies.

 

In the past, following periods of volatility in the market price of a company’s securities, securities class action litigation has often been instituted. A securities class action suit against us could result in substantial costs and divert our management’s time and attention, which would otherwise be used to benefit our business.

 

Offers or availability for sale of a substantial number of shares of our common stock may cause the price of our common stock to decline.

 

The existence of shares of common stock issuable upon conversion of outstanding shares of Preferred Stock, creates a circumstance commonly referred to as an “overhang” which can act as a depressant to our common stock price. The existence of an overhang, whether sales have occurred or are occurring, also could make our ability to raise additional financing through the sale of equity or equity-linked securities more difficult in the future at a time and price that we deem reasonable or appropriate. If our existing shareholders and investors seek to sell a substantial number of shares of our common stock, such selling efforts may cause significant declines in the market price of our common stock.

 

Because we may issue preferred stock without the approval of our shareholders and have other anti-takeover defenses, it may be more difficult for a third party to acquire us and could depress our stock price.

 

In general, our Board may issue, without a vote of our shareholders, one or more additional series of preferred stock that have more than one vote per share. Additionally, issuance of preferred stock could block an acquisition resulting in both a drop in our stock price and a decline in interest of our common stock. This could make it more difficult for shareholders to sell their common stock. This could also cause the market price of our common stock shares to drop significantly, even if our business is performing well.

 

Because certain of our stockholders control a significant number of shares of our voting capital stock, they have effective control over actions requiring stockholder approval.

 

As of August 14, 2023, Lawrence Garcia, our Chief Executive Officer, effectively held 86.26% of the Company’s issued and outstanding common stock. As a result, Mr. Garcia can control the outcome of matters submitted to our stockholders for approval, including the election of directors and any merger, consolidation or sale of all or substantially all our assets. In addition, Mr. Garcia can control the management and affairs of our company. Accordingly, any investors who purchase shares will be minority shareholders and as such will have little to no say in the direction of us and the election of directors. Additionally, this concentration of ownership might harm the market price of our common stock by:

 

  delaying, deferring or preventing a change in corporate control;

 

  impeding a merger, consolidation, takeover or other business combination involving us; or

 

  discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us

 

10

 

 

Our common stock is considered a “penny stock.”

 

The SEC has adopted regulations which generally define “penny stock” to be an equity security that has a market price of less than $5.00 per share, subject to specific exemptions. The market price of our common stock is currently less than $5.00 per share and therefore may be a “penny stock.” Brokers and dealers effecting transactions in “penny stock” must disclose certain information concerning the transaction, obtain a written agreement from the purchaser and determine that the purchaser is reasonably suitable to purchase the securities. These rules may restrict the ability of brokers or dealers to sell our common stock and may affect your ability to sell shares.

 

Shareholders may be limited to a specific forum for bringing actions against the Company.

 

The Company has selected the Eighth Judicial District Court of Clark County, Nevada, to be the sole and exclusive forum for each of the following: (a) any derivative action or proceeding brought in the name or right of the Corporation or on its behalf, (b) any action asserting a claim for breach of any fiduciary duty owed by any director, officer, employee or agent of the Corporation to the Corporation or the Corporation’s stockholders, (c) any action arising or asserting a claim arising pursuant to any provision of NRS Chapters 78 or 92A or any provision of the Articles of Incorporation or these By-laws or (d) any action asserting a claim governed by the internal affairs doctrine, including, without limitation, any action to interpret, apply, enforce or determine the validity of the Articles of Incorporation or these By-laws. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the corporation shall be deemed to have notice of and consented to this provision. This could make it harder for a shareholder to bring an action against the Company or any of the officers or directors of the Company.

 

11

 

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This prospectus includes forward-looking statements. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to several risks, uncertainties and assumptions described in “Risk Factors” and elsewhere in this prospectus.

 

Other sections of this prospectus may include additional factors that could adversely affect our business and financial performance. Moreover, we operate in a highly regulated, very competitive and rapidly changing environment. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

 

We undertake no obligation to update publicly or revise any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events or performance. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or will occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. We have an ongoing obligation to continually disclose material future changes in the Company and its operations.

 

12

 

 

USE OF PROCEEDS

 

We will not receive any of the proceeds from the sale of the common stock by the Selling Shareholders.

 

13

 

 

DETERMINATION OF OFFERING PRICE

 

The offering price of $1.18 per share was determined based upon a premium to the current market price. The Selling Shareholder will sell their shares pursuant to the Company’s Registration Statement at the fixed price of $1.18. We will not receive any proceeds from the sale of shares by the Selling Shareholder.

 

14

 

 

THE SELLING SHAREHOLDERS

 

A portion of the Selling Shareholders held their shares for approximately ten (10) years, with them currently restricted under the Securities Act of 1933, as amended. A certain Selling Shareholder was issued his shares in 2014 with a Rule 144 legend on it. Certain shareholders were issued an aggregate of 675,000 shares upon the conversion of preferred shares. The remaining Selling Shareholders were issued their shares of common stock on or about December 9, 2022, pursuant to the AGSS Merger Agreement, whereby Ameriguard became a wholly owned subsidiary of AGSS, and AGSS its only shareholder. The Selling Shareholders relinquished all of their Ameriguard common shares, in exchange for the shares of common stock being registered in this registration statement on Form S-1.

 

All expenses incurred with respect to the registration of the common stock will be borne by the Company, but we will not be obligated to pay any underwriting fees, discounts, commission or other expenses incurred by Selling Shareholders in connection with the sale of such shares. 

 

Other than Martha Garcia, Lawrence Garcia, Jr., and Laura Garcia, none of the Selling Shareholders nor any of their associates or affiliates has held any position, office, or other material relationship with us in the past three years. Martha Garcia is the mother of Lawrence Garcia Lawrence Garcia, Jr. is the son of Mr. Garcia. Laura Garcia is sister of Mr. Garcia. None of these three individuals would be deemed affiliates, as each is an adult individual, living in a separate residence from Lawrence Garcia, our CEO.

 

The following table sets forth the name of the Selling Shareholders, the number of shares of common stock beneficially owned by the Selling Shareholders as of the date hereof and the number of shares of common stock being offered by the Selling Shareholders. The offer and sale of the shares are being registered herein. The Selling Shareholders are under no obligation to sell all or any portion of such shares. All information with respect to share ownership has been furnished by the Selling Shareholders, respectively. The “Amount Beneficially Owned After the Offering” column assumes the sale of all shares offered herein.

 

Name   Shares of
Common Stock
Beneficially
Owned prior to
Offering
    Maximum
Number of
Shares of
Common Stock
to be Offered
    Number of
Shares of
Common
Stock
Beneficially
Owned after
Offering
    Percent
Ownership
after Offering
 
STEPHANIE POPE(1)     140,625       140,625       0       0 %
STACEY VARGAS(1)     140,625       140,625       0       0 %
MICHAEL ROMERO(1)     140,625       140,625       0       0 %
MARTHA GARCIA(1)     140,625       140,625       0       0 %
LEO REIJNDERS(1)     140,625       140,625       0       0 %
LAWRENCE GARCIA JR.(1)     140,625       140,625       0       0 %
LAURA GARCIA(1)     140,625       140,625       0       0 %
HARLAN HARTMAN(1)     140,625       140,625       0       0 %
GCT EQUITY HOLDINGS, LLC(1)     1,125,000       1,125,000       0       0 %
ALI MUSLEH(1)     140,625       140,625       0       0 %
                                 
ALMORLI ADVISORS, INC.(2)     5,000       5,000       0       0 %
WALD BLOISE(2)     2,500       2,500       0       0 %
INTERED, INC(2)     2,500       2,500       0       0 %
JOSEPH BROPHY(2)     16,983       16,983       0       0 %
CARL ABBONIZIO(2)     2,500       2,500       0       0 %
DANNY FEDER(2)     6,250       6,250       0       0 %
ROBERT FREEDMAN(2)     7,500       7,500       0       0 %
SERGE MILMAN(2)     1,250       1,250       0       0 %
ROY LANTZ(2)     517       517       0       0 %
ALAN DRUCKER(2)     1,429       1,429       0       0 %
JIA LI(2)     179       179       0       0 %
SUSAN HUDDLESTON(2)     715       715       0       0 %
RONNIE EBANKS(2)     1,250       1,250       0       0 %
VALERIE A. RINKLE(2)     1,000       1,000       0       0 %
GREGORY S. DAHL(2)     90       90       0       0 %

 

15

 

 

JAMES MCCORMACK(2)     36,667       36,667       0       0 %
JOSEPH E. TOENISKOETER(2)     100       100       0       0 %
KEITH LUNEBURG(2)     36,667       36,667       0       0 %
ROBERTA A. ANDERSON(2)     1,000       1,000       0       0 %
DEAN BOYER(2)     32,250       32,250       0       0 %
BRUCE A OSBORN(2)     554       554       0       0 %
DANIEL J HAPNER(2)     893       893       0       0 %
DENISE WILLIAMS(2)     1,647       1,647       0       0 %
GARRY BACHER(2)     200       200       0       0 %
MARILYN HAPNER(2)     179       179       0       0 %
PEGGY M HAPNER(2)     358       358       0       0 %
SECURE INVESTIGATION CONSULTING(2)     900       900       0       0 %
MARIO SCINICARIELLO(2)     10,078       10,078       0       0 %
FINEST MANAGEMENT LLC(2)     2,500       2,500       0       0 %
LOUIS J. ALIMENA(2)     5,000       5,000       0       0 %
ANTHONY MANGANARO(2)     2,692       2,692       0       0 %
DONNA RUDOLPH(2)     274       274       0       0 %
ELEANOR EDELSTEIN(2)     138       138       0       0 %
EMILY EDELSTEIN(2)     410       410       0       0 %
GARRY CONNELL(2)     2,692       2,692       0       0 %
JUGNA SHAH(2)     4,543       4,543       0       0 %
KAREL GINSBERG(2)     1,363       1,363       0       0 %
LINDA PRESTO(2)     410       410       0       0 %
LINDA RUBINOWITZ(2)     1,363       1,363       0       0 %
PEGGY HAPNER(2)     1,363       1,363       0       0 %
S&S FISCHER HOLDINGS, LP(2)     6,814       6,814       0       0 %
SAM CZYSZ(2)     274       274       0       0 %
SAM WAKSMAN(2)     2,726       2,726       0       0 %
CHRISTIE RAMPONE(2)     1,250       1,250       0       0 %
FIDELIS HOLDINGS LLC(2)     4,499       4,499       0       0 %
BRADLEY JAMES COHEN(2)     10,384       10,384       0       0 %
EDWARD ROSENTHAL(2)     3,750       3,750       0       0 %
MARTIN J. HASEY(2)     15,117       15,117       0       0 %
RICHARD COHEN & WILLA COHEN TEN ENT(2)     10,385       10,385       0       0 %
VINCENT BURKE AND TONI BURKE TEN ENT(2)     2,017       2,017       0       0 %
DIRING HOLDING LLC(2)     341       341       0       0 %
DON LUNEBURG(2)     70,697       70,697       0       0 %
GLENN COTTON(2)     101,639       101,639       0       0 %
WILLIAM E. SCHIFFER(2)     59,024       59,024       0       0 %
                                 
HERBERT C POHLMANN, JR. TR(3)     37,500       37,500       0       0 %
                                 
BIOMEDICAL INSTITUTIONAL VALUE FUND, L.P.(4)     75,262       75,262       0       0 %
BIOMEDICAL OFFSHORE VALUE FUND, LTS.(4)     166,137       166,137       0       0 %
BIOMEDICAL VALUE FUND, L.P.(4)     293,132       293,132       0       0 %
CLASS D SERIES GEF-PS, L.P.(4)     122,788       122,788       0       0 %
WS INVESTMENTS II, LLC(4)     17,682       17,682       0       0 %

 

 
(1) These Selling Shareholders were issued their 2,390,625 shares of common stock on or about December 9, 2022, pursuant to the AGSS Merger Agreement, whereby Ameriguard became a wholly owned subsidiary of AGSS, and AGSS its only shareholder.
(2) These Selling Shareholders were issued an aggregate of 482,821 restricted shares between February 15, 2012 and October 9, 2013, by the prior management of the Company.
(3) This Selling Shareholder was issued the 37,500 shares on April 23, 2014 by the prior management of the Company.
(4) These Selling Shareholders were issued the aggregate of 675,000 shares in March of 2023, upon the conversion of their preferred stock.

 

16

 

 

PLAN OF DISTRIBUTION

 

This prospectus relates to the resale of up to 3,585,946 shares of our common stock by the Selling Shareholders, at a fixed price per share of $1.18, issued pursuant to the AGSS Merger Agreement.

 

Each of the Selling Shareholders is an “underwriter” within the meaning of Section 2(a)(11) of the Securities Act.

 

The Selling Shareholders, and any of their pledgees, donees, assignees and other successors-in-interest may, from time to time sell any or all their shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These sales must be at a fixed price of $1.18 per share. The Selling Shareholders may use any one or more of the following methods when selling shares:

 

  ordinary brokerage transactions and transactions in which the broker-dealer solicits the purchaser;
     
  block trades in which the broker-dealer will attempt to sell the shares as agent but may position and resell a portion of the block as principal;
     
  facilitate the transaction;
     
  purchases by a broker-dealer as principal and resale by the broker-dealer for its account;
     
  an exchange distribution in accordance with the rules of the applicable exchange;
     
  privately negotiated transactions;
     
  broker-dealers may agree with the Selling Shareholders to sell a specified number of such shares at the fixed price per share of $1.18;
     
  through the writing of options on the shares
     
  a combination of any such methods of sale; and
     
  any other method permitted pursuant to applicable law.

 

The Selling Shareholders, as applicable, shall have the sole and absolute discretion not to accept any purchase offer or make any sale of shares if it deems the purchase price to be unsatisfactory at any time.

 

The Selling Shareholders may also sell the shares directly to market makers acting as principals and/or broker-dealers acting as agents for themselves or their customers. Such broker-dealers may receive compensation in the form of discounts, concessions or commissions from the Selling Shareholders and/or the purchasers of shares for whom such broker-dealers may act as agents or to whom they sell as principal or both, which compensation as to a particular broker-dealer might be more than customary commissions. Market makers and block purchasers purchasing the shares will do so for their own account and at their own risk. Each such registered broker-dealer will be an underwriter within the meaning of Section 2(a)(11) of the Securities Act. We cannot assure that all or any of the shares offered in this prospectus will be sold by the Selling Shareholders. The Selling Shareholders, and any broker-dealers or agents, upon completing the sale of any of the shares offered in this prospectus, will be deemed to be “underwriters” as that term is defined under the Securities Act, the Exchange Act and the rules and regulations of such acts. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the shares purchased by them will be deemed to be underwriting commissions or discounts under the Securities Act.

 

The Selling Shareholders, alternatively, may sell all or any part of the shares offered in this prospectus through an underwriter. The Selling Shareholders have not entered into any agreement with a prospective underwriter and there is no assurance that any such agreement will be entered.

 

17

 

 

The Selling Shareholders may pledge its shares to its brokers under the margin provisions of customer agreements. If any of the Selling Shareholders default on a margin loan, the broker may, from time to time, offer and sell the pledged shares. The Selling Shareholders, and any other persons participating in the sale or distribution of the shares will be subject to applicable provisions of the Exchange Act, and the rules and regulations under such act, including, without limitation, Regulation M. These provisions may restrict certain activities of and limit the timing of purchases and sales of any of the shares by any of the Selling Shareholders, or any other such person. Under Regulation M, persons engaged in a distribution of securities are prohibited from simultaneously engaging in market making and certain other activities with respect to such securities for a specified period prior to the commencement of such distributions, subject to specified exceptions or exemptions. All these limitations may affect the marketability of the shares.

 

The Selling Shareholders will be offering such shares for its own account. We do not know for certain how or when the Selling Shareholders will choose to sell its shares of common stock. However, it can sell such shares at any time or through any manner set forth in this plan of distribution.

 

To permit the Selling Shareholders to resell the shares of common stock issued to it, we agreed to file a registration statement, of which this prospectus is a part, and all necessary amendments and supplements with the SEC for the purpose of registering and maintaining the registration of the shares. We will bear all costs relating to the registration of the common stock offered by this prospectus, other than the costs of our independent legal review. We will keep the registration statement effective until the earlier of (i) the date after which all of the shares of common stock held by the Selling Shareholders that are covered by the registration statement have been sold by the Selling Shareholders pursuant to such registration statement and (ii) the first day of the month next following the 36-month anniversary of the date the registration statement, to which this prospectus is made a part, is declared effective by the SEC.

 

18

 

 

BUSINESS

 

Changes to the Business.

 

We intend to continue Ameriguard’s line of business. Ameriguard principally provides guard services to governmental, quasi-governmental and commercial property management. Guard services generated $24.6 million in revenues for the fiscal year ended December 31, 2022. Guard services include, providing armed and unarmed uniformed security personnel for access control, mobile patrols, traffic control, security console/system operators, fire safety directors, communication, reception, concierge and front desk/doorman operations.

 

Corporation Information

 

Our principal executive offices are currently located at 5470 W Spruce Ave Suite 102 Fresno CA 93722.

 

Our website; www.ameriguardsecurity.com.

 

Employees

 

As of June 30, 2023, we had 253 full-time employees, 181 of these employees are represented by collective bargaining agreements and the Company considers its relations with its employees to be very good.

 

Corporate History

 

The Company was incorporated in Nevada on December 13, 2010.

 

The Company intended to become a provider of revenue cycle services to a broad range of healthcare providers. We offer our customers integrated solutions designed around their specific business needs, including revenue cycle data analysis, contract and outsourced coding, billing, coding and compliance audits, coding education, coding consulting, physician coding services and ICD-10 education and transition services.

 

On February 10, 2012, the Company entered into an Agreement and Plan of Merger and Reorganization (the “HRAA Merger Agreement”) with Health Revenue Assurance Holdings, Inc. (formerly known as Anvex International, Inc., “HRAH”), a Nevada company, and its wholly-owned subsidiary Health Revenue Acquisition Corporation (“Acquisition Sub”), which was treated for accounting purposes as a reverse recapitalization with HRAA, considered the accounting acquirer. Each share of HRAA’s common stock was exchanged for the right to receive approximately 1,271 shares of HRAH’s common stock. Before their entry into the HRAA Merger Agreement, no material relationship existed between HRAH and Acquisition Sub or HRAA. On April 27, 2012, the Company completed a 12.98 to 1 forward stock split. On May 2, 2012, the Company changed its ticker symbol from ANVX to HRAA.

 

The Company then went dormant in August 2014.

 

On July 14, 2020, as a result of a custodianship in Clark County, Nevada, Case Number: A816259, Custodian Ventures LLC (“Custodian”) was appointed Custodian of the Company.

 

On July 15, 2020 Custodian appointed David Lazar as the Company’s Chief Executive Officer, President, Secretary, Chief Financial Officer, Chief Executive Officer and Chairman of the Board of Directors.

 

On September 8, 2021, under the terms of a private stock purchase agreement, 10,000,000 shares of Series A-1 Preferred Stock, $0.001 par value per share (the “Shares”) of the Company, were transferred from Custodian Ventures, LLC to Ameriguard Security Services, Inc. California corporation (Ameriguard). As a result, Ameriguard became holder of approximately 91% of the voting rights of the issued and outstanding share capital of the Company on a fully-diluted basis of the Company, and became the controlling shareholder. The consideration paid for the Shares was $500,000. In connection with the transaction, David Lazar forgave the Company from all debts owed to him and/or Custodian Ventures, LLC.

 

19

 

 

On September 8, 2021, the Company accepted the resignations from David Lazar as the Company’s Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary and as a Member of the Board of Directors. Effective on the same date to fill the vacancies created by Mr. Lazar’s resignations, the Company appointed Lawrence Garcia as the Company’s President, CEO, CFO, Treasurer, Secretary, and Chairman of the Board of Directors. These resignations are in connection with the consummation of the private stock purchase agreement and was not the result of any disagreement with Company on any matter relating to Company’s operations, policies or practices.

 

On March 11, 2022, the Company, amended its articles of incorporation to change its name to Ameriguard Security Services, Inc. from Health Revenue Assurance Holdings, Inc. The name was deemed effective by FINRA on March 17, 2022.

 

Pursuant to the AGSS Merger Agreement, we acquired the business of Ameriguard and will continue the existing business of Ameriguard as our wholly owned subsidiary.

 

Ameriguard was formed on November 14, 2002. The corporation was incorporated with the issuance of 1,000 common shares formerly held by Lawrence Garcia, President and CEO with 550 shares and Lillian Flores, former VP of Operations with 450 shares. On July 12, 2022 under the terms of a Settlement Agreement, Flores exchanged her 450 shares for consideration of $3,384,950 and a promissory note in that amount secured by a stock pledge. Ameriguard provides armed guard services as a federal contractor with licenses in 7 states and provides commercial guard services in California.

 

Our Industry

 

Security guard and related services in the US is comprised of over 11,000 companies and 900,000 officers. We compete with top firms, such as Allied Universal, Securitas, G4S and Prosegur Security, which control the majority of the industry. Ameriguard’s approximately $24.6 million in annual revenue places it in a strong competitive position.

 

We believe that the top 40 companies have the resources to harness technology, to expand their business into related services other than guard services. Companies with over $50 million in revenue have, over the last 10 years, experienced steady growth while those guard companies under $20 million, the remaining 9,900 firms, have experienced declining revenues. We believe that the principal reason for this is the steady diversification of security services away from the traditional guard services to areas of utilization of technology requiring capital. Along with this, we believe that the profitability challenges below $20 million annual sales are much more difficult that above $50 million is sales, largely due to the significant economies of scale achieve at the higher revenue levels.

 

The proliferation of technology while increasing efficacy in performance and inevitably lower costs in the future, the impact on the contract security industry will likely have mixed results – positive for companies who harness technology into their service delivery strategies – and negative for those companies who fail to invest in or adopt these service-enhancing capabilities. Despite the advances in the U.S. contract guarding business over recent years, there remains a question as to the industry’s viability in view of the increasing trend for integrating manned services with security systems (i.e. security video, access control and monitoring) along with the emergence of other new smart technology options and solutions (i.e. robotics, drones, cybersecurity and crowd sharing alert notification).

 

The recent merger and acquisition trend, primarily by the major national and international security organizations and fueled by investment and funding from private equity firms, is continuing. The underlying reason for this shift is less obvious and suggests an increasing number of sellers who concluded that their better option was to exit and sell rather than remain in the marketplace and try to compete and organically grow their market share.

 

Despite its low barriers of entry and nominal capital requirements, the security guard business has become more challenging for the smaller owner/operator. The traditionally historic advantage of the smaller operator’s ability to offer relationship-driven customized services is no longer totally sufficient for sustainable growth – especially with the increasing regulatory challenges of the Affordable Care Act, federal and state minimum wage laws, Family Medical Leave Act and state laws (i.e. meal and rest break reporting and now, predictive scheduling).

 

Even stronger local and smaller regional companies are finding it more difficult to protect their client base and grow revenues under increasing regulatory as well as competitive pressures. Larger regional and national organizations are dealing with the regulatory climate while growing market share by leveraging infrastructure, technology, economies of scale with more aggressive pricing and better service reliability. This approach appears to offer a more compelling value proposition from the client’s perspective, which seems evident by the higher client retention rates reported by the major security companies.

 

20

 

 

However, this consolidating trend may not be inevitable for the future as newer, more tech-savvy owner/operators enter the business and recognize how to adopt best practices with a variety of sophisticated third-party software platforms and applications to help level the playing field. These include talent management and on-boarding applications to attract, hire and maintain a more skilled and reliable workforce; integrated labor management platforms to control scheduling, compliance, operations, payroll, billing and financial reporting; and state-of-the-art social media marketing applications.

 

The contract security industry should now be able to more effectively capitalize on and penetrate opportunities in a $20 billion in-house market – especially for those companies who have invested and integrated technology into a more highly reliable ecosystem of protective services.

 

For the foreseeable future, the U.S. manned guarding business seems likely for continued sustainable growth. While the technology/manpower ratio may shift the revenue mix going forward, based on today’s currently expanding U.S. economy, the prospects for an aggregate growth rate of four percent or more seem realistic and perhaps even conservative, especially for ownership who have prudently invested in technology enhancements to their core guarding operations.

 

Providing these strategies can yield an attractive ROI, increase operating profits (EBITDA ranges of four to six percent and higher) and enterprise valuations, this industry seems not only viable but also opportune for further investment consideration

 

(The above industry data taken from https://www.nasco.org/wp-content/uploads/2021/08/2021-Bob-Perry-Contract-Security-Industry-White-Paper-1.pdf)

 

Competitive Position

 

We believe that, based on our structure, we are uniquely positioned in the market currently allowing us to acquire additional government contracts and acquire competing companies in our industry. Our status as a small business that is minority and disabled veteran owned, gives us an edge on the special “carve out” contracts that we have discussed previously. The number of companies that meet this special criterion are fewer, increasing our odds of being awarded certain contracts. At the same time, having access to the public capital market could provide the capital needed to purchase competitors participating in the government market. Our experience and administrative capacity could ensure positive bottom-line impact from each acquisition. The Company does not currently have any agreements with potential acquisition targets. Additionally, our Board members have been selected due to their experience within the government contracting market. This adds support and insight that could be valuable to the successful bidding process. Finally, we believe that access to the capital could allow us to acquire businesses not in directly in our industry but can bring added value to our Company, such as: Cyber Security, Transportation, Surveillance, and industry related supplies.

 

TransportUS, Inc.

 

While the Company explored the purchase of TransportUS, Inc., a California corporation owned by Lawrence Garcia, the board of directors has determined, following due diligence, that the financial statements of TransportUS, Inc. are not in a form that can be audited under US GAAP. We have therefore abandoned such undertaking for the foreseeable future.

 

Regulatory Matters/Compliance

 

Each State has specific licensing requirements companies must meet to perform guard services, especially armed guard services. To date, the Company holds firearm licenses in over twelve States and does not foresee any license or governmental requirements preventing us from continuing to operate in any State a contract is awarded to us. As a company with over 300 employees, we are subject to all of the standard federal and state labor laws and have consistently met those requirements to date, including ERISA.

 

The Company is governed by individual State firearms laws.

 

Properties

 

The Company’s corporate headquarters is located at 5470 W. Spruce Avenue, Suite 102, Fresno CA. The lease is currently month to month. Landlord has not indicated a desire for a new lease. Our lease payments are a total of $55,767 for the entire term (or, $4,230 per month), which we believe is the current market rate.

 

21

 

 

Legal Proceedings

 

While we have not been involved in any litigation related to the performance of our guard services, armed or otherwise, to date, as an armed guard Company with contracts with Governmental entities is a possibility of legal proceedings that could be more serious than the average business. From time to time, the Company is involved in matters relating to claims arising from the ordinary course of business, but those claims have been labor and union related and have been settled on an administrative level not in court.

 

While the results of such claims and legal actions cannot be predicted with certainty, the Company’s management does not believe that there are claims or actions, pending or threatened against the Company, the ultimate disposition of which would have a material adverse effect on our business, results of operations, financial condition or cash flows.

 

22

 

 

MANAGEMENT’S DISCUSSION AND ANALYSIS AND RESULTS OF OPERATIONS

 

Management’s Discussion and Analysis and Results of Operations

 

This Item 7 contains forward-looking statements. Forward-looking statements in this Registration Statement on Form S-1 are subject to a number of risks and uncertainties, some of which are beyond our control. Our actual results, performance, prospects or opportunities could differ materially from those expressed in or implied by the forward-looking statements. Additional risks of which we are not currently aware or which we currently deem immaterial could also cause our actual results to differ, including those discussed in the sections entitled “Forward-Looking Statements” and “Risk Factors” included elsewhere in this Annual Report.

 

Management’s Discussion and Analysis should be read in conjunction with the financial statements included in this Registration Statement on Form S-1 (the “Financial Statements”). The financial statements have been prepared in accordance with generally accepted accounting policies in the United States (“GAAP”). Except as otherwise disclosed, all dollar figures included therein and in the following management discussion and analysis are quoted in United States dollars.

 

The following discussion of the Company’s financial condition and the results of operations should be read in conjunction with the Financial Statements and footnotes thereto appearing elsewhere in this Report.

 

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements. In order to comply with the terms of the safe harbor, the Company notes that in addition to the description of historical facts contained herein, this report contains certain forward-looking statements that involve risks and uncertainties as detailed herein and from time to time in the Company’s other filings with the Securities and Exchange Commission and elsewhere. Such statements are based on management’s current expectations and are subject to a number of factors and uncertainties, which could cause actual results to differ materially from those, described in the forward-looking statements. These factors include, among others: (a) the Company’s fluctuations in sales and operating results; (b) regulatory, competitive and contractual risks; (c) development risks; (d) the ability to achieve strategic initiatives, including but not limited to the ability to achieve sales growth, and (e) unknown litigation.

 

Corporate Structure

 

As previously mentioned, on December 9, 2022, AGSS executed a reverse merger with AmeriGuard resulting in AGSS becoming the sole owner of AmeriGuard. This merger establishes AGSS as a company operating a viable guard company with annual sales of approximately $24,000,000. It also is in the position to access the capital market to generate the capital needed to begin its growth strategy of mergers and acquisitions within the security industry. The Company does not currently have any agreements with potential acquisition targets.

 

Prior to and after the merger, AGSS has been working on developing the leadership team needed. We have in place a CEO with 20 years of experience in our industry and has been very successful in the government contracting market. Our CFO has over 35 years of business finance experience, the last 15 of which he has been focusing on organizational development consulting across multiple industries, and an Operations team on the east coast managing IT and our federal contracts.

 

23

 

 

Results of Operations for the fiscal year ending December 31, 2022

 

Revenues and Cost of Goods Sold

 

2022 experienced a 10% increase of $2.2 million in security services revenue. The majority of which was from federal contracts in the amount of approximately $1.5 million and the remaining $700,000 from commercial guard services. The contract services revenue increase was the result of monthly fee increases within the four existing contract operated for during 2022 and 2021. As the costs of labor increases within the unionized contract so does the revenue. For the Commercial operations we saw a significant increase in demand for services, specifically our patrol services. Patrol services solve the problem of delayed police response. Our patrol officers respond to all alarms regardless of cause within 15 minutes of activation. This is a cost effect way for businesses to have protection without the high expense of a posted guard. This is an area of service we are continuing to expand.

 

Currently we have four federal contracts that approximate 87% of our total guard service revenue for the year ended December 31,2022. All federal contracts are awarded with a term of 5 years, with annual renewals. At the end of each contract year the government has the option to renew, cancel or renegotiate. Our four contracts and their respective terms are as follows:

 

  Social Security Administration, NSC   -

September 2022 through September 2027

Annual Revenue of approx. $3.145M

           
  Social security Administration, SSC    -

June 2022 through June 2027

Annual Revenue of approx. $4.932M

           
  Social Security Administration, WBDOC   -

June 2021 through July 2026

Annual Revenue of approx. $5.838M

           
  National Institute of Health- EPA   -

May 2020 through March 2023

Annual Revenue of approx. $7.514M

 

We also had a significant increase of over $280,000 in other related income. This increase was due to a change in accounting practices. Prior to 2022, overhead expenses included management salaries were allocated to between AmeriGuard and three other related companies. As part of our transition to prepare for the reverse merger we shifted to management agreements between AmeriGuard and the other related entities. As a result, we saw both an increase in other revenues along with an increase in administrative expenses.

 

As with all professional service industries the vast majority of expense in with direct labor and expenses associated with that labor. We are not an exception. Our direct expenses average around 89% of revenues. Total cost of services increased approximately $1.3 million in 2022, and that increase is expected in relation to the revenue increase in 2022 as previously discussed.

 

Operating Expenses and Other Expense

 

Operation expenses, overhead expenses, increased in 2022 over 2021 by approximately $1.3 million. Slightly more than half of that increase was in administrative salaries and related payroll expenses, of approximately $796,000. As mentioned earlier in 2021 overhead expenses included administrative salaries were allocated between related companies. In 2022, all the salaries were expensed to AmeriGuard. Also, during 2022 as part of the reverse merger preparations, we added to our administrative team a full-time CFO, an HR Manager and an Operations Management team along with the necessary support positions in payroll and accounting. This was done in the preparations for the merger and the following expansion.

 

Other areas of expense increase were in the cost of vehicle operations of approximately $138,000 due to the leasing of four additional vehicles for patrols along with an increase in fuel costs. The category of General administrative expenses increased approximately $350,000. Approximately $100,000 of the increase related to expenses no longer allocated to the related companies as we did in 2021. Then the merger related expenses new to 2022 such as office rent in New York, marketing expenses, travel, shareholder buyout loan expense and Board of Director expenses totaling approximately $200,000. The remainder of the increase were minor changes in other operational expenses.

 

24

 

 

Other expenses in the amount of $344,105 that occurred in 2022, but not in 2021 are non-operational expenses related specifically to the preparations for and after the reverse merger. These expenses are legal, compliance, accounting and merger related expenses that are treated as non-operational expense to prevent distortions of operational net income or loss. It is anticipated that there will be continued non-operational expenses from ongoing capital raise activities moving forward.

 

At this time, our operating structure and current level of expense can handle twice the revenue stream with minor increases to our operating overhead expenses. This allows the entire gross profit of any new contract or company acquisition to go straight to the bottom line, providing a consistent return on investment.

 

Net Income/(Loss) from Operations

 

We had a net loss from operations of $74,003 in the year ending December 31, 2022. The Company had a net income from operations of $128,038 in the year ending December 31, 2021. The decrease in the Company’s income from operations can be attributed to the increase in expenses we incurred in the year ended December 31, 2022. Our operational structure that drives these costs has excess capacity in anticipation of significant growth via new contracts or more specifically, company acquisitions. This allows additional revenue to go directly to our bottom line (see moving forward comments).

 

After including the other expenses discussed above and the taxes paid each year, the year ending December 31, 2022, experience a Net Loss of $428,458, while the year ending December 31, 2021, resulted in a Net Income of $94,115.

 

Liquidity and Capital Resources

 

The Company’s principal sources of liquidity include cash from operations and proceeds from long-term debt financing. During the year ended December 31, 2022, operations generated net cash increase of approximately $258,100 while cash used from investing activities during the same period was approximately $230,100, with cash used from financing activities was approximately $930,100. The Company did not receive and proceeds from long term debt in 2022. The net decrease in cash for 2022 was approximately $902,000.

 

The main use of cash from financing activities was the first payment to shareholder from the shareholder buyout agreement signed in July 2022 in the amount of $686,990, as previously discussed. Other finance activities usage was SBA loan payments of $180,000 and owner distributions before merger in the amount of $63,000. The main use of cash in investing activities were office remodel expenses. The SBA loan is a 10-year loan with monthly principal and interest payments. Interest rate is variable at prime rate plus 2.75%, adjusted every calendar quarter. The interest rate on December 31, 2022, was 9%. Additional information is found in Note 6 of the notes to the financial statements.

 

On December 31, 2022, the Company had cash on hand of $1,226,600, with total current assets of $3,207,750.

 

25

 

 

Results of Operations for the six months ending June 30, 2023

 

Revenues and Cost of Goods Sold

 

For the first six months of 2023 AGSS experienced a 5.4% decrease of approximately $683,500 in overall revenue over the previous year. The was a decline in federal contracts, in the amount of approximately $846,000, with an increase in commercial services in the amount of approximately $162,500. The contract services revenue decrease was the result of the National Institute of Health- EPA contract ending mid-May and the Social Security Administration, WBDOC contract reducing total hours in 2023 over 2022. For the Commercial operations the increase was due to additional demand for services, along with the reorganization of duties allowing for one of the managers to focus on sales. We are experiencing a continued demand for our services and expect the growth in the commercial service revenues to continue.

 

Like other professional service industries most of the expense is direct labor and the expenses associated with that labor. We are not an exception. Our direct expenses average around 90% of revenues. However, during the first 6 months of 2023 we saw that cost increase to 96% of revenue. This increase is due to labor shortages resulting in an increase in overtime paid to contract guards. Total labor cost of services increased approximately $165,800 in 2023 over 2022. We have increased recruitment activities and are working with the staff to address the overtime expenses.

 

Other Related Income

 

Other income increased in 2023 slightly compared to 2022, by approximately $1,400.

 

Operating Expenses

 

Operation expenses, overhead expenses, increased in 2023 over 2022 by approximately $700,000. Slightly more than half of that increase was in administrative salaries and related payroll expenses, of approximately $366,000. As part of the reverse merger preparations, we added to our administrative team a full-time CFO, an HR Management team and an Operations Management team along with the necessary support positions in payroll and accounting. We also experienced an increase in professional fees of approximately $65,000. These increases relate to the preparations for the merger and the following corporate expansion. We have established an administrative team with the capacity available to take the company to annual sales of $200 million and beyond.

 

The remaining increase in operations expenses fall into a few general categories. One such category is expenses related to public company operations incurred in 2023 and not in 2022. The total of these expenses is approximately $100,200. Another category of expenses is that of loan fees which increased by approximately $120,000 over 2022. The majority of this increase is from the shareholder buyout loan of $73,000 of accrued interest. The final category of general operational expenses such as rent, general liability insurance, marketing, guard training, increased approximately $135,000.

 

At this time, our operating structure and current level of expense can handle several times more revenue with minor increases to our operating overhead expenses. This allows the entire gross profit of any new contract or company acquisition to go straight to the bottom line, providing a consistent return on investment. However, due to a delay in our initial capital raise, management is taking steps to reduce costs over the next 6 months. The Company does not currently have any agreements with potential acquisition targets.

 

Other Income (Expense)

 

Other income increased in 2023 significantly compared to 2022, by approximately $3,278,000. This increase was attributable to the receipt of an Employee Retention Tax Credit (ERTC) payment of $3,288,033 and related interest in the amount of $129,800, from tax year 2021. This is a one-time credit. Funds have been set aside to cover related income taxes and debt coverage for the 2023 year. The remaining cash will be utilized for operations.

 

26

 

 

Net Income

 

Net income for the first six months of 2023 was $1,009,357. An increase over the loss in 2022 of $250,257. The net income increase was the direct result of the ERTC reviewed in the above section Other Income (Expense). Operationally Net Income declined during this period due to expenses incurred in 2023 relating to the management of the public company not incurred in 2022. As previously mentioned, our operational structure that drives these costs has excess capacity in anticipation of significant growth via new contracts or more specifically, company acquisitions. This allows additional revenue to go directly to our bottom line (see moving forward comments).

 

Liquidity and Capital Resources

 

The Company’s principal sources of liquidity include cash from operations and proceeds from long-term debt financing. During the six months ending June 30, 2023, operations generated net increase in cash of approximately $1,762,000 resulting from the ERTC money received in June. While cash provided by general operations was approximately $1,807,000. While cash used for investing and financing activities total approximately $45,000.

 

On June 30, 2023, the Company had cash on hand of $2,990,014, with total current assets of $4,530,325.

 

Moving Forward

 

During the past twenty-one months we have been working to get to where we are today. It has been difficult and expensive to get to this point of being a public company with the corporate structure, systems and team that can expand our business with increasing profitability. Our current overhead expense structure has the capacity to manage two to three times the revenues from one of two strategic sources.

 

Our first source is to continue down our historical path of seeking out contracts that meet our sweet spot and bidding with hope of successful award. However, this path is time consuming and isn’t a guarantee of the growth we desire and is outside of our control.

 

Our second source of growth is merger and acquisition. While the Company does not currently have any agreements with potential acquisition targets, we now have the capital market available to us and our industry is positioned for long term growth, now is the time. The security industry continues to grow in opportunity, and at the same there’s a lot of consolidation occurring. We plan to be a company acquiring others and quickly doubling our revenues with one or two key acquisitions. After which we could see all the gross profit from those companies going directly to our bottom line.

 

There are also potential acquisition opportunities in several other industries that could fit our business model. Those include transportation, cyber security, private security, ammunition manufacturing, and surveillance. The Company does not currently have any agreements with potential acquisition targets.

 

Management is very positive regarding profitable operations for the next twelve months based on the following:

 

  AGSS operates in a growing industry.

 

  The security industry is favorably positioned, even in a recession.

 

  There are over 10,000 security companies operating in our market, with 50% available for acquisition.

 

  Our management team, Board of Directors and supporting equity professionals can get the job done.

 

  We have been and will continue to be a company that is very conservative with our resources and will use every possible dollar provide strength and good return to our investors.

 

  We are in it for the long haul.

 

  We make profits the old fashion way, hard work.

 

27

 

 

Management Discussion of Strategic Plans

 

On December 9, 2022, AGSS acquired AmeriGuard via a stock exchange. After which, AmeriGuard became the 100% subsidiary of AGSS resulting in the consolidated annual revenue of AGSS exceeding $22 million. We hope to achieve material growth following a very simple menu:

 

  Aggressive bidding on new and current Federal Guard Contracts.

 

  Meet the growing needs in the Commercial Guard services.

 

  Acquisitions of Federal Contracting competitors, specifically those with high level secret security clearance.

 

  Acquisition of businesses operating in the governmental contracting market which may achieve greater margins such as the transportation industry and technology, specifically cyber-security and related IT services.

 

Government Contracts

 

We intend to continue to take advantage of our federal contracting bidding category of a veteran owned, minority owned, small business (initially) narrowing the field of competition for each contract. The small business category is defined as average sales over 5 years at or below $25.5 million. We project that we will remain below that level for the next two calendar years. Another category that increases contracting opportunities is the much-coveted position of having high level secret clearance. We have held this clearance in the past and are actively seeking to gain such clearance again.

 

With over 20 years of experience with government contracts providing significant understanding of the bidding process along with a team of 5 individuals processing contract bids, we are confident of being awarded two or three new contracts in the next eighteen months.

 

As previously mentioned in the industry discussion, the industry is going through a merger and acquisition phase driven by the need to consolidate overhead and a significant percentage of owner retirements. One key reason for the creation of this public company is to gain the significant capital necessary to acquire two or three companies already in the governmental contract market.

 

Commercial Guard Services

 

With the increasing crime rates in most major cities across the country the gap between what the business owners expect from law enforcement and what law enforcement can deliver is widening. A specific concern is the amount of time it takes from the moment an alarm is triggered and the arrival of an officer. This can be multiple hours and sometimes not at all for local police departments. The time gap as described could mean the difference between a broken window to a multi thousand-dollar loss.

 

It is a part of our regular service to dispatch an armed officer to respond quickly to the alarm, secure the scene and await law enforcement or the business owner. We believe that this quick response ensures a higher level of security for our customers. We provide the complete package of alarms, video cameras to armed response. This complete vertical can be duplicated in any town USA. It is true that other guard companies do provide armed response, yet not many also have surveillance systems under their operational control and monitored with local dispatch as we do.

 

Our strategy is to acquire commercial guard companies in the states where we have federal contracts allowing us to establish a kind of farm system for guards who can start at a no experience entry position, receive experience and training to ultimately be employed at the high value level of unionized federal guard. Like many industries, it is extremely difficult to find and keep the employees needed for our federal contracts. This negatively impacts the bottom-line success of a contract due to extra overtime not anticipated. A program like this will allow individuals to start and build a career, not just a job.

 

Other Business Acquisitions

 

AGSS will look to identify a few potential Cyber Security/IT companies that could be acquired. We see the acquisition of a quality Cyber Security company and an important aspect of our strategic plan. The Executive Team will identify potential acquisitions with great urgency. The Company does not currently have any agreements with potential acquisition targets.

 

28

 

 

Implementation and Timeline

 

For the acquisitions we will identify target companies that meets the specific strategic and financial criteria established by the board, and then seek the necessary capital. The acquisition offer will include both cash and AGSS stock.

 

The criteria that management is currently using to identify acquisition target are:

 

  1. Currently holding governmental contracts in good standing and/or with solid commercial operations.

 

  2. Companies in related industries provide significant value to our company’s bottom line.

 

  3. A minimum of a 10% EBTIDA (non-guard companies), and guard companies with the majority of revenues from government contracts with an EBTIDA of 2.5+%.

 

  4. Consolidation savings will bring EBTIDA to 15% (non-guard companies), and 8-10% for guard companies.

 

  5. Monthly revenues exceeding $500,000.

 

  6. Has a clear path for revenue growth.

 

  7. If the company does not meet the criteria in 1-6. It needs to demonstrate an ability to grow 10% per year or more and bring positive cash flow to the company.

 

For new government contracts, this approach is a bit more time-consuming and competitive. Preparing proposals for the contracts that become available is not the problem, the time aspect is the dates the contracts are awarded.

 

The capital required component of these contracts is twofold. First, the contract often requires new equipment and vehicles. Second, the bidding company must have enough working capital to cover the first three months of payroll. With payroll cost being 80% of the contract and various equipment requirements, the required capital on hand can be significant. For a contract that has $15 million per year in revenue the capital on hand requirement would exceed $3,000,000.

 

The following is a description of the assumptions made for each quarter of operation.

 

Third quarter of operation, July – September 30, 2023

 

During this quarter our focus will be acquiring a guard company of a large enough size to have annual sales over $10 million, with the hopes of providing additional cash from operations at 6% of annual sales. Management is confident they will be able to find a few companies that meet our acquisition requirements.

 

At this point AGSS should have a complete Executive Team, full Board of Directors, processes and procedures in place and will be aggressively working to achieve our goal of $100 million in annual sales.

 

As previously indicated it is anticipated that AGSS will acquire additional Security Companies competing with AGSS in the government contracting market, along with companies that meet the acquisition criteria previously mentioned, from June 2023 through the end of the year. The previous comments and timeline reflect management’s expectations that are achievable and are at the minimum of management’s intentions. Based on market activities and investor readiness, the pace of acquisitions and contract awards could accelerate.

 

Off-Balance Sheet Arrangements

 

We have no off-balance sheet arrangements.

 

29

 

 

Critical Accounting Policies and Estimates

 

Our discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. These principles require us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenue and expenses, cash flow and related disclosure of contingent assets and liabilities. Our estimates include those related to revenue recognition, accounts receivable reserves, income and other taxes, stock-based compensation and equipment and contingent obligations. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from these estimates. To the extent that there are material differences between these estimates and our actual results, our future financial statements will be affected.

 

We define our “critical accounting policies” as those U.S. generally accepted accounting principles that require us to make subjective estimates about matters that are uncertain and are likely to have a material impact on our financial condition and results of operations as well as the specific way we apply those principles. Our estimates are based upon assumptions and judgments about matters that are highly uncertain at the time the accounting estimate is made and applied and require us to continually assess a range of potential outcomes. A detailed discussion of the critical accounting policies that most affect our company is in Footnote 2 of the notes to our financial statements.

 

30

 

 

DESCRIPTION OF PROPERTY

 

The Company’s corporate headquarters is located at 5470 W. Spruce Avenue, Suite 102, Fresno CA. The lease is currently month to month. Landlord has not indicated a desire for a new lease. Our lease payments are a total of $55,767 for the entire term (or, $4,230 per month).

 

31

 

 

LEGAL PROCEEDINGS

 

The Company is not presently a party to any legal proceedings. From time to time, the Company is involved in matters relating to claims arising from the ordinary course of business, but those claims have been labor and union related and have been settled on an administrative level not in court.

 

While the results of such claims and legal actions cannot be predicted with certainty, the Company’s management does not believe that there are claims or actions, pending or threatened against the Company, the ultimate disposition of which would have a material adverse effect on our business, results of operations, financial condition or cash flows.

 

During the past ten years no current or incoming director, executive officer, promoter or control person of the Company has been involved in the following:

 

(1) A petition under the Federal bankruptcy laws or any state insolvency law which was filed by or against, or a receiver, fiscal agent or similar officer was appointed by a court for the business or property of such person, or any partnership in which he was a general partner at or within two years before the time of such filing, or any corporation or business association of which he was an executive officer at or within two years before the time of such filing;

 

(2) Such person was convicted in a criminal proceeding or is a named subject of a pending criminal proceeding (excluding traffic violations and other minor offenses);

 

(3) Such person was the subject of any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from, or otherwise limiting, the following activities:

 

i. Acting as a futures commission merchant, introducing broker, commodity trading advisor, commodity pool operator, floor broker, leverage transaction merchant, any other person regulated by the Commodity Futures Trading Commission, or an associated person of any of the foregoing, or as an investment adviser, underwriter, broker or dealer in securities, or as an affiliated person, director or employee of any investment company, bank, savings and loan association or insurance company, or engaging in or continuing any conduct or practice in connection with such activity;

 

ii. Engaging in any type of business practice; or

 

iii. Engaging in any activity in connection with the purchase or sale of any security or commodity or in connection with any violation of Federal or State securities laws or Federal commodities laws;

 

(4) Such person was the subject of any order, judgment or decree, not subsequently reversed, suspended or vacated, of any Federal or State authority barring, suspending or otherwise limiting for more than 60 days the right of such person to engage in any activity described in paragraph (f)(3)(i) of this section, or to be associated with persons engaged in any such activity;

 

(5) Such person was found by a court of competent jurisdiction in a civil action or by the Commission to have violated any Federal or State securities law, and the judgment in such civil action or finding by the Commission has not been subsequently reversed, suspended, or vacated;

 

(6) Such person was found by a court of competent jurisdiction in a civil action or by the Commodity Futures Trading Commission to have violated any Federal commodities law, and the judgment in such civil action or finding by the Commodity Futures Trading Commission has not been subsequently reversed, suspended or vacated;

 

32

 

 

(7) Such person was the subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of:

 

i. Any Federal or State securities or commodities law or regulation; Or

 

ii. Any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease and desist order, or removal or prohibition order; Or

 

iii. Any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; Or

 

(8) Such person was the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

 

33

 

 

DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS

 

Directors, Executive Officers and Corporate Governance.

 

Set forth below is information regarding our directors and executive officers following the closing of the AGSS Merger. Pursuant to the terms of the AGSS Merger, our sole officer and director, Lawrence Garcia, was appointed as President and Chief Executive Officer, was appointed as our Chief Operating Officer, Secretary and Treasurer, Michael Goossen as our Chief Financial Officer. In addition, in connection with the AGSS Merger, Douglas Anderson was appointed to serve as a director on December 9, 2022

 

The following persons became our executive officers and directors upon effectiveness of the AGSS Merger, and hold the positions set forth opposite their respective names.

 

Name   Age   Position
Lawrence Garcia   50   Chairman of the Board, President and Chief Executive Officer
        Chief Operating Officer, Secretary, Treasurer and Director
         
Michael Goossen, CPA   61  

Chief Marketing Officer and Director

Chief Financial Officer

         
Douglas Anderson*   60   Director
         
General Russel Honoré#   75   Director

 

 
*

Appointed December 9, 2022.

# Appointed March 23, 2023.

 

Directors serve until the next annual meeting and until their successors are elected and qualified. The directors of our company are elected by the vote of a majority in interest of the holders of the voting stock of our company and hold office until the expiration of the term for which he or she was elected and until a successor has been elected and qualified.

 

Most of the authorized number of directors constitutes a quorum of the Board for the transaction of business. The directors must be present in person or telephonically at the meeting to constitute a quorum. However, any action required or permitted to be taken by the Board may be taken without a meeting if all members of the Board individually or collectively consent in writing to the action.

 

Directors may receive compensation for their services and reimbursement for their expenses as shall be determined from time to time by resolution of the Board. Our directors currently do not receive monetary compensation for their service on the Board of Directors.

 

Officers are appointed to serve until such time as their successors have been duly appointed by the Board of Directors.

 

The principal occupations for the past five years (and, in some instances, for prior years) of each of our executive officers and directors, followed by our key employees, are as follows:

 

Officers

 

Lawrence Garcia is the CEO and President of Ameriguard Security Service, Inc incorporated in state of California in 2002. Lawrence is a disabled veteran of the United States Navy and of Hispanic dissent. He has led the company from a small local guard company to a national company currently managing five Federal Government armed guard contracts with annual revenue of over $22 million. Mr. Garcia has twice been named, “Businessman of the Year” in the State of California.

 

Michael Goossen, CPA is the Chief Financial Officer of Ameriguard Security Services, Inc., a California Corporation. Michael has been a CPA since 1986, has worked in multiple industries as a CFO and CEO. During the past 20 years he has been providing small business consulting, offering CFO services and executive leadership development. Michael began working with Ameriguard as a CFO consultant and business strategic services 3 years ago and became the full time CFO for Ameriguard in August 2022.

 

34

 

 

Board of Directors

 

Douglas Anderson, Board Director. Mr. Anderson is the CEO of Wall Street Capital Partners and has been involved in or exposed to most aspects of corporate finance with over 20 years on Wall Street. Prior to his work in corporate finance, he served in the U.S. Marine Corps, including the elite Marine Reconnaissance Battalion. He held a Top-Secret clearance while serving operationally in the U.S. State Department at American Embassies overseas, as well as at the U.N. in New York, where he participated in Security Enhancement programs. Mr. Anderson was formally trained on Wall Street as an Underwriter. He has been interviewed and broadcast nationally and internationally, many times as an expert both on NASDAQ and at the NYSE. Mr. Anderson earned his undergraduate degree from the University of Washington and postgraduate graduate education includes executive education from Harvard in Finance and Texas A&M in Agriculture Science. Mr. Anderson has served as an Advisor, Director, public company CEO and public company Board Director over his career.

 

General Russel Honoré, Board Director. General Russel Honoré is a decorated 37-year army veteran and a global authority on leadership, disaster management, and climate preparedness. At the request of the Speaker of the House, the General led Task Force 1-6 Capitol Security Review to improve Capitol security following the attacks on January 6, 2021. As the commander of Joint Task Force Katrina, he became known as the “Category 5 General” for his leadership in coordinating military relief efforts in post-hurricane New Orleans. General Honoré knows that the future of our national security depends on protecting our environment, and he’s fighting for a brighter future for us all. A Louisiana native, he founded GreenARMY, a coalition of environmental experts and advocates, to protect against pollution while fighting climate change and the natural disasters it causes. During his military career, General Honoré held numerous commands, including Vice Director for Operations for the Joint Chiefs of Staff and Commander of the Standing Joint Force Headquarters-Homeland Security.

 

Family Relationships

 

There are no family relationships among our executive officers and directors.

 

Board Leadership Structure and Role in Risk Oversight

 

Our Board of Directors focuses on the most significant risks facing our company and our company’s general risk management strategy, and ensure that risks undertaken by our Company are consistent with the Board’s appetite for risk. While the Board oversees our company’s risk management, management is responsible for day-to-day risk management processes. We believe this division of responsibilities is the most effective approach for addressing the risks facing our company and that our Board leadership structure supports this approach.

 

Limitation of Liability and Indemnification of Officers and Directors

 

Under Nevada General Corporation Law and our articles of incorporation, our directors will have no personal liability to us or our stockholders for monetary damages incurred as the result of the breach or alleged breach by a director of his “duty of care.” This provision does not apply to the directors’ (i) acts or omissions that involve intentional misconduct or a knowing and culpable violation of law, (ii) acts or omissions that a director believes to be contrary to the best interests of the corporation or our shareholders or that involve the absence of good faith on the part of the director, (iii) approval of any transaction from which a director derives an improper personal benefit, (iv) acts or omissions that show a reckless disregard for the director’s duty to the corporation or our shareholders in circumstances in which the director was aware, or should have been aware, in the ordinary course of performing a director’s duties, of a risk of serious injury to the corporation or our shareholders, (v) acts or omissions that constituted an unexcused pattern of inattention that amounts to an abdication of the director’s duty to the corporation or our shareholders, or (vi) approval of an unlawful dividend, distribution, stock repurchase or redemption. This provision would generally absolve directors of personal liability for negligence in the performance of duties, including gross negligence.

 

The effect of this provision in our articles of incorporation is to eliminate the rights of the Company and our stockholders (through stockholder’s derivative suits on behalf of the Company to recover monetary damages against a director for breach of his fiduciary duty of care as a director (including breaches resulting from negligent or grossly negligent behavior) except in the situations described in clauses (i) through (vi) above. This provision does not limit nor eliminate the rights of the Company or any stockholder to seek non-monetary relief such as an injunction or rescission in the event of a breach of a director’s duty of care. In addition, our Articles of Incorporation provide that if Nevada law is amended to authorize the future elimination or limitation of the liability of a director, then the liability of the directors will be eliminated or limited to the fullest extent permitted by the law, as amended. Nevada General Corporation Law grants corporations the right to indemnify their directors, officers, employees and agents in accordance with applicable law. Our bylaws provide for indemnification of such persons to the full extent allowable under applicable law. These provisions will not alter the liability of the directors under federal securities laws.

 

35

 

 

We intend to enter into agreements to indemnify our directors and officers, in addition to the indemnification provided for in our bylaws. These agreements, among other things, indemnify our directors and officers for certain expenses (including attorneys’ fees), judgments, fines, and settlement amounts incurred by any such person in any action or proceeding, including any action by or in the right of the Company, arising out of such person’s services as a director or officer of the Company, any subsidiary of the Company or any other company or enterprise to which the person provides services at the request of the Company. We believe that these provisions and agreements are necessary to attract and retain qualified directors and officers.

 

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the Company pursuant to the foregoing provisions, the Company has been informed that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

 

Related Party Transactions

 

On July 7, 2022, the Ameriguard entered into a buyout agreement with its minority shareholder Lillian Flores. The value of Ameriguard to be used for the buyout agreement was calculated using an independent evaluation service which determined the December 31, 2020 value to be approximately $6,400,000. As a 45% owner, Mrs. Flores’ share was approximately $2,885,000. After negotiation of some additional funds due Mrs. Flores, the final buyout amount was approximately $3,385,000. A 5-year promissory note was executed and the note is secured by a stock pledge.

 

As part of the executed agreement the first payment of $676,990 was issued July 12, 2022. The agreement stipulates 4 additional payments of $739,508, principal and interest, starting December 31, 2023, with final payment made December 31, 2026.

 

Director Independence

 

Lawrence Garcia, CEO and majority Shareholder is our only non-independent director.

 

Because our common stock is not currently listed on a national securities exchange, we have used the definition of “independence” of The NASDAQ Stock Market to make this determination. NASDAQ Listing Rule 5605(a)(2) provides that an “independent director” is a person other than an officer or employee of the company or any other individual having a relationship which, in the opinion of the company’s board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. The NASDAQ listing rules provide that a director cannot be considered independent if:

 

  the director is, or at any time during the past three years was, an employee of the Company;
     
  the director or a family member of the director accepted any compensation from the Company in excess of $120,000 during any period of 12 consecutive months within the three years preceding the independence determination (subject to certain exclusions, including, among other things, compensation for board or board committee service);
     
  a family member of the director is, or at any time during the past three years was, an executive officer of the Company;
     
  the director or a family member of the director is a partner in, controlling stockholder of, or an executive officer of an entity to which the Company made, or from which the Company received, payments in the current or any of the past three fiscal years that exceed 5% of the recipient’s consolidated gross revenue for that year or $200,000, whichever is greater (subject to certain exclusions);
     
  the director or a family member of the director is employed as an executive officer of an entity where, at any time during the past three years, any of the executive officers of the Company served on the compensation committee of such other entity; or
     
  the director or a family member of the director is a current partner of the Company’s outside auditor, or at any time during the past three years was a partner or employee of the Company’s outside auditor, and who worked on the company’s audit.

 

36

 

 

Involvement in Certain Legal Proceedings

 

To our knowledge, during the past ten years, none of our directors, executive officers, promoters, control persons, or nominees has:

 

  been convicted in a criminal proceeding or been subject to a pending criminal proceeding (excluding traffic violations and other minor offenses)

 

  had any bankruptcy petition filed by or against the business or property of the person, or of any partnership, corporation or business association of which he was a general partner or executive officer, either at the time of the bankruptcy filing or within two years prior to that time;

 

  been found by a court of competent jurisdiction in a civil action or by the Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;

 

  been the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated (not including any settlement of a civil proceeding among private litigants), relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or
     
  been the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

 

Code of Ethics

 

We have not adopted a code of ethics that applies to our principal executive officer, principal financial officer, principal accounting officer, or persons performing similar functions, because of the small number of persons involved in the management of the Company.

 

Director and Executive Compensation

 

No compensation has been paid and no stock options granted to any of our officers or directors in the last three fiscal years.

 

Employment Agreements

 

Prior to AGSS Merger date no employment agreements were in place. It is the intention of ownership to rely on the recommendation of the compensation committee to be appointed by the Board of Directors 

 

2023 Equity Incentive Plan

 

Our Board of Directors and stockholders owning a majority of our outstanding shares plan to adopt an Equity Incentive Plan. Details of the plan will be developed with the input of the Board of Directors along with the then established compensation committee.

 

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

 

Under the supervision and with the participation of our senior management, including our Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15I and 15d-15(e) under the Exchange Act. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded as of the Evaluation Date that our disclosure controls and procedures were not effective such that the information relating to us required to be disclosed in our Securities and Exchange Commission (“SEC”) reports (i) is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and (ii) is accumulated and communicated to our management, including our Chief Executive Officer and chief financial officer, as appropriate to allow timely decisions regarding required disclosure. The Company’s former management abandoned all operations for many years, and only recently did the Company appoint new management to make filings with the SEC on behalf of the Company. As of December 31, 2022 we have concluded that our disclosure controls and procedures were not effective.

 

37

 

 

Management’s Annual Report on Internal Control over Financial Reporting

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rule 13a-15(f) under the Securities Exchange Act, as amended. Internal control over financial reporting is a process designed by, or under the supervision of, the Chief Executive Officer and Principal Accounting Officer and effected by our Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

 

The framework our management uses to evaluate the effectiveness of our internal control over financial reporting is based on the guidance provided by the Committee of Sponsoring Organizations (COSO) of the Treadway Commission in its 1992 report: INTERNAL CONTROL - INTEGRATED FRAMEWORK. Based on our evaluation under the framework described above, our management has concluded that our internal control over financial reporting was ineffective as of December 31, 2022 due to the same material weaknesses that rendered our disclosure controls and procedures ineffective. The Company’s internal control over financial reporting is not effective due to a lack of sufficient resources to hire a support staff in order to separate duties between different individuals. The Company lacks the appropriate personnel to handle all the varying recording and reporting tasks on a timely basis. The Company plans to address these material weaknesses as resources become available by hiring additional professional staff, such as a Chief Financial Officer, as funding becomes available, outsourcing certain aspects of the recording and reporting functions, and separating responsibilities. We have identified the following material weaknesses.

 

1. As of December 31, 2022, we did not maintain effective controls over the control environment. Specifically, we have not developed and effectively communicated to our employees the accounting policies and procedures. This has resulted in inconsistent practices. Further, the Board of Directors does not currently have any independent members and no director qualifies as an audit committee financial expert as defined in Item 407(d)(5)(ii) of Regulation S-K. Since these entity level programs have a pervasive effect across the organization, management has determined that these circumstances constitute a material weakness.

 

2. As of December 31, 2022, we did not maintain effective controls over financial statement disclosure. Specifically, controls were not designed and in place to ensure that all disclosures required were originally addressed in our financial statements. Accordingly, management has determined that this control deficiency constitutes a material weakness.

 

Because of these material weaknesses, management has concluded that the Company did not maintain effective internal control over financial reporting as of December 31, 2022, based on the criteria established in “INTERNAL CONTROL-INTEGRATED FRAMEWORK” issued by the COSO. Management believes that the material weaknesses set forth above did not have an effect on our financial results because the activity during this period was nominal. However, management believes that the lack of a functioning audit committee and the lack of a majority of outside Directors on our Board of Directors results in ineffective oversight in the establishment and monitoring of required internal controls and procedures, which could result in a material misstatement in our financial statements in future periods. Management to further recruit qualified individuals, establish an audit committee, appoint independent directors, and ensure that board members have current and pertinent financial experience.

 

Change In Internal Control Over Financial Reporting

 

There were no changes in our internal control over financial reporting that occurred during our last fiscal year that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

Attestation Report of the Registered Public Accounting Firm

 

This annual report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our registered public accounting firm pursuant to temporary rules of the SEC that permit us to provide only management’s report in this annual report.

 

38

 

 

EXECUTIVE COMPENSATION

 

Employment Agreements

 

There are no employment agreements were in place. It is the intention of ownership to rely on the recommendation of the compensation committee to be appointed by the Board of Directors.

 

Outstanding Equity Awards at Fiscal Year-End

 

There were no outstanding equity awards held by our officers as of June 30, 2023.

 

Board of Directors

 

All directors hold office until the next annual meeting of shareholders and until their successors have been duly elected and qualified, or until their earlier death, resignation or removal. Officers are elected by and serve at the discretion of the board.

 

Our directors are reimbursed for expenses incurred by them in connection with attending board meetings and receive a monthly honorarium for serving on the board.

 

Compensation committee

 

The board of directors plans to establish a compensation committee as required by Sarbanes-Oxley Act. The committee will make compensation recommendation to the board.

 

2023 Equity Incentive Plan

 

Our Board of Directors and stockholders owning a majority of our outstanding shares plans to adopt an Equity Incentive Plan following the AGSS Merger. Details of the plan will be developed with the input of the Board of Directors along with the then established compensation committee.

 

Executive Officer Compensation

 

The following table sets forth the annual compensation for years ended December 31, 2022, and 2021 to our Officers.

 

Executive positions and salaries:

 

Name and Position   Year   Salary
($)
    Bonus
($)
    Other
Compensation
($)
    Total
($)
 
Lawrence Garcia - CEO   2022     146,551       -       21,279       167,830  
    2021     129,190       -       19,789       148,979  
                                     
Michael Goossen, CPA - CFO(1)   2022     134,250       -       650       134,900  
    2021     98,423       -       -       98,423  

 

 
(1) Mr. Goossen was an independent consultant until August 1, 2022.

 

Director Compensation

 

Our directors are reimbursed for expenses incurred by them in connection with attending board meetings and receive a monthly honorarium for serving on the board.

 

39

 

 

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
RELATED STOCKHOLDER MATTERS.

 

The following table sets forth certain information regarding beneficial ownership of our common stock as of August 14, 2023 by (i) each person (or group of affiliated persons) who is known by us to own more than five percent of the outstanding shares of our common stock, (ii) each director, executive officer and director nominee, and (iii) all of our directors, executive officers and director nominees as a group. As of August 14, 2023, we had 93,418,292 shares of common stock issued and outstanding.

 

Beneficial ownership is determined in accordance with SEC rules and generally includes voting or investment power with respect to securities. All share ownership figures include shares of our Common Stock issuable upon securities convertible or exchangeable into shares of our Common Stock within sixty (60) days of August 14, 2023 which are deemed outstanding and beneficially owned by such person for purposes of computing his or her percentage ownership, but not for purposes of computing the percentage ownership of any other person.

 

Name and Address  

Beneficial

Ownership

   

Percentage
of Class(1)

 
Lawrence Garcia     80,578,125       86,26 %
Michael Goossen, CPA     2,671,875       2.86 %
Douglas Anderson*     3,515,625       3.76 %
General Russel Honoré#     562,500       .6 %
All officers/directors as a group (4 people)     87,328,125       93.48 %

 

 
(1) Based on 93,418,292 shares of common stock outstanding as of August 14, 2023. There are no shares of Preferred stock outstanding.
* Appointed on December 9, 2022.
# Appointed on March 23, 2023.

 

40

 

 

CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

 

Certain Relationships and Related Transactions

 

Notes Payable – Related Party

 

On July 7, 2022, Ameriguard entered into a buyout agreement with its minority shareholder Lillian Flores. The value of Ameriguard to be used for the buyout agreement was calculated using an independent evaluation service which determined the December 31, 2020 value to be approximately $6,400,000. As a 45% owner, Mrs. Flores’ share was approximately $2,885,000. After negotiation of some additional funds due Mrs. Flores, the final buyout amount was approximately $3,385,000. A 5-year promissory note was executed.

 

Director Independence

 

We currently have two independent directors as that term is defined in Rule 4200 of Nasdaq’s listing standards.

 

41

 

 

DESCRIPTION OF SECURITIES

 

Authorized Capital Stock

 

Our authorized capital stock consists of five hundred million (500,000,000) shares of common stock, par value $0.001 per share. Immediately after giving effect to the AGSS Merger and related transactions, there were 93,417,302 shares of our common stock issued and outstanding.

 

Common Stock

 

The following is a summary of the material rights and restrictions associated with our common stock.

 

The holders of our common stock currently have (i) equal ratable rights to dividends from funds legally available therefore, when, as and if declared by the Board of Directors of the Company; (ii) are entitled to share ratably in all of the assets of the Company available for distribution to holders of common stock upon liquidation, dissolution or winding up of the affairs of the Company (iii) do not have preemptive, subscription or conversion rights and there are no redemption or sinking fund provisions or rights applicable thereto; and (iv) are entitled to one non-cumulative vote per share on all matters on which stock holders may vote. Please refer to the Company’s Articles of Incorporation, Bylaws and the applicable statutes of the State of Nevada for a more complete description of the rights and liabilities of holders of the Company’s securities.

 

Preferred Stock

 

There are no shares of Preferred stock outstanding. The 10,000,000 authorized and designated Series A-1 Preferred Stock (i) have preferred equal ratable rights to dividends from funds legally available therefore, when, as and if declared by the Board of Directors of the Company; (ii) hold distribution preferences upon liquidation, dissolution or winding up of the affairs of the Company (iii) convert into seventy-two (72) shares, for each share of Series A-1 Preferred Stock, at the discretion of the holder; and (iv) are entitled to seventy-two (72) votes per share of Series A-1 Preferred Stock on all matters on which stock holders may vote.

 

Following the AGSS Merger there were and are no Preferred Stock outstanding. Any future issuance will be at the discretion of the Board of Directors.

 

Dividend Policy

 

We have never declared or paid any cash dividends on our common stock. We currently intend to retain future earnings, if any, to finance the expansion of our business. As a result, we do not anticipate paying any cash dividends in the foreseeable future.

 

Transfer Agent

 

The transfer agent for our common stock is VStock Transfer, and its telephone number is (727) 289-0010.

 

Trading Information

 

Our common stock is currently approved for quotation on OTC Markets (otcmarkets.com) under the symbol “AGSS”.

 

42

 

 

MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

 

Market Information

 

AGSS’s common stock is quoted through the over-the-counter market on the OTC Market Pink under the symbol “AGSS.” There is a limited trading of AGSS’s common stock. The following table sets forth high and low sales prices of AGSS common stock for each fiscal quarter for the last two fiscal years as reported by the OTC Markets., based on closing prices. The prices in the table reflect inter-dealer prices, without retail markup, markdown or commission and may not represent actual transactions.

 

    High     Low  
Third Quarter ended September 30, 2021   $ 4.39     $ 0.50  
Fourth Quarter ended December 31, 2021   $ 4.39     $ 0.50  
                 
First Quarter ended March 31, 2022   $ 4.39     $ 0.50  
Second Quarter ended June 30, 2022   $ 5.34     $ 1.70  
Third Quarter ended September 30, 2022   $ 3.00     $ 1.25  
Fourth Quarter ended December 31, 2022   $ 3.38     $ 1.00  
                 
First Quarter ended March 31, 2023   $ 3.35     $ 1.975  
Second Quarter ended June 30, 2023   $ 1.7     $ 0.52  

 

As of August 14, 2023, there were approximately 95 record holders of AGSS common stock, not including shares held in “street name” in brokerage accounts. As of August 14, 2023, there were 93,418,292 shares of AGSS’s common stock issued and outstanding on record.

 

Dividends

 

AGSS has not declared or paid any cash dividends on its common stock.

 

Transfer Agent and Registrar

 

The transfer agent and registrar for AGSS’s common stock VStock Transfer LLC, 18 Lafayette Place, Woodmere, NY 11598, telephone number 212-828-8436.

 

Repurchases of Our Securities

 

None of the shares of our common stock were repurchased by the Company during the fiscal year ended December 31, 2022.

 

Sales of Our Unregistered Securities during 2022 Not Previously Disclosed

 

None

 

43

 

 

Penny Stock Considerations

 

Our common stock will be deemed to be “penny stock” as that term is generally defined in the Securities Exchange Act of 1934 to mean equity securities with a price of less than $5.00. Our shares thus will be subject to rules that impose sales practice and disclosure requirements on broker-dealers who engage in certain transactions involving a penny stock.

 

Under the penny stock regulations, a broker-dealer selling a penny stock to anyone other than an established customer or accredited investor must make a special suitability determination regarding the purchaser and must receive the purchaser’s written consent to the transaction prior to the sale, unless the broker-dealer is otherwise exempt. Generally, an individual with a net worth more than $1,000,000 or annual income exceeding $100,000 individually or $300,000 together with his or her spouse is considered an accredited investor. In addition, under the penny stock regulations the broker-dealer is required to:

 

Deliver, prior to any transaction involving a penny stock, a disclosure schedule prepared by the SEC relating to the penny stock market, unless the broker-dealer or the transaction is otherwise exempt.

 

Disclose commissions payable to the broker-dealer and our registered representatives and current bid and offer quotations for the securities.

 

Send monthly statements disclosing recent price information pertaining to the penny stock held in a customer’s account, the account’s value and information regarding the limited market in penny stocks; and

 

Make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction, prior to conducting any penny stock transaction in the customer’s account.

 

Because of these regulations, broker-dealers may encounter difficulties in their attempt to buy or sell shares of our common stock, which may affect the ability of Belair or other holders to sell their shares in the secondary market and have the effect of reducing the level of trading activity in the secondary market. These additional sales practice and disclosure requirements could impede the sale of our common stock even if our common stock becomes publicly traded. In addition, the liquidity for our common stock may be decreased, with a corresponding decrease in the price of our common stock. Our shares are likely to be subject to such penny stock rules for the foreseeable future.

 

Reports to Stockholders

 

We have filed all necessary periodic reports, and other information with the SEC. We have provided annual reports to our stockholders containing audited financial statements.

 

CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

None

 

44

 

 

DISCLOSURE OF COMMISSION POSITION OF INDEMNIFICATION FOR SECURITIES ACT LIABILITIES

 

Our Bylaws, subject to the provisions of the Nevada Revised Statutes, contain provisions which allow the Company to indemnify any person against liabilities and other expenses incurred as the result of defending or administering any pending or anticipated legal issue in connection with service to us if it is determined that person acted in good faith and in a manner which he reasonably believed was in or not opposed to the best interest of the Company. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to our directors, officers and controlling persons, we have been advised that in the opinion of the Securities and Exchange Commission, such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore, unenforceable.

 

Forum Selection

 

The Company has selected the Eighth Judicial District Court of Clark County, Nevada, to be the sole and exclusive forum for each of the following: (a) any derivative action or proceeding brought in the name or right of the Corporation or on its behalf, (b) any action asserting a claim for breach of any fiduciary duty owed by any director, officer, employee or agent of the Corporation to the Corporation or the Corporation’s stockholders, (c) any action arising or asserting a claim arising pursuant to any provision of NRS Chapters 78 or 92A or any provision of the Articles of Incorporation or these By-laws or (d) any action asserting a claim governed by the internal affairs doctrine, including, without limitation, any action to interpret, apply, enforce or determine the validity of the Articles of Incorporation or these By-laws. Any person or entity purchasing or otherwise acquiring any interest in shares of capital stock of the corporation shall be deemed to have notice of and consented to this provision. Actions arising under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, shall not be governed by this provision and may be brought in any federal jurisdiction.

 

EXPERTS

 

Financial Auditors

 

Our most current audited consolidated financial statements for the years ending December 31, 2022 and December 31, 2021, are included in this prospectus have been so included in reliance on the reports of BF Borgers CPA PC), Lakewood, CO, independent public accountants, given on this firm’s authority as experts in auditing and accounting.

 

Legal Counsel Providing Legal Opinion

 

The validity of the issuance of the shares of common stock will be passed upon for the company by McMurdo Lawa Group, LLC. Counsel has additionally consented to his opinion being included as an exhibit to this filing. Additionally, counsel has consented to being named in the prospectus.

 

The legal counsel that passed their opinion on the legality of these securities is:

 

Matthew McMurdo, Esq.

McMurdo Law Group, LLC

1185 Avenue of the Americas, 3rd Floor

New York, NY 10036

 

45

 

 

WHERE YOU CAN FIND MORE INFORMATION

 

We have filed with the SEC a registration statement on Form S-1 (File Number 333-271200) under the Securities Act of 1933 regarding the shares of common stock offered hereby. This prospectus does not contain all the information found in the registration statement, portions of which are omitted as permitted under the rules and regulations of the SEC. For further information regarding us and the securities offered by this prospectus, please refer to the registration statement, including its exhibits and schedules. Statements made in this prospectus concerning the contents of any contract, agreement or other document filed as an exhibit to the registration statement are summaries of the terms of those documents. The registration statement of which this prospectus forms a part, including its exhibits and schedules, may be inspected and copied at the public reference room maintained by the SEC at 100 F Street, N.E., Washington, D.C. 20549. You may obtain information on the operation of the public reference room by calling the SEC at 1-800-SEC-0330.

 

The SEC maintains a web site on the Internet at www.sec.gov. Our registration statement and other information that we file with the SEC are available at the SEC’s website.

 

We make available to our stockholders annual reports (on Form 10-K) containing our audited consolidated financial statements and make available quarterly reports (on Form 10-Q) containing our unaudited interim consolidated financial information for the first three fiscal quarters of each of our fiscal years.

 

If you are a stockholder, you may request a copy of these filings at no cost by contacting us at:

 

Ameriguard Security Services, Inc.

5470 W. Spruce Avenue, Suite 102

Fresno, CA

Telephone number: (559) 271-5984

 

46

 

 

Financial Statements

 

Index to Financial Statements

 

    Page
Report of Independent Registered Public Accounting Firm   F-2
     
Balance Sheets as of December 31, 2022 and 2021   F-3
     
Statements of Operations for the Years Ended December 31, 2022 and 2021   F-4
     
Statement of Shareholders’ Deficit for the Two Years Ended December 31, 2022   F-5
     
Statements of Cash Flows for the Years Ended December 31, 2022 and 2021   F-6
     
Notes to the Financial Statements for the Years Ended December 31, 2022 and 2021   F-7

 

Condensed Consolidated Balance Sheets-June 30, 2023 and December 31,2022   F-13
     
Condensed Consolidated Statements of Income – for the Six Months ended June 30,2023 and 2022   F-14
     
Condensed Consolidated Statements of Stockholders Equity for the six months ended June 30, 2023   F-15
     
Condensed Consolidated Statements of Cash Flows- for the six months ended June 30,2023 and 2022   F-16
     
Notes to Condensed Consolidated Financial Statements   F-17

 

F-1

 

 

Report of Independent Registered Public Accounting Firm

 

To the shareholders and the board of directors of Ameriguard Security Services, Inc.

 

Opinion on the Financial Statements

 

We have audited the accompanying consolidated balance sheets of Ameriguard Security Services, Inc. as of December 31, 2022 and 2021, the related statements of operations, stockholders’ equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States.

 

Basis for Opinion

 

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

 

Critical Audit Matter

 

Critical audit matters are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.

 

We determined that there are no critical audit matters.

 

/s/ BF Borgers CPA PC (PCAOB ID 5041)

We have served as the Company’s auditor since 2021

Lakewood, CO

March 30, 2023

 

F-2

 

 

AmeriGuard Security Services, Inc.

CONSOLIDATED BALANCE SHEETS

 

                 
    December 31,     December 31,  
    2022     2021  
Assets                
Current Assets                
Cash   $ 1,227,654     $ 2,129,801  
Accounts receivable, net (note 1)     1,869,268       2,215,197  
Prepaid insurance     110,829       107,884  
Related Party Receivable (note 3)     -       -  
Total Current Assets     3,207,751       4,452,882  
                 
Other Non-Current Assets                
Fixed assets, net depreciation (note 4)     298,806       132,802  
Operating Lease     302,695       -  
Total Non-Current Assets     601,501       132,802  
Total Assets   $ 3,809,252     $ 4,585,684  
                 
Liabilities                
Current Liabilities                
Accounts payable   $ 761,515     $ 418,342  
Accrued Interest Due (note 6)     49,035       -  
Accrued Payroll     737,143       657,741  
Payroll liability - Pension (note 5)     453,965       616,579  
Current portion of notes payable (note 6)     719,563       127,615  
Total Current Liabilities     2,721,221       1,820,277  
                 
Long Term Liabilities                
Long term portion of notes payable (note 6)     2,782,784       780,845  
Operating Lease     294,387       -  
Total Liabilities     5,798,392       2,601,122  
                 
Stockholders’ equity                
Common stock, $.001 par value, 94,471,302 shares issued and outstanding at December 31, 2022 and 2021 (Note 7)     158,346       158,346  
Retained earnings/(deficit)     (2,147,486 )     1,816,216  
Total Stockholders’ Equity     (1,989,140 )     1,974,562  
Total Liabilities and Stockholders’ Equity   $ 3,809,252     $ 4,575,684  

 

See accompanying notes to financial statements

 

F-3

 

 

AmeriGuard Security Services, Inc.

CONSOLIDATED STATEMENTS OF OPERATIONS

 

                 
    For the
Years Ended
 
    December 31,     December 31,  
    2022     2021  
Revenue                
Security Services   $ 24,643,096     $ 22,418,328  
Other related income     304,305       24,185  
Total Revenue     24,947,401       22,442,513  
                 
Cost of Services                
Salaries and related taxes     15,030,738       13,873,241  
Employee benefits     3,052,774       2,915,322  
Sub-Contractor payments     3,467,391       3,433,959  
Guard training     202,826       222,298  
Vehicles and equipment expenses     194,889       184,176  
Total Cost of Services     21,948,618       20,628,996  
                 
Gross Margin     2,998,783       1,813,517  
                 
Operating Expenses                
Salaries, payroll taxes and benefits     1,161,982       365,433  
Vehicle expense     433,424       295,054  
Professional services     361,314       318,442  
Cellular services     106,382       112,140  
General liability insurance     87,119       111,287  
Advertising and marketing     128,544       77,349  
General and administrative expenses     645,268       294,062  
Loan interest     105,826       59,439  
Depreciation expense     42,927       52,273  
Total Operating Expenses     3,072,786       1,685,479  
                 
Net Income/(Loss) from Operations     (74,003 )     128,038  
                 
Other Income (Expenses)                
Other Income     -       -  
Other (Expense)     (344,105 )     -  
Total Other Income     (344,105 )     -  
                 
Net Income/(loss) before Income Taxes     (418,108 )     128,038  
                 
Income tax expense     10,350       33,923  
                 
Net Income/(loss)   $ (428,458 )   $ 94,115  
                 
Net Income/(loss) per Common Share - Basic and Diluted   $ (0.0046 )   $ 0.0010  
                 
Weighted Average Number of Common Shares Outstanding - Basic and Diluted     93,417,302       93,417,302  

 

See accompanying notes to financial statements

 

F-4

 

 

AmeriGuard Security Services, Inc.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

FOR THE YEARS ENDED December 31, 2021 and 2022

 

 

                                                         
    Common Stock     Preferred Stock     Additional
Paid-In
    Stockholders’     Total
Stockholders’
 
    Shares     Amount     Shares     Amount     Capital     Equity     Equity  
Balance, December 31, 2020     2,743,302     $ 69,346       675,000     $ 10,000     $ 9,976,045     $ (7,191,705 )   $ 2,863,685  
Owner draws (pre-merger)     -       -                               (473,238 )     (473,238 )
Equity Merger     89,999,000       89,000               (10,000 )     (579,000 )             (500,000 )
Cancelation and conversion of preferred stock     675,000               (675,000 )                                
Net Income for year ended December 31, 2021                                             94,115       94,115  
Balance, December 31, 2021     93,417,302     $ 158,346       -     $ -     $ 9,397,045     $ (7,570,828 )   $ 1,984,562  
Owner draws (pre-merger)                                             (62,824 )     (62,824 )
Shareholder buyout                                     (3,384,950 )           (3,384,950 )
Retained Deficit of merger with related entity                                             (97,470 )     (97,470 )
Net (Loss) for year ended December 31, 2022             -                -                (428,458 )   (428,458 )
Balance, December 31, 2022     93,417,302     $ 158,346       -     $ -     $ 6,012,095     $ (8,159,580 )   $ (1,989,140 )

 

See accompanying notes to financial statements

 

F-5

 

 

AmeriGuard Security Services, Inc.

STATEMENTS OF CASH FLOWS

 

                 
    For the Years Ended  
    December 31,     December 31,  
    2022     2021  
Cash Flows from Operating Activities                
Net Income/(Loss)   $ (428,458 )   $ 94,115  
Adjustment to reconcile net loss from operations:                
Changes in Operating Assets and Liabilities                
Accounts receivable, net     345,929       (23,372 )
Prepaid insurance     (2,945 )     (32,949 )
Accounts payable     343,172       33,742  
Accrued Interest     49,035       -  
Accrued Payroll     79,402       75,693  
Payroll liability - Pension     (162,614 )     77,237  
Depreciation     42,927       52,273  
Operating lease liability     (79,358 )     -  
Operating lease asset     71,049       -  
Net Cash (Used)/provided in Operating Activities     258,139       276,739  
                 
Cash Flows (Used)/Provided from Investing Activities                
Purchase of fixed assets     (6,043 )     (24,552 )
Building improvements     (224,132 )     -  
Purchase of Shell Corporations - AGSS     -       (500,000 )
Net Cash Used by Investing Activities     (230,175 )     (524,552 )
                 
Cash (Used)/Provided from Financing Activities                
Secure Transportation vehicle loan     -       21,500  
Payment for Shareholder buyout     (686,990.00 )     -  
Loan principle payments     (180,298 )     (227,097 )
Owner distributions     (62,824 )     (473,238 )
Net Cash Provided by Financing Activities     (930,112 )     (678,835 )
                 
Net Increase (Decrease) in Cash     (902,148 )     (926,648 )
Cash at Beginning of Period     2,129,801       3,056,449  
Cash at End of Period   $ 1,227,653     $ 2,129,801  
                 
Supplemental Cash Flow Information:                
Income Taxes Paid   $ 10,350     $ 33,923  
Interest Paid   $ 105,826     $ 59,439  
Supplemental disclosure of non-cash financing activities:                
Shareholder Loan   $ 3,384,950          
Operating leases - right of use asset   $ 302,695          
Operating leases - lease liability   $ 294,387          

 

See accompanying notes to financial statements

 

F-6

 

 

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

 

AmeriGuard Security Services, Inc. (the Company), was incorporated on November 14, 2002, with an S-Corp tax election. The corporation was incorporated with the issuance of 1,000 shares of no-par value stock held by Lawrence Garcia, President and CEO with 550 shares and Lillian Flores, VP of Operations with 450 shares. The Company provides armed guard services as a federal contractor with licenses in 5 states and provides commercial guard services in California.

 

On July 7, 2021, the Company, entered into an agreement to gain 100% control of Health Revenue Assurance Holdings, Inc (HRAA) a public corporation, incorporated in Nevada, by the purchase of 10,000,000 shares of Preferred A-1 Stock from the seller, Custodian Ventures LLC. The purchase of HRAA allowed the Company to begin plans to consummate a reverse merger with HRAA becoming a wholly owned subsidiary of a public company. In March of 2022, a Certificate of Amendment was filed with the Nevada Secretary of State, changing the name of HRAA, to Ameriguard Security Services, Inc. (AGSS). Shortly thereafter, a stock name and ticker change report was filed with the SEC and the stock ticker of HRAA was changed to AGSS.

 

On December 9, 2022, the Company executed the reverse merger agreement and became the subsidiary of AGSS. From that point forward, the financial statement filings will be the consolidation of Ameriguard Security Services, Inc, a Nevada company with Ameriguard Security Services, Inc. a California company.

 

The Company’s accounting year end is December 31.

 

Basis of Presentation

 

These financial statements are presented in United States dollars and have been prepared in accordance with United States generally accepted accounting principles.

 

Risks and Uncertainties

 

The risks and uncertainties described below may not be the only ones we are or may face in the future. If any of the following do occur, our business, financial condition or results of operations could be materially adversely affected.

 

The company receives over 90% of its total revenue from four Federal contracts as described in Note 9 below. These contracts have specific terms, typically five years with the opportunity for extension, but there are no assurances they will be extended. Although we have had several extended in the past, there is no guarantee this will again happened in the future. However, there are significant direct expenses for each contract that also are removed from operations at the end of a contract. As a result, the revenue lost from a completed contract does not affect the bottom-line profits in an amount equal to the revenue lost. The actual net income impact depends on the contract.

 

The process required to acquire a government contract takes several months to complete prior to delivery of the proposal to the contracting agency. Due to the time span required to prepare a proposal and wining the contract is not guaranteed, the company maintains a department of individuals who monitor and write proposals for all government contracts that become open for bid on a continuing basis. It is important to the company that new contracts are acquired consistently to maintain and grow annual revenue.

 

Other risks to operations consist of State and Federal regulations, accelerating inflation, and overall business environment issues we cannot foresee.

 

F-7

 

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Use of Estimates

 

In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, along with the collectability of some receivables from customers.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. On December 31, 2022, and December 31, 2021, the Company had cash and cash equivalents totaling $1,227,654 and $2,129,801 respectively.

 

Accounts Receivable

 

We record accounts receivable at net realizable value. This value includes an appropriate allowance for estimated uncollectible accounts to reflect any loss anticipated on the accounts receivable balances and is charged to other bad debt expense. We calculate this allowance based on our history of write-offs, the level of past-due accounts based on the contractual terms of the receivables, and our relationships with, and the economic status of, our customers. With over ninety percent of year end accounts receivable balance from Federal contracts that require payment, and the uncollectable amount historically has been less than 1%. As of December 31, 2022, and 2021, an allowance for estimated uncollectible accounts was determined to be unnecessary.

 

Property and Equipment

 

Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment is retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses other depreciation methods (generally accelerated) for tax purposes where appropriate. The estimated useful life for Machinery and Equipment, and Vehicles is 5 years, with Leasehold improvements useful life is 10 Years.

 

Operating Leases

 

In February 2016, FASB ASU No. 2016-02 established ASC Topic 842, Leases, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. Effective December 31, 2022, we have implemented ASU No. 2016-02 and booked the operating lease asset and the related liability.

 

We have leased vehicles that are classified as operating leases per the guidelines. The Balance Sheet & the Statement of Cash Flows reflects the implementation of this guideline. The Balance Sheet reflects the asset and liability of the operating leases. The Statement of Cash Flows reflects the implementation of this guideline as transactions that affected cash flow and non-cash financing activities. The change in the operating lease liability of ($79,358) is the difference of the total liability of our lease ($373,745) from the total liability balance of ($294,387) as of December 31,2022. The ($79,358) change in the operating lease liability consists of the total lease payments made for the year. The change in operating lease asset of $71,049 is the net of the total asset of the leases ($373,745) and the remaining asset balance of $302,695 as of December 31, 2022. The $71,049 is the amortization of the lease for the year.

 

F-8

 

 

Net Income/(Loss) per Share

 

Net income/(loss) per common share is computed by dividing net income or loss by the weighted average common shares outstanding during the period as defined by Financial Accounting Standards, ASC Topic 260, “Earnings per Share”. Basic earnings/(loss) per common share (“EPS”) calculations are determined by dividing net income/(loss) by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.

 

Revenue Recognition

 

We recognize revenue when the Invoice for contracted services is issued as stipulated by the contract. Other services provided are recognized at the time the service is provided. Ninety eight percent of revenues are billed monthly and recognized in the month the services were provided. Refunds and returns, which are minimal, are recorded as a reduction of revenue. The Company has not recorded a reserve for returns on December 31, 2022, or 2021 since it does not believe such returns will be material.

 

Fair Value of Financial Instruments

 

The Company applies the accounting guidance under Financial Accounting Standards Board (“FASB”) ASC 820-10, “Fair Value Measurements”, as well as certain related FASB staff positions. This guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance.

 

The guidance also establishes a fair value hierarchy for measurements of fair value as follows:

 

  Level 1 - quoted market prices in active markets for identical assets or liabilities.
     
  Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
     
 

Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

The carrying amount of the Company’s financial instruments approximates their fair value as of December 31, 2021 and December 31, 2022, due to the short-term nature of these instruments.

 

NOTE 3 – RELATED PARTY RECEIVABLE

 

On July 7, 2021, the company has entered into an agreement to purchase 100% of the Preferred A-1 Stock of Health Revenue Assurance Holdings, Inc. a SEC registered company for $500,000. In March 2022, Health Revenue Assurance Holdings, Inc. name was changed to Ameriguard Security Services Inc. (AGSS). On December 9, 2022, we signed the definitive merger agreement initiating a reverse merger with AGSS, resulting in the Company becoming a 100% owned subsidiary of AGSS. Prior to the merger, the Company funded the operational expenses of AGSS and treated these expenses as related party expenses. These expenses we eliminated when the two companies were consolidated for the financial statement presentation.

 

The receivable balances on December 31, 2022, and 2021 were $57,971 and $10,596 respectively. Balances adjusted to zero as a result of consolidation.

 

F-9

 

 

NOTE 4 – FIXED ASSETS

 

Fixed assets consist of the following on December 31, 2022, and 2021:

 

               
    2021     2020  
Leasehold Improvements     224,132       -  
Machinery and Equipment     278,551       246,974  
Vehicles     110,274       131,775  
Total Fixed Assets     612,957       378,749  
Accumulated Depreciation     (314,151 )     (245,947 )
Fixed Assets, Net   $ 298,806     $ 132,802  

 

NOTE 5 – PAYROLL LIABILITY – PENSION

 

The company offers various pension plans to employee groups based on location of employment. Corporate office employees and guards have an option to participate in a 401K sponsored by the company with a matching program up to 5% of employee salary. Federal contracts have union agreements that define the pension calculation and due dates. It is the responsibility of the company to calculate the pension benefit amount each month and contribute the amount due to the plan designated. The pension balances due on December 31, 2022, and 2021 for all plans was $453,965 and $616,579 respectively.

 

NOTE 6 – NOTES PAYABLE

 

In June 2020, AmeriGuard Security Services, Inc. received an SBA Loan through Fresno First Bank in the amount of $1,080,000 that was used to close out the Citibank loan in the amount of $312,339 with the remaining balance after expenses held in reserve. The SBA loan is a 10-year loan with monthly principal and interest payments. Interest rate is variable at prime rate plus 2.75%, adjusted every calendar quarter. Interest rate on December 31, 2022, and 2021 was 9% and 4.01% respectively. Balance remaining on the SBA loan was $804,387 and $888,845 as of December 31, 2022, and 2021 respectively.

 

In January 2020, the Company entered into a financing agreement with Master Security Company for the purchase of vehicles, guns, and guard equipment for the National Institute of Health USEPA contract which began May 2020. The principal financed was $150,000, with interest of 4% for a term of 21 months. Resulting in a monthly principal and interest payment of $7,406. Balance remaining in the amount of $0 and $7,729 as of December 31, 2022, and 2021 respectively.

 

In December 2021, the Company entered into a financing agreement with Secure Transportation Inc. for the purchase of three used vehicles in the amount of $21,500. Note requires 12 equal payments of $1,900 with a calculated interest rates of 5% with the first payment December 15, 2021. Balance remaining in the amount of $0 and $19,615 as of December 31, 2022, and 2021 respectively.

 

On July 7, 2022, the Company entered into a buyout agreement with a shareholder Lillian Flores. The total buyout amount was $3,384,950 representing 45% of the calculated business value as of December 31, 2020. Following the initial payment of $686,990, the company agreed to make 4 equal installments of principal and interest of $739,508 each December 31, starting 2023. Interest is calculated at a fixed rate of 3.110% compounded semi-annually. The company has accrued interest on December 31, 2022, of $49,035. Balance remaining in the amount of $2,697,960.

 

The following schedule details the loans active as of December 31, 2022, and 2021:

 

                 
    2022     2021  
Current Portion:                
Notes and loans payable   $ 719,563     $ 127,615  
Total Current Portion     719,563       127,615  
Long term Portion:                
Notes and loans payable     2,782,784       780,845  
Total Long-term Portion     2,782,784       780,845  
    $ 3,502,347     $ 908,460  

 

F-10

 

 

NOTE 7 – STOCKHOLDERS’ EQUITY

 

On December 9, 2022, the Company executed a reverse merger agreement with AGSS resulting in significant adjustments to the equity section of both companies. The result of the merger was AGSS became the sole owner of the Company. Although the merger is dated December 9, 2022, for financial statement presentation purposes, we have presented the Equity Section as if the merger occurred in 2021.

 

The first significant impact on stockholders’ equity was the issuance of 90,000,000 AGSS shares to the shareholders of Ameriguard Security Services, Inc (the Company) in exchange for 1000 shares of the Company, adding a net increase in common shares outstanding of 89,999,000. Next was the cancelation and conversion of series 675,000 A-1 preferred shares held by AGSS on December 31, 2020. The final result in the total number of shares outstanding is 93,417,302.

 

The next part of stockholder’s equity impacted was Additional Paid-in Capital. The impact was a reduction of Paid-in Capital of $579,000. This reduction was caused by an $89,999 impact of issuing new shares, a $10,000 impact form the cancelation of preferred shares and finally the $500,000 cost of the Company’s purchase of AGSS, formally Heath Revenue Assurance Holdings, Inc.

 

There were two other transactions that impacted stockholders’ equity that occurred to the Company’s equity section relating to owner draws and the merger with a related company. As a part of the normal activity of the privately held Company, an S-Corp, shareholders were distributed funds accounted for as Owner Draws. The owner draw accounts were used primarily for taxes paid by the shareholders due to profits of the S-Corp being transferred to their personal returns along with some personal expenses and personal cash needs. For 2021, there was approximately $105,000 posted as Owner draw from historical balances of related party receivables. As part of the preparation for merger these inter-company balances were removed through the owner draw accounts. Total owner draw amounts were $473,238 and $62,824 for December 31, 2022, and 2021 respectively.

 

NOTE 8 – COMMITMENTS AND CONTINGENCIES

 

The company has a multiple vehicle lease agreement with Enterprise Leasing. As of December 31, 2022, the company had 19 vehicles under lease. The lease agreement includes maintenance services along physical damage insurance. The term of the lease agreement varies based on the date vehicle were leased and the respective terms for each vehicle. The master lease is updated annually and requires annual internal financial reports and company tax return.

 

NOTE 9 – CONCENTRATION OF SALES

 

The company generated approximately $24,600,000 and $22,100.000 in guard service revenue for the years 2022 and 2021 respectively. Of the total guard service revenue, approximately 87% was earned from four federal contracts operated by the company. The contracts and their respective terms are as follows:

 

  Social Security Administration, NSC   -

September 2022 through September 2027

Annual Revenue of approx. $3.145M

           
  Social security Administration, SSC   -

June 2022 through June 2027

Annual Revenue of approx. $4.932M

           
  Social Security Administration, WBDOC   -

June 2021 through July 2026

Annual Revenue of approx. $5.838M

           
  National Institute of Health- EPA   -

May 2020 through March 2023

Annual Revenue of approx. $7.514M

 

F-11

 

 

NOTE 10 – LITIGATION AND CLAIMS

 

As of December 31, 2022, there was one employment issue pending. The issue involves a terminated employee alleging discrimination and wrongful termination. A lawsuit has not been filed only a demand letter has been presented. Management has been working with the attorneys to find a reasonable settlement to this dispute without going to trial. After several months of discussion and negotiation it appears that the complaint will be settled for $23,000. It is anticipated that an agreement may be reached by the end of March 2023.

 

Per Attorney letters received there are no other pending cases or legal matters.

 

NOTE 11 – INCOME TAXES

 

Prior to the merger the Company had elected, with the consent of its stockholders, to be treated as an S Corporation under the Internal Revenue Code. In lieu of corporate income taxes, the stockholders of an S Corporation are taxed on their proportionate share of the Company’s income. As a result of the merger on December 9, 2022, the S Corporation status ends, and the consolidated 2022 tax return will be filed as a standard corporation. However, due to the losses incurred during the tax year ending 2022, there will be no tax liability for 2022. Therefore, no provision for income taxes has been included in the accompanying financial statements.

 

NOTE 12 – SUBSEQUENT EVENTS

 

On March 22, 2023, The Company was notified by the Contracting Officer of National Institute of Health-EPA our contract with them was not continuing and they were invoking the 45 days cancelation clause in the contract. As a result, the company will transition the closure of the contract on or about April 30, 2023. This will reduce on our annual revenue in the amount of approximately $5,122,000 in 2023, along with direct expenses that will be reduced by $4,650,000.

 

On March 23, 2023, the board of directors approved the purchase of TransportUS, Inc. While the Company explored the purchase of TransportUS, Inc., owned by Lawrence Garcia, the board of directors has determined, following due diligence, that the financial statements of TransportUS, Inc. are not in a form that can be audited under US GAAP. We have therefore abandoned such undertaking for the foreseeable future.

 

F-12

 

 

AmeriGuard Security Services, Inc.

CONSOLIDATED BALANCE SHEETS

 

                 
    June 30,     December 31,  
    2023     2022  
Assets                
Current Assets                
Cash   $ 2,990,014     $ 1,227,654  
Accounts receivable, net (note 1)     1,408,266       1,869,268  
Prepaid insurance     132,045       110,829  
Related Party Receivable (note 3)     -       -  
Total Current Assets     4,530,325       3,207,751  
                 
Other Non-Current Assets                
Fixed assets, net depreciation (note 4)     288,477       298,806  
Operating Lease     302,695       302,695  
Total Non-Current Assets     591,172       601,501  
Total Assets   $ 5,121,497     $ 3,809,252  
                 
Liabilities                
Current Liabilities                
Accounts payable   $ 1,172,116       761,515  
Accrued Interest Due (note 6)     91,635       49,035  
Accrued Payroll     732,364       737,143  
Payroll liability - Pension (note 5)     345,140       453,965  
Current portion of notes payable (note 6)     719,563       719,563  
Total Current Liabilities     3,060,818       2,721,221  
                 
Long Term Liabilities                
Long term portion of notes payable (note 6)     2,746,075       2,782,784  
Operating Lease     294,387       294,387  
Total Liabilities     6,101,280       5,798,393  
                 
Stockholders’ equity                
Common stock, $.001 par value, 94,471,302 shares issued and outstanding at June 30, 2023 and 2022     158,346       158,346  
Retained (deficit)     (1,138,129 )     (2,147,486 )
Total Stockholders’ Deficit     (979,783 )     (1,989,140 )
Total Liabilities and Stockholders’ Equity   $ 5,121,497     $ 3,809,252  

 

See accompanying notes to financial statements

 

F-13

 

 

AmeriGuard Security Services, Inc.

CONSOLIDATED STATEMENTS OF OPERATIONS

For the Six Months Ending June 30, 2023 and 2022

 

                 
    2023     2022  
Revenue                
Security Services   $ 11,068,409     $ 11,751,908  
Other related income     117,389       115,974  
Total Revenue     11,185,798       11,867,882  
                 
Cost of Services                
Salaries and related taxes     7,675,360       7,205,687  
Employee benefits     1,566,148       1,496,612  
Sub-Contractor payments     1,331,446       1,703,987  
Guard training     104,041       111,985  
Vehicles and equipment expenses     106,785       99,652  
Total Cost of Services     10,783,780       10,617,923  
                 
Gross Margin     402,018       1,249,959  
                 
Operating Expenses                
Salaries, payroll taxes and benefits     836,457       470,077  
Vehicle expense     192,693       226,741  
Professional services     249,266       188,226  
Cellular services     58,492       53,870  
General liability insurance     108,088       51,108  
Advertising and marketing     60,097       53,852  
General and administrative expenses     430,810       262,573  
Loan interest     97,862       24,628  
Depreciation expense     18,834       22,188  
Total Operating Expenses     2,052,600       1,353,263  
                 
Net Income/(Loss) from Operations     (1,650,582 )     (103,304 )
                 
Other Income (Expenses)                
Other Income     3,302,312       23,982  
Other (Expense)     (642,373 )     (170,935 )
Total Other Income (Expense)     2,659,939     (146,953 )
                 
Net Income/(loss) before Income Taxes     1,009,357       (250,257 )
                 
Income tax expense     -       -  
                 
Net Income/(loss)   $ 1,009,357     $ (250,257 )
                 
Net Income/(loss) per Common Share - Basic and Diluted   $ 0.0108     $ (0.0027 )
                 
Weighted Average Number of Common Shares Outstanding - Basic and Diluted     93,417,302       93,417,302  

 

See accompanying notes to financial statements

 

F-14

 

 

AmeriGuard Security Services, Inc.

CONSPIDATED STATEMENTS OF STOCKHOLDERS’ DEFICIT

For the Six Months Ending June 30, 2023

 

                                                         
    Common Stock     Preferred Stock     Additional
Paid-In
    Stockholders’     Total
Stockholders’
 
    Shares     Amount     Shares     Amount     Capital     Equity     Equity  
Balance, December 31, 2022     93,417,302     $ 158,346       -     $ -     $ 6,012,095     $ (8,159,580 )   $ (1,989,140 )
                                                         
Net Income for the period             -                -        -        1,009,357       1,009,357  
                                                         
Balance, June 30, 2023     93,417,302     $ 158,346       -     $ -     $ 6,012,095     $ (7,150,223 )   $ (979,783 )

 

See accompanying notes to financial statements

 

F-15

 

 

AmeriGuard Security Services, Inc.

STATEMENTS OF CASH FLOWS

 

                 
    For the
Six Months Ending
 
    June 30,     June 30,  
    2023     2022  
Cash Flows from Operating Activities                
Net Income/(Loss)   $ 1,009,357     $ (250,257 )
Adjustment to reconcile net loss from operations:                
Changes in Operating Assets and Liabilities                
Accounts receivable, net     461,002       (121,650 )
Prepaid insurance     (21,215 )     (9,171 )
Depreciation     18,834       47,465  
Accounts payable     405,822       329,744  
Accrued Interest     42,600       -  
Payroll liability - Pension     (108,825 )     (102,571 )
Net Cash (Used)/provided in Operating Activities     1,807,575       (106,440 )
                 
Cash Flows Used/(Provided) from Investing Activities                
Building improvements     (505 )     (122,226 )
Equipment     (8,000 )     (25,535 )
Sales of Vehicle     -       21,500  
Net Cash Used by Investing Activities     (8,505 )     (126,261 )
                 
Cash Provided/(Used) from Financing Activities                
Loan principle payments     (36,709 )     (45,677 )
Net adjustments, Equity     -       (125,316 )
Net Cash Provided by Financing Activities     (36,709 )     (170,993 )
                 
Net Increase (Decrease) in Cash     1,762,360       (403,693 )
Cash at Beginning of Period     1,227,654       2,129,801  
Cash at End of Period   $ 2,990,014     $ 1,726,108  
                 
Supplemental Cash Flow Information:                
Income Taxes Paid   $ -     $ -  
Interest Paid   $ 97,862     $ 24,628  
Supplemental disclosure of non-cash financing activities:                
Operating leases - right of use asset   $ 302,695     $ -  
Operating leases - lease liability   $ 294,387     $ -  

 

See accompanying notes to financial statements

 

F-16

 

 

AmeriGuard Security Services, Inc.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

 

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

 

AmeriGuard Security Services, Inc. (the Company), was incorporated on November 14, 2002, with an S-Corp tax election. The corporation was incorporated with the issuance of 1,000 shares of no-par value stock held by Lawrence Garcia, President and CEO with 550 shares and Lillian Flores, VP of Operations with 450 shares. The Company provides armed guard services as a federal contractor with licenses in 5 states and provides commercial guard services in California.

 

On July 7, 2021, the Company, entered into an agreement to gain 100% control of Health Revenue Assurance Holdings, Inc (HRAA) a public corporation, incorporated in Nevada, by the purchase of 10,000,000 shares of Preferred A-1 Stock from the seller, Custodian Ventures LLC. The purchase of HRAA allowed the Company to begin plans to consummate a reverse merger with HRAA becoming a wholly owned subsidiary of a public company. In March of 2022, a Certificate of Amendment was filed with the Nevada Secretary of State, changing the name of HRAA, to Ameriguard Security Services, Inc. (AGSS). Shortly thereafter, a stock name and ticker change report were filed with the SEC and the stock ticker of HRAA was changed to AGSS.

 

On December 9, 2022, the Company executed the reverse merger agreement and became the subsidiary of AGSS. From that point forward, the financial statement filings will be the consolidation of Ameriguard Security Services, Inc, a Nevada company with Ameriguard Security Services, Inc. a California company.

 

The Company’s accounting year end is December 31.

 

Basis of Presentation

 

These financial statements are presented in United States dollars and have been prepared in accordance with United States generally accepted accounting principles.

 

Risks and Uncertainties

 

The risks and uncertainties described below may not be the only ones we are or may face in the future. If any of the following do occur, our business, financial condition or results of operations could be materially adversely affected.

 

The company receives over 86% of its total revenue from four Federal contracts as described in Note 9 below. These contracts have specific terms, typically five years with the opportunity for extension, but there are no assurances they will be extended. Although we have had several extended in the past, there is no guarantee this will again happened in the future. However, there are significant direct expenses for each contract that also are removed from operations at the end of a contract. As a result, the revenue lost from a completed contract does not affect the bottom-line profits in an amount equal to the revenue lost. The actual net income impact depends on the contract.

 

The process required to acquire a government contract takes several months to complete prior to delivery of the proposal to the contracting agency. Due to the time span required to prepare a proposal and winning the contract is not guaranteed, the company maintains a department of individuals who monitor and write proposals for all government contracts that become open for bid on a continuing basis. It is important to the company that new contracts are acquired consistently to maintain and grow annual revenue.

 

Other risks to operations consist of State and Federal regulations, staffing shortages, accelerating inflation, and overall business environment issues we cannot foresee.

 

F-17

 

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Use of Estimates

 

In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, along with the collectability of some receivables from customers.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. On June 30, 2023, and December 31, 2022, the Company had cash and cash equivalents totaling $2,970439 and $1,227,654 respectively.

 

Accounts Receivable

 

We record accounts receivable at net realizable value. This value includes an appropriate allowance for estimated uncollectible accounts to reflect any loss anticipated on the accounts receivable balances and is charged to other bad debt expense. We calculate this allowance based on our history of write-offs, the level of past-due accounts based on the contractual terms of the receivables, and our relationships with, and the economic status of, our customers. With over 86% percent of year end accounts receivable balance from Federal contracts that require payment, and the uncollectable amount historically has been less than 1%. As of June 30, 2023, and December 31, 2022, an allowance for estimated uncollectible accounts was determined to be unnecessary.

 

Property and Equipment

 

Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment is retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses other depreciation methods (generally accelerated) for tax purposes where appropriate. The estimated useful life for Machinery and Equipment, and Vehicles is 5 years, with Leasehold improvements useful life is 10 Years.

 

Operating Leases

 

In February 2016, FASB ASU No. 2016-02 established ASC Topic 842, Leases, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. Effective December 31, 2022, we have implemented ASU No. 2016-02 and booked the operating lease asset and the related liability.

 

Net Income/(Loss) per Share

 

Net income/(loss) per common share is computed by dividing net income or loss by the weighted average common shares outstanding during the period as defined by Financial Accounting Standards, ASC Topic 260, “Earnings per Share”. Basic earnings/(loss) per common share (“EPS”) calculations are determined by dividing net income/(loss) by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.

 

F-18

 

 

Revenue Recognition

 

We recognize revenue when the Invoice for contracted services is issued as stipulated by the contract. Other services provided are recognized at the time the service is provided. Ninety eight percent of revenues are billed monthly and recognized in the month the services were provided. Refunds and returns, which are minimal, are recorded as a reduction of revenue. The Company has not recorded a reserve for returns on June 30, 2023, or 2022 since it does not believe such returns will be material.

 

Fair Value of Financial Instruments

 

The Company applies the accounting guidance under Financial Accounting Standards Board (“FASB”) ASC 820-10, “Fair Value Measurements”, as well as certain related FASB staff positions. This guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance.

 

The guidance also establishes a fair value hierarchy for measurements of fair value as follows:

 

  Level 1 - quoted market prices in active markets for identical assets or liabilities.
     
  Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
     
  Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

The carrying amount of the Company’s financial instruments approximates their fair value as of June 30, 2023 and December 31, 2022, due to the short-term nature of these instruments.

 

NOTE 3 – RELATED PARTY RECEIVABLE

 

On July 7, 2021, the company entered into an agreement to purchase 100% of the Preferred A-1 Stock of Health Revenue Assurance Holdings, Inc. a SEC registered company for $500,000. In March 2022, Health Revenue Assurance Holdings, Inc. name was changed to Ameriguard Security Services Inc. (AGSS). On December 9, 2022, we signed the definitive merger agreement initiating a reverse merger with AGSS, resulting in the Company becoming a 100% owned subsidiary of AGSS. Prior to the merger, the Company funded the operational expenses of AGSS and treated these expenses as related party expenses. These expenses we eliminated when the two companies were consolidated for the financial statement presentation.

 

The receivable balances on June 30, 2023, and December 31, 2022, were $57,971. Related party receivables are eliminated upon consolidation.

 

F-19

 

 

NOTE 4 – FIXED ASSETS

 

Fixed assets consist of the following on June 30, 2023, and December 31, 2022:

 

               
    2023     2022  
Leasehold Improvements     224,637       224,132  
Machinery and Equipment     286,551       278,551  
Vehicles     110,742       110,274  
Total Fixed Assets     621,426       612,957  
Accumulated Depreciation     (332,985 )     (314,151 )
Fixed Assets, Net   $ 288,477     $ 298,806  

 

NOTE 5 – PAYROLL LIABILITY – PENSION

 

The company offers various pension plans to employee groups based on location of employment. Corporate office employees and guards have an option to participate in a 401K sponsored by the company with a matching program up to 5% of employee salary. Federal contracts have union agreements that define the pension calculation and due dates. It is the responsibility of the company to calculate the pension benefit amount each month and contribute the amount due to the plan designated. The pension balances due on June 30, 2023, and December 31, 2022, for all plans were $345,140 and $453,965 respectively.

 

NOTE 6 – NOTES PAYABLE

 

In June 2020, AmeriGuard Security Services, Inc. received an SBA Loan through Fresno First Bank in the amount of $1,080,000 that was used to close out the Citibank loan in the amount of $312,339 with the remaining balance after expenses held in reserve. The SBA loan is a 10-year loan with monthly principal and interest payments. Interest rate is variable at prime rate plus 2.75%, adjusted every calendar quarter. Interest rate on June 30, 2023, and December 31, 2022, was 10.75% and 9% respectively. Balance remaining on the SBA loan was $767,678 and $785,988 as of June 30, 2023, and December 31, 2022, respectively.

 

On July 7, 2022, the Company entered into a buyout agreement with a shareholder Lillian Flores. The total buyout amount was $3,384,950 representing 45% of the calculated business value as of December 31, 2020. Following the initial payment of $686,990, the company agreed to make 4 equal instalments of principal and interest of $739,508 each December 31, starting 2023. Interest is calculated at a fixed rate of 3.110% compounded semi-annually. The company has accrued interest on June 30, 2023, of $91,635. Balance remaining in the amount of $2,697,960.

 

The following schedule details the loans active as of June 30, 2023, and December 31, 2022:

 

               
    2023     2022  
Current Portion:                
Notes and loans payable   $ 719,563     $ 719,563  
Total Current Portion     719,563       719,563  
Long term Portion:                
Notes and loans payable     2,746,075       2,782,784  
Total Long-term Portion     2,746,075       2,782,784  
    $ 3,465,638     $ 3,502,347  

 

F-20

 

 

NOTE 7 – STOCKHOLDERS’ EQUITY 

 

From December 31, 2022, to June 30,2023 the only impact to equity was the Net Income for the period of $1,030,950.

 

NOTE 8 – COMMITMENTS AND CONTINGENCIES

 

The company has a multiple vehicle lease agreement with Enterprise Leasing. As of June 30, 2023, the company had 19 vehicles under lease. The lease agreement includes maintenance services. The term of the lease agreement varies based on the date vehicle were leased and the respective terms for each vehicle. The master lease is updated annually and requires annual internal financial reports and company tax return.

 

NOTE 9 – CONCENTRATION OF SALES

 

The company generated approximately $10,972,000 and $11,709,000 in guard service revenue for the six-month ending June 30, 2023 and 2022 respectively. Of the total guard service revenue, approximately 87% was earned from four federal contracts operated by the company. The contracts, their respective terms and approximate revenues are as follows:

 

  Social Security Administration, NSC -

September 2022 through September 2027

Six-month revenue - $2,770,000

         
  Social security Administration, SSC -

June 2022 through June 2027

Six-month revenue - $1,511,000

         
  Social Security Administration, WBDOC -

June 2021 through July 2026

Six-month revenue - $2,770,000

         
  National Institute of Health- EPA -

May 2020 through May 2023

Six-month revenue - $2,904,000

 

NOTE 10 – OTHER INCOME (EXPENSE)

 

The company received an Employee Retention Tax Credit of (ERTC) payment of $3,288,000 from the tax year 2021. The company also experienced a related expense of approximately $473,000 for professional services related to the ERTC filing.

 

NOTE 11 – LITIGATION AND CLAIMS

 

As of December 31, 2022, there was one employment issue pending. The issue involves a terminated employee alleging discrimination and wrongful termination. A lawsuit has not been filed, only a demand letter has been presented. Management has been working with the attorneys to find a reasonable settlement to this dispute without going to trial. After several months of discussion and negotiation it appears that the complaint will be settled for $23,000. As of March 31, 2023, the final agreement was signed which pays out the $23,000 settlement in three monthly installments starting May 15, 2023, Per Attorney letters received there are no other pending cases or legal matters.

 

F-21

 

 

PART II – INFORMATION NOT REQUIRED IN PROSPECTUS

 

ITEM 13. OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION

 

The following are our expenses related to our offering:

 

Securities and Exchange Commission Registration Fee   $  
Legal Fees   $ 25,000.00  
Accounting Fees*   $ 25,000.00  
Printing and Engraving*   $ -  
Blue Sky Qualification Fees and Expenses*   $ -  
Transfer Agent Fee*   $ -  
Miscellaneous*   $  
TOTAL   $ 50,000.00  

 

 
* Estimated costs

 

ITEM 14. INDEMNIFICATION OF DIRECTORS AND OFFICERS

 

The Registrant is a Nevada corporation, and the provisions of the Nevada Revised Statutes will be applicable to the indemnification the Registrant offers to its officers, directors and agents. In its By-laws the Registrant generally agrees to indemnify each person who is a director or officer of the Registrant or serves at the request of a director or officer as a director, officer, employee or agent of another company, in accordance with the Registrant’s By-laws, to the fullest extent permissible by the Nevada Revised Statutes or other applicable laws. In its By-laws the Registrant indicates that, in connection with any such indemnification, it is within the discretion of the Board of Directors whether to advance any funds in advance of disposition of any action, suit or proceeding.

 

Under the Articles of Incorporation, the By-laws, and the Nevada Revised Statutes, no director of the Registrant will be personally liable to the Registrant or its stockholders for monetary damages, or expenses in defense of an action, for breach of fiduciary duty as a director or by reason of the fact that he is or was a director, officer, employee or agent of the Registrant, or serving in such capacity for another entity at the request of the Registrant, except for liability (i) for any breach of the director’s duty of loyalty to the Registrant or its stockholders, (ii) for acts or omissions not in good faith or there is reasonable cause to believe it was unlawful, or (iii) for any transaction from which the director derived an improper personal benefit. The Registrant has the power to purchase and maintain insurance on behalf of any persons potentially eligible for indemnification. The rights to indemnification are also applicable to those persons entitled to such rights by virtue of the Registrant’s consummation of a business combination, including such consummations wherein the Registrant is merged into or reorganized as a new entity.

 

The foregoing description of available indemnification is a summary only and is qualified in its entirety by the complete terms and provisions of the Nevada Revised Statutes and the Registrant’s Articles of Incorporation and By-laws, filed herewith as exhibits.

 

ITEM 15RECENT SALES OF UNREGISTERED SECURITIES

 

Below is a chart of all the shareholders who purchased shares since December 31, 2022.

 

None.

 

II-1

 

 

ITEM 16. EXHIBITS

 

Exhibit       Incorporated by Reference   Filed Furnished  
No.   Exhibit Description   Form   Date   Herewith  
2.1   Definitive Share Exchange Agreement   8-K   12/14/2022      
3.1   Amended and Restated Articles of Incorporation of AMERIGUARD SECURITY SERVICES, INC. (Nevada)   8-K   12/14/2022      
3.2   Amended and Restated Bylaws of AMERIGUARD SECURITY SERVICES, INC. (Nevada)   8-K   12/14/2022      
3.3   Articles of Incorporations Ameriguard Security Services, Inc. (Ameriguard)(California)   8-K   12/14/2022      
3.4   Bylaws AGS, Inc. (Ameriguard) (California)   8-K   12/14/2022      
3.5   Certificate of Designation of the Series A-1 Preferred Stock   S-1/A   5/19/2023      
5.1   Opinion of McMurdo Law Group, LLC, legal counsel   S-1   4/10/2023      
10.1   Promissory Note (Secured by Stock Pledge)   8-K   12/14/2022      
10.2   Stock Pledge Agreement   8-K   12/14/2022      
10.3   Buyout documents   S-1/A   5/19/2023      
23.1   Consent of BF Borgers CPA PC           Filed  
23.2   Consent of McMurdo Law Group, LLC (included in Exhibit 5.1)   S-1   4/10/2023      
107   Filing fee schedule           Filed  

 

II-2

 

 

ITEM 17UNDERTAKINGS

 

UNDERTAKINGS

 

The Registrant undertakes:

 

1. Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.

 

The Registrant is registering securities under Rule 415 of the Securities Act and hereby undertakes:

 

1. To file, during any period in which it offers or sells securities, a post-effective amendment to this registration statement to:

 

(i) Include any prospectus required by Section 10(a)(3) of the Securities Act;

 

(ii) Reflect in the prospectus any facts or events which, individually or together, represent a fundamental change in the information in the registration statement; and notwithstanding the forgoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospects filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in the volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement.

 

(iii) Include any additional or changed material information on the plan of distribution.

 

2. That, for the purposes of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

 

3. To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

 

II-3

 

 

4. The undersigned Registrant hereby undertakes that:

 

A. For determining liability of the undersigned issuer under the Securities Act to any purchaser in the initial distribution of the securities, the undersigned issuer undertakes that in a primary offering of securities of the undersigned issuer pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned issuer will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser:

 

i. Any preliminary prospectus or prospectus of the undersigned issuer relating to the offering required to be filed pursuant to Rule 424;

 

ii. Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned issuer or used or referred to by the undersigned issuer;
   
iii. The portion of any other free writing prospectus relating to the offering containing material information about the undersigned issuer or its securities provided by or on behalf of the undersigned issuer; and

 

iv. Any other communication that is an offer in the offering made by the undersigned issuer to the purchaser.

 

B. That for the purpose of determining liability under the Securities Act to any purchaser:

 

Each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use.

 

“Insofar as indemnification for liabilities arising under the Securities Act of 1933 (the “Act”) may be permitted to directors, officers and controlling persons of the issuer pursuant to the foregoing provisions, or otherwise, the issuer has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable.”

 

In the event that a claim for indemnification against such liabilities (other than the payment by the issuer of expenses incurred or paid by a director, officer or controlling person of the issuer in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the issuer will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

 

II-4

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized in Fresno, California on August 25, 2023.

 

  AMERIGUARD SECURITY SERVICES, INC.
     
  By: /s/ Lawrence Garcia
    Lawrence Garcia
   

Chairman of the Board,
Chief Executive Officer,
and Principal Executive Officer

 

In accordance with the requirements of the Securities Act of 1933, this registration statement was signed by the following persons in the capacities and on the dates stated.

 

/s/ Lawrence Garcia   Dated: August 25, 2023

Lawrence Garcia
Chairman of the Board,
Chief Executive Officer,
and Principal Executive Officer

   
     
/s/ Michael Goossen   Dated: August 25, 2023

Michael Goossen
Chief Financial Officer, Director,
and Principal Accounting Officer

   
     
/s/ Douglas Anderson   Dated: August 25, 2023

Douglas Anderson

Director

   

 

/s/ General Russel Honoré   Dated: August 25, 2023

General Russel Honoré

Director

   

 

II-5

EX-23.1 2 ameriguardsec_ex23-1.htm EXHIBIT 23.1

 

Exhibit 23.1

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the incorporation in this Registration Statement on Form S-1-A3 of our report dated March 30, 2023, relating to the financial statements Ameriguard Security Services, Inc. for the years ended December 31, 2022 and 2021 and to all references to our firm included in this Registration Statement.

 

 

Certified Public Accountants

Lakewood, CO

August 25, 2023

 

 
EX-FILING FEES 3 ameriguardsec_ex107.htm EXHIBIT 107

 

Exhibit 107

 

Calculation of Filing Fee Tables

 

Form S-1
(Form Type)

 

AMERIGUARD SECURITY SERVICES, INC.
(Exact Name of Registrant as Specified in its Charter)

 

Table 1: Newly Registered and Carry Forward Securities

 

Security Type  Security
Class Title
  Fee
Calculation
or
Carry
Forward Rule
  Amount
Registered
   Proposed
Maximum
Offering Price
Per Unit
   Maximum
Aggregate
Offering
Price
   Fee Rate   Amount of
Registration
Fee
 
Common Stock, par value $0.001 per share  Common  CFR 229   3,585,946   $1.50   $5,378,919    0.000110200   $592.76 
                                
Total Offering Amounts                               
                                
Net Fee Due                            $592.76*

 

 

*Previously paid

 

 

GRAPHIC 4 ex23-1_001.jpg GRAPHIC begin 644 ex23-1_001.jpg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end EX-101.SCH 5 hraad-20230630.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - CONSOLIDATED BALANCE SHEET link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - CONSOLIDATED BALANCE SHEET (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - CONSOLIDATED STATEMENT OF OPERATIONS link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - STATEMENT OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000008 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000009 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000010 - Statement - CONSPIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000011 - Statement - STATEMENTS OF CASH FLOWS (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - RELATED PARTY RECEIVABLE link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - FIXED ASSETS link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - PAYROLL LIABILITY – PENSION link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - NOTES PAYABLE link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - CONCENTRATION OF SALES link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - LITIGATION AND CLAIMS link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - INCOME TAXE link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - OTHER INCOME (EXPENSE) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - FIXED ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - NOTES PAYABLE (Tables) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - RELATED PARTY RECEIVABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - FIXED ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - PAYROLL LIABILITY – PENSION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - NOTE PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - NOTES PAYABLE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - STOCKHOLDERS’ EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - CONCENTRATION OF SALES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - LITIGATION AND CLAIMS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - INCOME TAXE (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - NOTES PAYABLE (Details) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - OTHER INCOME (EXPENSE) (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 hraad-20230630_cal.xml XBRL CALCULATION FILE EX-101.DEF 7 hraad-20230630_def.xml XBRL DEFINITION FILE EX-101.LAB 8 hraad-20230630_lab.xml XBRL LABEL FILE Entity Addresses, Address Type [Axis] Business Contact [Member] Product and Service [Axis] Security Services [Member] Other Related Income [Member] Salaries And Related Taxes [Member] Employee Benefits [Member] Sub Contractor Payments [Member] Guard Training [Member] Vehicles And Equipment Expenses [Member] Equity Components [Axis] Common Stock [Member] Preferred Stock [Member] Additional Paid-in Capital [Member] Stockholders Equity [Member] Title of Individual [Axis] Chief Executive Officer [Member] Lillian Flores [Member] Related Party, Type [Axis] Custodian Ventures [Member] Long-Lived Tangible Asset [Axis] Machinery and Equipment [Member] Vehicles [Member] Leasehold Improvements [Member] Debt Instrument [Axis] SBA Loan [Member] Counterparty Name [Axis] Master Security Company [Member] Secure Transportation Inc [Member] Short-Term Debt, Type [Axis] Notes And Loans Payable [Member] Legal Entity [Axis] Ameriguard Security Services [Member] Guard Service [Member] Concentration Risk Benchmark [Axis] Revenue Benchmark [Member] Concentration Risk Type [Axis] Product Concentration Risk [Member] Customer [Axis] Subsequent Event Type [Axis] Subsequent Event [Member] Social Security Administration N S C [Member] Social Security Administration S S C [Member] Social Security Administration W B D O C [Member] National Institute Of Health E P A [Member] Entity Addresses [Table] Entity Addresses [Line Items] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Contact Personnel Name Statement of Financial Position [Abstract] Assets Current Assets Cash Accounts receivable, net (note 1) Prepaid insurance Related Party Receivable (note 3) Total Current Assets Other Non-Current Assets Fixed assets, net depreciation (note 4) Operating Lease Total Non-Current Assets Total Assets Liabilities Current Liabilities Accounts payable Accrued Interest Due (note 6) Accrued Payroll Payroll liability - Pension (note 5) Current portion of notes payable (note 6) Total Current Liabilities Long Term Liabilities Long term portion of notes payable (note 6) Operating Lease Total Liabilities Stockholders’ equity Common stock, $.001 par value, 94,471,302 shares issued and outstanding at December 31, 2022 and 2021 (Note 7) Retained earnings/(deficit) Total Stockholders’ Equity Total Liabilities and Stockholders’ Equity Common Stock, Par or Stated Value Per Share Common Stock, Shares, Outstanding Common Stock, Shares, Issued Statement [Table] Statement [Line Items] Revenue Total Revenue Cost of Services Total Cost of Services Gross Margin Operating Expenses Salaries, payroll taxes and benefits Vehicle expense Professional services Cellular services General liability insurance Advertising and marketing General and administrative expenses Loan interest Depreciation expense Total Operating Expenses Net Income/(Loss) from Operations Other Income (Expenses) Other Income Other (Expense) Total Other Income Net Income/(loss) before Income Taxes Income tax expense Net Income/(loss) Net Income/(loss) per Common Share - Basic and Diluted Weighted Average Number of Common Shares Outstanding - Basic and Diluted Beginning balance, value Beginning balance, Shares Owner draws (pre-merger) Shareholder buyout Retained Deficit of merger with related entity Equity Merger Equity Merger, Shares Cancelation and conversion of preferred stock Cancelation and conversion of preferred stock, Shares Net (Loss) for year ended December 31, 2022 Ending balance, value Ending balance, Shares Statement of Cash Flows [Abstract] Cash Flows from Operating Activities Net Income/(Loss) Adjustment to reconcile net loss from operations: Accounts receivable, net Prepaid insurance Accounts payable Accrued Interest Accrued Payroll Payroll liability - Pension Operating lease liability Operating lease asset Net Cash (Used)/provided in Operating Activities Cash Flows (Used)/Provided from Investing Activities Purchase of fixed assets Building improvements Net Cash Used by Investing Activities Cash (Used)/Provided from Financing Activities Secure Transportation vehicle loan Payment for Shareholder buyout Loan principle payments Owner distributions Net Cash Provided by Financing Activities Net Increase (Decrease) in Cash Cash at Beginning of Period Cash at End of Period Supplemental Cash Flow Information: Income Taxes Paid Interest Paid Supplemental disclosure of non-cash financing activities: Shareholder Loan Operating leases - right of use asset Operating leases - lease liability Related Party Receivable (note 3) Accounts payable Total Current Liabilities Total Liabilities Common stock, $.001 par value, 94,471,302 shares issued and outstanding at June 30, 2023 and 2022 Retained (deficit) Total Liabilities and Stockholders’ Equity Earnings Per Share, Diluted Weighted Average Number of Shares Outstanding, Diluted Beginning balance, value Net Income for the period Ending balance, value Changes in Operating Assets and Liabilities Depreciation Cash Flows Used/(Provided) from Investing Activities Equipment Sales of Vehicle Cash Provided/(Used) from Financing Activities Net adjustments, Equity Cash at Beginning of Period Cash at End of Period Accounting Policies [Abstract] ORGANIZATION AND DESCRIPTION OF BUSINESS SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Related Party Transactions [Abstract] RELATED PARTY RECEIVABLE Property, Plant and Equipment [Abstract] FIXED ASSETS Payroll Liability Pension PAYROLL LIABILITY – PENSION Debt Disclosure [Abstract] NOTES PAYABLE Equity [Abstract] STOCKHOLDERS’ EQUITY Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Concentration Of Sales CONCENTRATION OF SALES Litigation And Claims LITIGATION AND CLAIMS Income Tax Disclosure [Abstract] INCOME TAXE Subsequent Events [Abstract] SUBSEQUENT EVENTS Other Income and Expenses [Abstract] OTHER INCOME (EXPENSE) Use of Estimates Cash and Cash Equivalents Accounts Receivable Property and Equipment Operating Leases Net Income/(Loss) per Share Revenue Recognition Fair Value of Financial Instruments Schedule of fixed assets Schedule of the loan active Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table] Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items] Number of share issued Preferred A-1 Stock, Shares Authorized Holder ownership Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Cash Estimated useful life Operating lease liability Operating lease cost Operating Lease, Liability, Noncurrent Increase Decrease In Operting Lease Assets Total asset of the leases Amortization of the lease Reserve for returns Consideration paid Shares Notes Receivablerelated Party Total Fixed Assets Accumulated Depreciation Fixed Assets, Net Pension balances Schedule of Short-Term Debt [Table] Short-Term Debt [Line Items] Total Current Portion Total Long-term Portion Notes Payable Principal amount Expenses held in reserve Term Interest rate is variable Interest rate Notes Payable Periodic payment Initial Payment Accrued Liabilities, Current Debt Instrument, Interest Rate Terms Number of shares issued Number of shares exchanged Increase in common shares outstanding Conversion of shares Shares Outstanding Reduction of Paid-in Capital Equity description Related party receivables Owner draws (pre-merger) Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Revenues Concentration Risk, Percentage Litigation settlement amount Tax liability Subsequent Event [Table] Subsequent Event [Line Items] Annual revenue reduced Reduction in direct expenses Subsequent Event, Description Other Operating Income (Expense), Net Assets, Current Assets [Default Label] TotalCurrentLiabilities Other Liabilities Equity, Attributable to Parent TotalLiabilitiesAndStockholdersEquity Gross Profit Operating Expenses [Default Label] Operating Income (Loss) Other Nonoperating Expense Other Nonoperating Income (Expense) Equity, Including Portion Attributable to Noncontrolling Interest Increase (Decrease) in Accounts Receivable Increase (Decrease) in Prepaid Insurance Increase (Decrease) in Accounts Payable Increase (Decrease) in Accrued Interest Receivable, Net Increase (Decrease) in Employee Related Liabilities Net Cash Provided by (Used in) Operating Activities PaymentsToAcquirePurchaseOfFixedAssets BuildingImprovements Net Cash Provided by (Used in) Investing Activities PaymentForShareholderBuyout LoanPrinciplePayments OwnerDistributions Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations RelatedPartyReceivable Accounts Payable, Current Liabilities, Current Liabilities [Default Label] Liabilities and Equity Payments to Acquire Property, Plant, and Equipment NetAdjustmentsEquity Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Cash [Default Label] Increase (Decrease) in Operating Lease Liability Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment NotePayable OwnerDrawsPremerger EX-101.PRE 9 hraad-20230630_pre.xml XBRL PRESENTATION FILE XML 10 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
6 Months Ended
Jun. 30, 2023
Entity Addresses [Line Items]  
Document Type S-1/A
Amendment Flag true
Amendment Description Amendment No.3
Entity Registrant Name AMERIGUARD SECURITY SERVICES, INC.
Entity Central Index Key 0001514443
Entity Incorporation, State or Country Code NV
Entity Address, Address Line One 5470 W. Spruce Avenue
Entity Address, Address Line Two Suite 102
Entity Address, City or Town Fresno
Entity Address, State or Province CA
Entity Address, Postal Zip Code 8950
City Area Code (559)
Local Phone Number 271-5984
Entity Filer Category Non-accelerated Filer
Entity Small Business true
Entity Emerging Growth Company false
Business Contact [Member]  
Entity Addresses [Line Items]  
Entity Address, Address Line One 50 West Liberty Street Suite 880
Entity Address, City or Town Reno
Entity Address, State or Province NV
Entity Address, Postal Zip Code 8950
City Area Code (775)
Local Phone Number 322-0626
Contact Personnel Name NEVADA AGENCY AND TRANSFER COMPANY
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.23.2
CONSOLIDATED BALANCE SHEET - USD ($)
Dec. 31, 2022
Dec. 31, 2021
Current Assets    
Cash $ 1,227,654 $ 2,129,801
Accounts receivable, net (note 1) 1,869,268 2,215,197
Prepaid insurance 110,829 107,884
Related Party Receivable (note 3)
Total Current Assets 3,207,751 4,452,882
Other Non-Current Assets    
Fixed assets, net depreciation (note 4) 298,806 132,802
Operating Lease 302,695
Total Non-Current Assets 601,501 132,802
Total Assets 3,809,252 4,585,684
Current Liabilities    
Accounts payable 761,515 418,342
Accrued Interest Due (note 6) 49,035
Accrued Payroll 737,143 657,741
Payroll liability - Pension (note 5) 453,965 616,579
Current portion of notes payable (note 6) 719,563 127,615
Total Current Liabilities 2,721,221 1,820,277
Long Term Liabilities    
Long term portion of notes payable (note 6) 2,782,784 780,845
Operating Lease 294,387
Total Liabilities 5,798,392 2,601,122
Stockholders’ equity    
Common stock, $.001 par value, 94,471,302 shares issued and outstanding at December 31, 2022 and 2021 (Note 7) 158,346 158,346
Retained earnings/(deficit) (2,147,486) 1,816,216
Total Stockholders’ Equity (1,989,140) 1,974,562
Total Liabilities and Stockholders’ Equity $ 3,809,252 $ 4,575,684
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.23.2
CONSOLIDATED BALANCE SHEET (Parenthetical) - $ / shares
Dec. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Common Stock, Par or Stated Value Per Share $ 0.001 $ 0.001
Common Stock, Shares, Outstanding 94,471,302 94,471,302
Common Stock, Shares, Issued 94,471,302 94,471,302
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.2
CONSOLIDATED STATEMENT OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Revenue    
Total Revenue $ 24,947,401 $ 22,442,513
Cost of Services    
Total Cost of Services 21,948,618 20,628,996
Gross Margin 2,998,783 1,813,517
Operating Expenses    
Salaries, payroll taxes and benefits 1,161,982 365,433
Vehicle expense 433,424 295,054
Professional services 361,314 318,442
Cellular services 106,382 112,140
General liability insurance 87,119 111,287
Advertising and marketing 128,544 77,349
General and administrative expenses 645,268 294,062
Loan interest 105,826 59,439
Depreciation expense 42,927 52,273
Total Operating Expenses 3,072,786 1,685,479
Net Income/(Loss) from Operations (74,003) 128,038
Other Income (Expenses)    
Other Income
Other (Expense) (344,105)
Total Other Income (344,105)
Net Income/(loss) before Income Taxes (418,108) 128,038
Income tax expense 10,350 33,923
Net Income/(loss) $ (428,458) $ 94,115
Net Income/(loss) per Common Share - Basic and Diluted $ (0.0046) $ 0.0010
Weighted Average Number of Common Shares Outstanding - Basic and Diluted 93,417,302 93,417,302
Security Services [Member]    
Revenue    
Total Revenue $ 24,643,096 $ 22,418,328
Other Related Income [Member]    
Revenue    
Total Revenue 304,305 24,185
Salaries And Related Taxes [Member]    
Cost of Services    
Total Cost of Services 15,030,738 13,873,241
Employee Benefits [Member]    
Cost of Services    
Total Cost of Services 3,052,774 2,915,322
Sub Contractor Payments [Member]    
Cost of Services    
Total Cost of Services 3,467,391 3,433,959
Guard Training [Member]    
Cost of Services    
Total Cost of Services 202,826 222,298
Vehicles And Equipment Expenses [Member]    
Cost of Services    
Total Cost of Services $ 194,889 $ 184,176
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.23.2
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
Common Stock [Member]
Preferred Stock [Member]
Additional Paid-in Capital [Member]
Stockholders Equity [Member]
Total
Beginning balance, value at Dec. 31, 2020 $ 69,346 $ 10,000 $ 9,976,045 $ (7,191,705) $ 2,863,685
Beginning balance, Shares at Dec. 31, 2020 2,743,302 675,000      
Owner draws (pre-merger)     (473,238) (473,238)
Equity Merger $ 89,000 $ (10,000) (579,000)   (500,000)
Equity Merger, Shares 89,999,000        
Cancelation and conversion of preferred stock, Shares 675,000 (675,000)      
Net (Loss) for year ended December 31, 2022       94,115 94,115
Ending balance, value at Dec. 31, 2021 $ 158,346 9,397,045 (7,570,828) 1,984,562
Ending balance, Shares at Dec. 31, 2021 93,417,302      
Owner draws (pre-merger)       (62,824) (62,824)
Shareholder buyout     (3,384,950)   (3,384,950)
Retained Deficit of merger with related entity       (97,470) (97,470)
Net (Loss) for year ended December 31, 2022   (428,458) (428,458)
Ending balance, value at Dec. 31, 2022 $ 158,346 6,012,095 (8,159,580) $ (1,989,140)
Ending balance, Shares at Dec. 31, 2022 93,417,302     93,417,302
Net (Loss) for year ended December 31, 2022 $ 1,009,357 $ 1,009,357
Ending balance, Shares at Jun. 30, 2023 93,417,302      
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.23.2
STATEMENT OF CASH FLOWS - USD ($)
6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Cash Flows from Operating Activities        
Net Income/(Loss) $ 1,009,357 $ (250,257) $ (428,458) $ 94,115
Adjustment to reconcile net loss from operations:        
Accounts receivable, net 461,002 (121,650) (345,929) 23,372
Prepaid insurance (21,215) (9,171) 2,945 32,949
Accounts payable 405,822 329,744 343,172 33,742
Accrued Interest 42,600 (49,035)
Accrued Payroll     79,402 75,693
Payroll liability - Pension (108,825) (102,571) (162,614) 77,237
Operating lease liability     (79,358)
Operating lease asset     71,049
Net Cash (Used)/provided in Operating Activities 1,807,575 (106,440) 258,139 276,739
Cash Flows (Used)/Provided from Investing Activities        
Purchase of fixed assets     6,043 24,552
Building improvements (505) (122,226) 224,132
Net Cash Used by Investing Activities (8,505) (126,261) (230,175) (524,552)
Cash (Used)/Provided from Financing Activities        
Secure Transportation vehicle loan     21,500
Payment for Shareholder buyout     (686,990.00)
Loan principle payments (36,709) (45,677) (180,298) (227,097)
Owner distributions     (62,824) (473,238)
Net Cash Provided by Financing Activities (36,709) (170,993) (930,112) (678,835)
Net Increase (Decrease) in Cash 1,762,360 (403,693) (902,148) (926,648)
Cash at Beginning of Period 1,227,653 2,129,801 2,129,801 3,056,449
Cash at End of Period     1,227,653 2,129,801
Supplemental Cash Flow Information:        
Income Taxes Paid 10,350 33,923
Interest Paid 97,862 24,628 105,826 $ 59,439
Supplemental disclosure of non-cash financing activities:        
Shareholder Loan     3,384,950  
Operating leases - right of use asset 302,695 302,695  
Operating leases - lease liability $ 294,387 $ 294,387  
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.23.2
CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Current Assets    
Cash $ 2,990,014 $ 1,227,654
Accounts receivable, net (note 1) 1,408,266 1,869,268
Prepaid insurance 132,045 110,829
Related Party Receivable (note 3)
Total Current Assets 4,530,325 3,207,751
Other Non-Current Assets    
Fixed assets, net depreciation (note 4) 288,477 298,806
Operating Lease 302,695 302,695
Total Non-Current Assets 591,172 601,501
Total Assets 5,121,497 3,809,252
Current Liabilities    
Accounts payable 1,172,116 761,515
Accrued Interest Due (note 6) 91,635 49,035
Accrued Payroll 732,364 737,143
Payroll liability - Pension (note 5) 345,140 453,965
Current portion of notes payable (note 6) 719,563 719,563
Total Current Liabilities 3,060,818 2,721,221
Long Term Liabilities    
Long term portion of notes payable (note 6) 2,746,075 2,782,784
Operating Lease 294,387 294,387
Total Liabilities 6,101,280 5,798,393
Stockholders’ equity    
Common stock, $.001 par value, 94,471,302 shares issued and outstanding at June 30, 2023 and 2022 158,346 158,346
Retained (deficit) (1,138,129) (2,147,486)
Total Stockholders’ Equity (979,783) (1,989,140)
Total Liabilities and Stockholders’ Equity $ 5,121,497 $ 3,809,252
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.23.2
CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - $ / shares
Dec. 31, 2022
Dec. 31, 2021
Statement of Financial Position [Abstract]    
Common Stock, Par or Stated Value Per Share $ 0.001 $ 0.001
Common Stock, Shares, Outstanding 94,471,302 94,471,302
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.23.2
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Revenue        
Total Revenue $ 11,185,798 $ 11,867,882 $ 24,947,401 $ 22,442,513
Cost of Services        
Total Cost of Services 10,783,780 10,617,923 21,948,618 20,628,996
Gross Margin 402,018 1,249,959 2,998,783 1,813,517
Operating Expenses        
Salaries, payroll taxes and benefits 836,457 470,077 1,161,982 365,433
Vehicle expense 192,693 226,741 433,424 295,054
Professional services 249,266 188,226 361,314 318,442
Cellular services 58,492 53,870 106,382 112,140
General liability insurance 108,088 51,108 87,119 111,287
Advertising and marketing 60,097 53,852 128,544 77,349
General and administrative expenses 430,810 262,573 645,268 294,062
Loan interest 97,862 24,628 105,826 59,439
Depreciation expense 18,834 22,188 42,927 52,273
Total Operating Expenses 2,052,600 1,353,263 3,072,786 1,685,479
Net Income/(Loss) from Operations (1,650,582) (103,304) (74,003) 128,038
Other Income (Expenses)        
Other Income 3,302,312 23,982
Other (Expense) (642,373) (170,935) (344,105)
Total Other Income 2,659,939 (146,953) (344,105)
Net Income/(loss) before Income Taxes 1,009,357 (250,257) (418,108) 128,038
Income tax expense 10,350 33,923
Net Income/(loss) $ 1,009,357 $ (250,257) (428,458) 94,115
Earnings Per Share, Diluted $ 0.0108 $ (0.0027)    
Weighted Average Number of Shares Outstanding, Diluted 93,417,302 93,417,302    
Security Services [Member]        
Revenue        
Total Revenue $ 11,068,409 $ 11,751,908 24,643,096 22,418,328
Other Related Income [Member]        
Revenue        
Total Revenue 117,389 115,974 304,305 24,185
Salaries And Related Taxes [Member]        
Cost of Services        
Total Cost of Services 7,675,360 7,205,687 15,030,738 13,873,241
Employee Benefits [Member]        
Cost of Services        
Total Cost of Services 1,566,148 1,496,612 3,052,774 2,915,322
Sub Contractor Payments [Member]        
Cost of Services        
Total Cost of Services 1,331,446 1,703,987 3,467,391 3,433,959
Guard Training [Member]        
Cost of Services        
Total Cost of Services 104,041 111,985 202,826 222,298
Vehicles And Equipment Expenses [Member]        
Cost of Services        
Total Cost of Services $ 106,785 $ 99,652 $ 194,889 $ 184,176
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.23.2
CONSPIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Unaudited) - USD ($)
Common Stock [Member]
Preferred Stock [Member]
Additional Paid-in Capital [Member]
Stockholders Equity [Member]
Total
Beginning balance, Shares at Dec. 31, 2020 2,743,302 675,000      
Net Income for the period       $ 94,115 $ 94,115
Ending balance, value at Dec. 31, 2021         1,974,562
Ending balance, Shares at Dec. 31, 2021 93,417,302      
Net Income for the period   (428,458) (428,458)
Ending balance, value at Dec. 31, 2022 $ 158,346 $ 6,012,095 (8,159,580) $ (1,989,140)
Ending balance, Shares at Dec. 31, 2022 93,417,302     93,417,302
Net Income for the period 1,009,357 $ 1,009,357
Ending balance, value at Jun. 30, 2023 $ 158,346 $ 6,012,095 $ (7,150,223) $ (979,783)
Ending balance, Shares at Jun. 30, 2023 93,417,302      
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.23.2
STATEMENTS OF CASH FLOWS (Unaudited) - USD ($)
6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
Cash Flows from Operating Activities        
Net Income/(Loss) $ 1,009,357 $ (250,257) $ (428,458) $ 94,115
Changes in Operating Assets and Liabilities        
Accounts receivable, net 461,002 (121,650) (345,929) 23,372
Prepaid insurance (21,215) (9,171) 2,945 32,949
Depreciation 18,834 47,465    
Accounts payable 405,822 329,744 343,172 33,742
Accrued Interest 42,600 (49,035)
Payroll liability - Pension (108,825) (102,571) (162,614) 77,237
Net Cash (Used)/provided in Operating Activities 1,807,575 (106,440) 258,139 276,739
Cash Flows Used/(Provided) from Investing Activities        
Building improvements (505) (122,226) 224,132
Equipment (8,000) (25,535)    
Sales of Vehicle 21,500    
Net Cash Used by Investing Activities (8,505) (126,261) (230,175) (524,552)
Cash Provided/(Used) from Financing Activities        
Loan principle payments (36,709) (45,677) (180,298) (227,097)
Net adjustments, Equity (125,316)    
Net Cash Provided by Financing Activities (36,709) (170,993) (930,112) (678,835)
Net Increase (Decrease) in Cash 1,762,360 (403,693) (902,148) (926,648)
Cash at Beginning of Period 1,227,654 2,129,801 2,129,801  
Cash at End of Period 2,990,014 1,726,108 1,227,654 2,129,801
Supplemental Cash Flow Information:        
Income Taxes Paid 10,350 33,923
Interest Paid 97,862 24,628 105,826 $ 59,439
Supplemental disclosure of non-cash financing activities:        
Operating leases - right of use asset 302,695 302,695  
Operating leases - lease liability $ 294,387 $ 294,387  
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.23.2
ORGANIZATION AND DESCRIPTION OF BUSINESS
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Accounting Policies [Abstract]    
ORGANIZATION AND DESCRIPTION OF BUSINESS

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

 

AmeriGuard Security Services, Inc. (the Company), was incorporated on November 14, 2002, with an S-Corp tax election. The corporation was incorporated with the issuance of 1,000 shares of no-par value stock held by Lawrence Garcia, President and CEO with 550 shares and Lillian Flores, VP of Operations with 450 shares. The Company provides armed guard services as a federal contractor with licenses in 5 states and provides commercial guard services in California.

 

On July 7, 2021, the Company, entered into an agreement to gain 100% control of Health Revenue Assurance Holdings, Inc (HRAA) a public corporation, incorporated in Nevada, by the purchase of 10,000,000 shares of Preferred A-1 Stock from the seller, Custodian Ventures LLC. The purchase of HRAA allowed the Company to begin plans to consummate a reverse merger with HRAA becoming a wholly owned subsidiary of a public company. In March of 2022, a Certificate of Amendment was filed with the Nevada Secretary of State, changing the name of HRAA, to Ameriguard Security Services, Inc. (AGSS). Shortly thereafter, a stock name and ticker change report were filed with the SEC and the stock ticker of HRAA was changed to AGSS.

 

On December 9, 2022, the Company executed the reverse merger agreement and became the subsidiary of AGSS. From that point forward, the financial statement filings will be the consolidation of Ameriguard Security Services, Inc, a Nevada company with Ameriguard Security Services, Inc. a California company.

 

The Company’s accounting year end is December 31.

 

Basis of Presentation

 

These financial statements are presented in United States dollars and have been prepared in accordance with United States generally accepted accounting principles.

 

Risks and Uncertainties

 

The risks and uncertainties described below may not be the only ones we are or may face in the future. If any of the following do occur, our business, financial condition or results of operations could be materially adversely affected.

 

The company receives over 86% of its total revenue from four Federal contracts as described in Note 9 below. These contracts have specific terms, typically five years with the opportunity for extension, but there are no assurances they will be extended. Although we have had several extended in the past, there is no guarantee this will again happened in the future. However, there are significant direct expenses for each contract that also are removed from operations at the end of a contract. As a result, the revenue lost from a completed contract does not affect the bottom-line profits in an amount equal to the revenue lost. The actual net income impact depends on the contract.

 

The process required to acquire a government contract takes several months to complete prior to delivery of the proposal to the contracting agency. Due to the time span required to prepare a proposal and winning the contract is not guaranteed, the company maintains a department of individuals who monitor and write proposals for all government contracts that become open for bid on a continuing basis. It is important to the company that new contracts are acquired consistently to maintain and grow annual revenue.

 

Other risks to operations consist of State and Federal regulations, staffing shortages, accelerating inflation, and overall business environment issues we cannot foresee.

 

NOTE 1 – ORGANIZATION AND DESCRIPTION OF BUSINESS

 

AmeriGuard Security Services, Inc. (the Company), was incorporated on November 14, 2002, with an S-Corp tax election. The corporation was incorporated with the issuance of 1,000 shares of no-par value stock held by Lawrence Garcia, President and CEO with 550 shares and Lillian Flores, VP of Operations with 450 shares. The Company provides armed guard services as a federal contractor with licenses in 5 states and provides commercial guard services in California.

 

On July 7, 2021, the Company, entered into an agreement to gain 100% control of Health Revenue Assurance Holdings, Inc (HRAA) a public corporation, incorporated in Nevada, by the purchase of 10,000,000 shares of Preferred A-1 Stock from the seller, Custodian Ventures LLC. The purchase of HRAA allowed the Company to begin plans to consummate a reverse merger with HRAA becoming a wholly owned subsidiary of a public company. In March of 2022, a Certificate of Amendment was filed with the Nevada Secretary of State, changing the name of HRAA, to Ameriguard Security Services, Inc. (AGSS). Shortly thereafter, a stock name and ticker change report was filed with the SEC and the stock ticker of HRAA was changed to AGSS.

 

On December 9, 2022, the Company executed the reverse merger agreement and became the subsidiary of AGSS. From that point forward, the financial statement filings will be the consolidation of Ameriguard Security Services, Inc, a Nevada company with Ameriguard Security Services, Inc. a California company.

 

The Company’s accounting year end is December 31.

 

Basis of Presentation

 

These financial statements are presented in United States dollars and have been prepared in accordance with United States generally accepted accounting principles.

 

Risks and Uncertainties

 

The risks and uncertainties described below may not be the only ones we are or may face in the future. If any of the following do occur, our business, financial condition or results of operations could be materially adversely affected.

 

The company receives over 90% of its total revenue from four Federal contracts as described in Note 9 below. These contracts have specific terms, typically five years with the opportunity for extension, but there are no assurances they will be extended. Although we have had several extended in the past, there is no guarantee this will again happened in the future. However, there are significant direct expenses for each contract that also are removed from operations at the end of a contract. As a result, the revenue lost from a completed contract does not affect the bottom-line profits in an amount equal to the revenue lost. The actual net income impact depends on the contract.

 

The process required to acquire a government contract takes several months to complete prior to delivery of the proposal to the contracting agency. Due to the time span required to prepare a proposal and wining the contract is not guaranteed, the company maintains a department of individuals who monitor and write proposals for all government contracts that become open for bid on a continuing basis. It is important to the company that new contracts are acquired consistently to maintain and grow annual revenue.

 

Other risks to operations consist of State and Federal regulations, accelerating inflation, and overall business environment issues we cannot foresee.

 

XML 22 R13.htm IDEA: XBRL DOCUMENT v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Accounting Policies [Abstract]    
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Use of Estimates

 

In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, along with the collectability of some receivables from customers.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. On June 30, 2023, and December 31, 2022, the Company had cash and cash equivalents totaling $2,970439 and $1,227,654 respectively.

 

Accounts Receivable

 

We record accounts receivable at net realizable value. This value includes an appropriate allowance for estimated uncollectible accounts to reflect any loss anticipated on the accounts receivable balances and is charged to other bad debt expense. We calculate this allowance based on our history of write-offs, the level of past-due accounts based on the contractual terms of the receivables, and our relationships with, and the economic status of, our customers. With over 86% percent of year end accounts receivable balance from Federal contracts that require payment, and the uncollectable amount historically has been less than 1%. As of June 30, 2023, and December 31, 2022, an allowance for estimated uncollectible accounts was determined to be unnecessary.

 

Property and Equipment

 

Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment is retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses other depreciation methods (generally accelerated) for tax purposes where appropriate. The estimated useful life for Machinery and Equipment, and Vehicles is 5 years, with Leasehold improvements useful life is 10 Years.

 

Operating Leases

 

In February 2016, FASB ASU No. 2016-02 established ASC Topic 842, Leases, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. Effective December 31, 2022, we have implemented ASU No. 2016-02 and booked the operating lease asset and the related liability.

 

Net Income/(Loss) per Share

 

Net income/(loss) per common share is computed by dividing net income or loss by the weighted average common shares outstanding during the period as defined by Financial Accounting Standards, ASC Topic 260, “Earnings per Share”. Basic earnings/(loss) per common share (“EPS”) calculations are determined by dividing net income/(loss) by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.

 

Revenue Recognition

 

We recognize revenue when the Invoice for contracted services is issued as stipulated by the contract. Other services provided are recognized at the time the service is provided. Ninety eight percent of revenues are billed monthly and recognized in the month the services were provided. Refunds and returns, which are minimal, are recorded as a reduction of revenue. The Company has not recorded a reserve for returns on June 30, 2023, or 2022 since it does not believe such returns will be material.

 

Fair Value of Financial Instruments

 

The Company applies the accounting guidance under Financial Accounting Standards Board (“FASB”) ASC 820-10, “Fair Value Measurements”, as well as certain related FASB staff positions. This guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance.

 

The guidance also establishes a fair value hierarchy for measurements of fair value as follows:

 

  Level 1 - quoted market prices in active markets for identical assets or liabilities.
     
  Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
     
  Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

The carrying amount of the Company’s financial instruments approximates their fair value as of June 30, 2023 and December 31, 2022, due to the short-term nature of these instruments.

 

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

Use of Estimates

 

In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, along with the collectability of some receivables from customers.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. On December 31, 2022, and December 31, 2021, the Company had cash and cash equivalents totaling $1,227,654 and $2,129,801 respectively.

 

Accounts Receivable

 

We record accounts receivable at net realizable value. This value includes an appropriate allowance for estimated uncollectible accounts to reflect any loss anticipated on the accounts receivable balances and is charged to other bad debt expense. We calculate this allowance based on our history of write-offs, the level of past-due accounts based on the contractual terms of the receivables, and our relationships with, and the economic status of, our customers. With over ninety percent of year end accounts receivable balance from Federal contracts that require payment, and the uncollectable amount historically has been less than 1%. As of December 31, 2022, and 2021, an allowance for estimated uncollectible accounts was determined to be unnecessary.

 

Property and Equipment

 

Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment is retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses other depreciation methods (generally accelerated) for tax purposes where appropriate. The estimated useful life for Machinery and Equipment, and Vehicles is 5 years, with Leasehold improvements useful life is 10 Years.

 

Operating Leases

 

In February 2016, FASB ASU No. 2016-02 established ASC Topic 842, Leases, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. Effective December 31, 2022, we have implemented ASU No. 2016-02 and booked the operating lease asset and the related liability.

 

We have leased vehicles that are classified as operating leases per the guidelines. The Balance Sheet & the Statement of Cash Flows reflects the implementation of this guideline. The Balance Sheet reflects the asset and liability of the operating leases. The Statement of Cash Flows reflects the implementation of this guideline as transactions that affected cash flow and non-cash financing activities. The change in the operating lease liability of ($79,358) is the difference of the total liability of our lease ($373,745) from the total liability balance of ($294,387) as of December 31,2022. The ($79,358) change in the operating lease liability consists of the total lease payments made for the year. The change in operating lease asset of $71,049 is the net of the total asset of the leases ($373,745) and the remaining asset balance of $302,695 as of December 31, 2022. The $71,049 is the amortization of the lease for the year.

 

 

Net Income/(Loss) per Share

 

Net income/(loss) per common share is computed by dividing net income or loss by the weighted average common shares outstanding during the period as defined by Financial Accounting Standards, ASC Topic 260, “Earnings per Share”. Basic earnings/(loss) per common share (“EPS”) calculations are determined by dividing net income/(loss) by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.

Revenue Recognition

 

We recognize revenue when the Invoice for contracted services is issued as stipulated by the contract. Other services provided are recognized at the time the service is provided. Ninety eight percent of revenues are billed monthly and recognized in the month the services were provided. Refunds and returns, which are minimal, are recorded as a reduction of revenue. The Company has not recorded a reserve for returns on December 31, 2022, or 2021 since it does not believe such returns will be material.

 

Fair Value of Financial Instruments

 

The Company applies the accounting guidance under Financial Accounting Standards Board (“FASB”) ASC 820-10, “Fair Value Measurements”, as well as certain related FASB staff positions. This guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance.

 

The guidance also establishes a fair value hierarchy for measurements of fair value as follows:

 

  Level 1 - quoted market prices in active markets for identical assets or liabilities.
     
  Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
     
 

Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

The carrying amount of the Company’s financial instruments approximates their fair value as of December 31, 2021 and December 31, 2022, due to the short-term nature of these instruments.

 

XML 23 R14.htm IDEA: XBRL DOCUMENT v3.23.2
RELATED PARTY RECEIVABLE
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Related Party Transactions [Abstract]    
RELATED PARTY RECEIVABLE

NOTE 3 – RELATED PARTY RECEIVABLE

 

On July 7, 2021, the company entered into an agreement to purchase 100% of the Preferred A-1 Stock of Health Revenue Assurance Holdings, Inc. a SEC registered company for $500,000. In March 2022, Health Revenue Assurance Holdings, Inc. name was changed to Ameriguard Security Services Inc. (AGSS). On December 9, 2022, we signed the definitive merger agreement initiating a reverse merger with AGSS, resulting in the Company becoming a 100% owned subsidiary of AGSS. Prior to the merger, the Company funded the operational expenses of AGSS and treated these expenses as related party expenses. These expenses we eliminated when the two companies were consolidated for the financial statement presentation.

 

The receivable balances on June 30, 2023, and December 31, 2022, were $57,971. Related party receivables are eliminated upon consolidation.

 

NOTE 3 – RELATED PARTY RECEIVABLE

 

On July 7, 2021, the company has entered into an agreement to purchase 100% of the Preferred A-1 Stock of Health Revenue Assurance Holdings, Inc. a SEC registered company for $500,000. In March 2022, Health Revenue Assurance Holdings, Inc. name was changed to Ameriguard Security Services Inc. (AGSS). On December 9, 2022, we signed the definitive merger agreement initiating a reverse merger with AGSS, resulting in the Company becoming a 100% owned subsidiary of AGSS. Prior to the merger, the Company funded the operational expenses of AGSS and treated these expenses as related party expenses. These expenses we eliminated when the two companies were consolidated for the financial statement presentation.

 

The receivable balances on December 31, 2022, and 2021 were $57,971 and $10,596 respectively. Balances adjusted to zero as a result of consolidation.

 

XML 24 R15.htm IDEA: XBRL DOCUMENT v3.23.2
FIXED ASSETS
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Property, Plant and Equipment [Abstract]    
FIXED ASSETS

NOTE 4 – FIXED ASSETS

 

Fixed assets consist of the following on June 30, 2023, and December 31, 2022:

 

               
    2023     2022  
Leasehold Improvements     224,637       224,132  
Machinery and Equipment     286,551       278,551  
Vehicles     110,742       110,274  
Total Fixed Assets     621,426       612,957  
Accumulated Depreciation     (332,985 )     (314,151 )
Fixed Assets, Net   $ 288,477     $ 298,806  

 

NOTE 4 – FIXED ASSETS

 

Fixed assets consist of the following on December 31, 2022, and 2021:

 

               
    2021     2020  
Leasehold Improvements     224,132       -  
Machinery and Equipment     278,551       246,974  
Vehicles     110,274       131,775  
Total Fixed Assets     612,957       378,749  
Accumulated Depreciation     (314,151 )     (245,947 )
Fixed Assets, Net   $ 298,806     $ 132,802  

 

XML 25 R16.htm IDEA: XBRL DOCUMENT v3.23.2
PAYROLL LIABILITY – PENSION
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Payroll Liability Pension    
PAYROLL LIABILITY – PENSION

NOTE 5 – PAYROLL LIABILITY – PENSION

 

The company offers various pension plans to employee groups based on location of employment. Corporate office employees and guards have an option to participate in a 401K sponsored by the company with a matching program up to 5% of employee salary. Federal contracts have union agreements that define the pension calculation and due dates. It is the responsibility of the company to calculate the pension benefit amount each month and contribute the amount due to the plan designated. The pension balances due on June 30, 2023, and December 31, 2022, for all plans were $345,140 and $453,965 respectively.

 

NOTE 5 – PAYROLL LIABILITY – PENSION

 

The company offers various pension plans to employee groups based on location of employment. Corporate office employees and guards have an option to participate in a 401K sponsored by the company with a matching program up to 5% of employee salary. Federal contracts have union agreements that define the pension calculation and due dates. It is the responsibility of the company to calculate the pension benefit amount each month and contribute the amount due to the plan designated. The pension balances due on December 31, 2022, and 2021 for all plans was $453,965 and $616,579 respectively.

 

XML 26 R17.htm IDEA: XBRL DOCUMENT v3.23.2
NOTES PAYABLE
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Debt Disclosure [Abstract]    
NOTES PAYABLE

NOTE 6 – NOTES PAYABLE

 

In June 2020, AmeriGuard Security Services, Inc. received an SBA Loan through Fresno First Bank in the amount of $1,080,000 that was used to close out the Citibank loan in the amount of $312,339 with the remaining balance after expenses held in reserve. The SBA loan is a 10-year loan with monthly principal and interest payments. Interest rate is variable at prime rate plus 2.75%, adjusted every calendar quarter. Interest rate on June 30, 2023, and December 31, 2022, was 10.75% and 9% respectively. Balance remaining on the SBA loan was $767,678 and $785,988 as of June 30, 2023, and December 31, 2022, respectively.

 

On July 7, 2022, the Company entered into a buyout agreement with a shareholder Lillian Flores. The total buyout amount was $3,384,950 representing 45% of the calculated business value as of December 31, 2020. Following the initial payment of $686,990, the company agreed to make 4 equal instalments of principal and interest of $739,508 each December 31, starting 2023. Interest is calculated at a fixed rate of 3.110% compounded semi-annually. The company has accrued interest on June 30, 2023, of $91,635. Balance remaining in the amount of $2,697,960.

 

The following schedule details the loans active as of June 30, 2023, and December 31, 2022:

 

               
    2023     2022  
Current Portion:                
Notes and loans payable   $ 719,563     $ 719,563  
Total Current Portion     719,563       719,563  
Long term Portion:                
Notes and loans payable     2,746,075       2,782,784  
Total Long-term Portion     2,746,075       2,782,784  
    $ 3,465,638     $ 3,502,347  

 

NOTE 6 – NOTES PAYABLE

 

In June 2020, AmeriGuard Security Services, Inc. received an SBA Loan through Fresno First Bank in the amount of $1,080,000 that was used to close out the Citibank loan in the amount of $312,339 with the remaining balance after expenses held in reserve. The SBA loan is a 10-year loan with monthly principal and interest payments. Interest rate is variable at prime rate plus 2.75%, adjusted every calendar quarter. Interest rate on December 31, 2022, and 2021 was 9% and 4.01% respectively. Balance remaining on the SBA loan was $804,387 and $888,845 as of December 31, 2022, and 2021 respectively.

 

In January 2020, the Company entered into a financing agreement with Master Security Company for the purchase of vehicles, guns, and guard equipment for the National Institute of Health USEPA contract which began May 2020. The principal financed was $150,000, with interest of 4% for a term of 21 months. Resulting in a monthly principal and interest payment of $7,406. Balance remaining in the amount of $0 and $7,729 as of December 31, 2022, and 2021 respectively.

 

In December 2021, the Company entered into a financing agreement with Secure Transportation Inc. for the purchase of three used vehicles in the amount of $21,500. Note requires 12 equal payments of $1,900 with a calculated interest rates of 5% with the first payment December 15, 2021. Balance remaining in the amount of $0 and $19,615 as of December 31, 2022, and 2021 respectively.

 

On July 7, 2022, the Company entered into a buyout agreement with a shareholder Lillian Flores. The total buyout amount was $3,384,950 representing 45% of the calculated business value as of December 31, 2020. Following the initial payment of $686,990, the company agreed to make 4 equal installments of principal and interest of $739,508 each December 31, starting 2023. Interest is calculated at a fixed rate of 3.110% compounded semi-annually. The company has accrued interest on December 31, 2022, of $49,035. Balance remaining in the amount of $2,697,960.

 

The following schedule details the loans active as of December 31, 2022, and 2021:

 

                 
    2022     2021  
Current Portion:                
Notes and loans payable   $ 719,563     $ 127,615  
Total Current Portion     719,563       127,615  
Long term Portion:                
Notes and loans payable     2,782,784       780,845  
Total Long-term Portion     2,782,784       780,845  
    $ 3,502,347     $ 908,460  

 

XML 27 R18.htm IDEA: XBRL DOCUMENT v3.23.2
STOCKHOLDERS’ EQUITY
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Equity [Abstract]    
STOCKHOLDERS’ EQUITY

NOTE 7 – STOCKHOLDERS’ EQUITY 

 

From December 31, 2022, to June 30,2023 the only impact to equity was the Net Income for the period of $1,030,950.

 

NOTE 7 – STOCKHOLDERS’ EQUITY

 

On December 9, 2022, the Company executed a reverse merger agreement with AGSS resulting in significant adjustments to the equity section of both companies. The result of the merger was AGSS became the sole owner of the Company. Although the merger is dated December 9, 2022, for financial statement presentation purposes, we have presented the Equity Section as if the merger occurred in 2021.

 

The first significant impact on stockholders’ equity was the issuance of 90,000,000 AGSS shares to the shareholders of Ameriguard Security Services, Inc (the Company) in exchange for 1000 shares of the Company, adding a net increase in common shares outstanding of 89,999,000. Next was the cancelation and conversion of series 675,000 A-1 preferred shares held by AGSS on December 31, 2020. The final result in the total number of shares outstanding is 93,417,302.

 

The next part of stockholder’s equity impacted was Additional Paid-in Capital. The impact was a reduction of Paid-in Capital of $579,000. This reduction was caused by an $89,999 impact of issuing new shares, a $10,000 impact form the cancelation of preferred shares and finally the $500,000 cost of the Company’s purchase of AGSS, formally Heath Revenue Assurance Holdings, Inc.

 

There were two other transactions that impacted stockholders’ equity that occurred to the Company’s equity section relating to owner draws and the merger with a related company. As a part of the normal activity of the privately held Company, an S-Corp, shareholders were distributed funds accounted for as Owner Draws. The owner draw accounts were used primarily for taxes paid by the shareholders due to profits of the S-Corp being transferred to their personal returns along with some personal expenses and personal cash needs. For 2021, there was approximately $105,000 posted as Owner draw from historical balances of related party receivables. As part of the preparation for merger these inter-company balances were removed through the owner draw accounts. Total owner draw amounts were $473,238 and $62,824 for December 31, 2022, and 2021 respectively.

 

XML 28 R19.htm IDEA: XBRL DOCUMENT v3.23.2
COMMITMENTS AND CONTINGENCIES
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]    
COMMITMENTS AND CONTINGENCIES

NOTE 8 – COMMITMENTS AND CONTINGENCIES

 

The company has a multiple vehicle lease agreement with Enterprise Leasing. As of June 30, 2023, the company had 19 vehicles under lease. The lease agreement includes maintenance services. The term of the lease agreement varies based on the date vehicle were leased and the respective terms for each vehicle. The master lease is updated annually and requires annual internal financial reports and company tax return.

 

NOTE 8 – COMMITMENTS AND CONTINGENCIES

 

The company has a multiple vehicle lease agreement with Enterprise Leasing. As of December 31, 2022, the company had 19 vehicles under lease. The lease agreement includes maintenance services along physical damage insurance. The term of the lease agreement varies based on the date vehicle were leased and the respective terms for each vehicle. The master lease is updated annually and requires annual internal financial reports and company tax return.

 

XML 29 R20.htm IDEA: XBRL DOCUMENT v3.23.2
CONCENTRATION OF SALES
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Concentration Of Sales    
CONCENTRATION OF SALES

NOTE 9 – CONCENTRATION OF SALES

 

The company generated approximately $10,972,000 and $11,709,000 in guard service revenue for the six-month ending June 30, 2023 and 2022 respectively. Of the total guard service revenue, approximately 87% was earned from four federal contracts operated by the company. The contracts, their respective terms and approximate revenues are as follows:

 

  Social Security Administration, NSC -

September 2022 through September 2027

Six-month revenue - $2,770,000

         
  Social security Administration, SSC -

June 2022 through June 2027

Six-month revenue - $1,511,000

         
  Social Security Administration, WBDOC -

June 2021 through July 2026

Six-month revenue - $2,770,000

         
  National Institute of Health- EPA -

May 2020 through May 2023

Six-month revenue - $2,904,000

 

NOTE 9 – CONCENTRATION OF SALES

 

The company generated approximately $24,600,000 and $22,100.000 in guard service revenue for the years 2022 and 2021 respectively. Of the total guard service revenue, approximately 87% was earned from four federal contracts operated by the company. The contracts and their respective terms are as follows:

 

  Social Security Administration, NSC   -

September 2022 through September 2027

Annual Revenue of approx. $3.145M

           
  Social security Administration, SSC   -

June 2022 through June 2027

Annual Revenue of approx. $4.932M

           
  Social Security Administration, WBDOC   -

June 2021 through July 2026

Annual Revenue of approx. $5.838M

           
  National Institute of Health- EPA   -

May 2020 through March 2023

Annual Revenue of approx. $7.514M

 

 

XML 30 R21.htm IDEA: XBRL DOCUMENT v3.23.2
LITIGATION AND CLAIMS
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Litigation And Claims    
LITIGATION AND CLAIMS

NOTE 11 – LITIGATION AND CLAIMS

 

As of December 31, 2022, there was one employment issue pending. The issue involves a terminated employee alleging discrimination and wrongful termination. A lawsuit has not been filed, only a demand letter has been presented. Management has been working with the attorneys to find a reasonable settlement to this dispute without going to trial. After several months of discussion and negotiation it appears that the complaint will be settled for $23,000. As of March 31, 2023, the final agreement was signed which pays out the $23,000 settlement in three monthly installments starting May 15, 2023, Per Attorney letters received there are no other pending cases or legal matters.

NOTE 10 – LITIGATION AND CLAIMS

 

As of December 31, 2022, there was one employment issue pending. The issue involves a terminated employee alleging discrimination and wrongful termination. A lawsuit has not been filed only a demand letter has been presented. Management has been working with the attorneys to find a reasonable settlement to this dispute without going to trial. After several months of discussion and negotiation it appears that the complaint will be settled for $23,000. It is anticipated that an agreement may be reached by the end of March 2023.

 

Per Attorney letters received there are no other pending cases or legal matters.

 

XML 31 R22.htm IDEA: XBRL DOCUMENT v3.23.2
INCOME TAXE
12 Months Ended
Dec. 31, 2022
Income Tax Disclosure [Abstract]  
INCOME TAXE

NOTE 11 – INCOME TAXES

 

Prior to the merger the Company had elected, with the consent of its stockholders, to be treated as an S Corporation under the Internal Revenue Code. In lieu of corporate income taxes, the stockholders of an S Corporation are taxed on their proportionate share of the Company’s income. As a result of the merger on December 9, 2022, the S Corporation status ends, and the consolidated 2022 tax return will be filed as a standard corporation. However, due to the losses incurred during the tax year ending 2022, there will be no tax liability for 2022. Therefore, no provision for income taxes has been included in the accompanying financial statements.

 

XML 32 R23.htm IDEA: XBRL DOCUMENT v3.23.2
SUBSEQUENT EVENTS
12 Months Ended
Dec. 31, 2022
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 12 – SUBSEQUENT EVENTS

 

On March 22, 2023, The Company was notified by the Contracting Officer of National Institute of Health-EPA our contract with them was not continuing and they were invoking the 45 days cancelation clause in the contract. As a result, the company will transition the closure of the contract on or about April 30, 2023. This will reduce on our annual revenue in the amount of approximately $5,122,000 in 2023, along with direct expenses that will be reduced by $4,650,000.

 

On March 23, 2023, the board of directors approved the purchase of TransportUS, Inc. While the Company explored the purchase of TransportUS, Inc., owned by Lawrence Garcia, the board of directors has determined, following due diligence, that the financial statements of TransportUS, Inc. are not in a form that can be audited under US GAAP. We have therefore abandoned such undertaking for the foreseeable future.

XML 33 R24.htm IDEA: XBRL DOCUMENT v3.23.2
OTHER INCOME (EXPENSE)
6 Months Ended
Jun. 30, 2023
Other Income and Expenses [Abstract]  
OTHER INCOME (EXPENSE)

NOTE 10 – OTHER INCOME (EXPENSE)

 

The company received an Employee Retention Tax Credit of (ERTC) payment of $3,288,000 from the tax year 2021. The company also experienced a related expense of approximately $473,000 for professional services related to the ERTC filing.

 

XML 34 R25.htm IDEA: XBRL DOCUMENT v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Accounting Policies [Abstract]    
Use of Estimates

Use of Estimates

 

In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, along with the collectability of some receivables from customers.

 

Use of Estimates

 

In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, along with the collectability of some receivables from customers.

 

Cash and Cash Equivalents

Cash and Cash Equivalents

 

The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. On June 30, 2023, and December 31, 2022, the Company had cash and cash equivalents totaling $2,970439 and $1,227,654 respectively.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. On December 31, 2022, and December 31, 2021, the Company had cash and cash equivalents totaling $1,227,654 and $2,129,801 respectively.

 

Accounts Receivable

Accounts Receivable

 

We record accounts receivable at net realizable value. This value includes an appropriate allowance for estimated uncollectible accounts to reflect any loss anticipated on the accounts receivable balances and is charged to other bad debt expense. We calculate this allowance based on our history of write-offs, the level of past-due accounts based on the contractual terms of the receivables, and our relationships with, and the economic status of, our customers. With over 86% percent of year end accounts receivable balance from Federal contracts that require payment, and the uncollectable amount historically has been less than 1%. As of June 30, 2023, and December 31, 2022, an allowance for estimated uncollectible accounts was determined to be unnecessary.

 

Accounts Receivable

 

We record accounts receivable at net realizable value. This value includes an appropriate allowance for estimated uncollectible accounts to reflect any loss anticipated on the accounts receivable balances and is charged to other bad debt expense. We calculate this allowance based on our history of write-offs, the level of past-due accounts based on the contractual terms of the receivables, and our relationships with, and the economic status of, our customers. With over ninety percent of year end accounts receivable balance from Federal contracts that require payment, and the uncollectable amount historically has been less than 1%. As of December 31, 2022, and 2021, an allowance for estimated uncollectible accounts was determined to be unnecessary.

 

Property and Equipment

Property and Equipment

 

Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment is retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses other depreciation methods (generally accelerated) for tax purposes where appropriate. The estimated useful life for Machinery and Equipment, and Vehicles is 5 years, with Leasehold improvements useful life is 10 Years.

 

Property and Equipment

 

Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment is retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses other depreciation methods (generally accelerated) for tax purposes where appropriate. The estimated useful life for Machinery and Equipment, and Vehicles is 5 years, with Leasehold improvements useful life is 10 Years.

 

Operating Leases

Operating Leases

 

In February 2016, FASB ASU No. 2016-02 established ASC Topic 842, Leases, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. Effective December 31, 2022, we have implemented ASU No. 2016-02 and booked the operating lease asset and the related liability.

 

Operating Leases

 

In February 2016, FASB ASU No. 2016-02 established ASC Topic 842, Leases, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. Effective December 31, 2022, we have implemented ASU No. 2016-02 and booked the operating lease asset and the related liability.

 

We have leased vehicles that are classified as operating leases per the guidelines. The Balance Sheet & the Statement of Cash Flows reflects the implementation of this guideline. The Balance Sheet reflects the asset and liability of the operating leases. The Statement of Cash Flows reflects the implementation of this guideline as transactions that affected cash flow and non-cash financing activities. The change in the operating lease liability of ($79,358) is the difference of the total liability of our lease ($373,745) from the total liability balance of ($294,387) as of December 31,2022. The ($79,358) change in the operating lease liability consists of the total lease payments made for the year. The change in operating lease asset of $71,049 is the net of the total asset of the leases ($373,745) and the remaining asset balance of $302,695 as of December 31, 2022. The $71,049 is the amortization of the lease for the year.

 

Net Income/(Loss) per Share

Net Income/(Loss) per Share

 

Net income/(loss) per common share is computed by dividing net income or loss by the weighted average common shares outstanding during the period as defined by Financial Accounting Standards, ASC Topic 260, “Earnings per Share”. Basic earnings/(loss) per common share (“EPS”) calculations are determined by dividing net income/(loss) by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.

 

 

Net Income/(Loss) per Share

 

Net income/(loss) per common share is computed by dividing net income or loss by the weighted average common shares outstanding during the period as defined by Financial Accounting Standards, ASC Topic 260, “Earnings per Share”. Basic earnings/(loss) per common share (“EPS”) calculations are determined by dividing net income/(loss) by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.

Revenue Recognition

Revenue Recognition

 

We recognize revenue when the Invoice for contracted services is issued as stipulated by the contract. Other services provided are recognized at the time the service is provided. Ninety eight percent of revenues are billed monthly and recognized in the month the services were provided. Refunds and returns, which are minimal, are recorded as a reduction of revenue. The Company has not recorded a reserve for returns on June 30, 2023, or 2022 since it does not believe such returns will be material.

 

Revenue Recognition

 

We recognize revenue when the Invoice for contracted services is issued as stipulated by the contract. Other services provided are recognized at the time the service is provided. Ninety eight percent of revenues are billed monthly and recognized in the month the services were provided. Refunds and returns, which are minimal, are recorded as a reduction of revenue. The Company has not recorded a reserve for returns on December 31, 2022, or 2021 since it does not believe such returns will be material.

 

Fair Value of Financial Instruments

Fair Value of Financial Instruments

 

The Company applies the accounting guidance under Financial Accounting Standards Board (“FASB”) ASC 820-10, “Fair Value Measurements”, as well as certain related FASB staff positions. This guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance.

 

The guidance also establishes a fair value hierarchy for measurements of fair value as follows:

 

  Level 1 - quoted market prices in active markets for identical assets or liabilities.
     
  Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
     
  Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

The carrying amount of the Company’s financial instruments approximates their fair value as of June 30, 2023 and December 31, 2022, due to the short-term nature of these instruments.

 

Fair Value of Financial Instruments

 

The Company applies the accounting guidance under Financial Accounting Standards Board (“FASB”) ASC 820-10, “Fair Value Measurements”, as well as certain related FASB staff positions. This guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance.

 

The guidance also establishes a fair value hierarchy for measurements of fair value as follows:

 

  Level 1 - quoted market prices in active markets for identical assets or liabilities.
     
  Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
     
 

Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

The carrying amount of the Company’s financial instruments approximates their fair value as of December 31, 2021 and December 31, 2022, due to the short-term nature of these instruments.

 

XML 35 R26.htm IDEA: XBRL DOCUMENT v3.23.2
FIXED ASSETS (Tables)
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Property, Plant and Equipment [Abstract]    
Schedule of fixed assets
               
    2023     2022  
Leasehold Improvements     224,637       224,132  
Machinery and Equipment     286,551       278,551  
Vehicles     110,742       110,274  
Total Fixed Assets     621,426       612,957  
Accumulated Depreciation     (332,985 )     (314,151 )
Fixed Assets, Net   $ 288,477     $ 298,806  
               
    2021     2020  
Leasehold Improvements     224,132       -  
Machinery and Equipment     278,551       246,974  
Vehicles     110,274       131,775  
Total Fixed Assets     612,957       378,749  
Accumulated Depreciation     (314,151 )     (245,947 )
Fixed Assets, Net   $ 298,806     $ 132,802  
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.23.2
NOTES PAYABLE (Tables)
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Debt Disclosure [Abstract]    
Schedule of the loan active
               
    2023     2022  
Current Portion:                
Notes and loans payable   $ 719,563     $ 719,563  
Total Current Portion     719,563       719,563  
Long term Portion:                
Notes and loans payable     2,746,075       2,782,784  
Total Long-term Portion     2,746,075       2,782,784  
    $ 3,465,638     $ 3,502,347  
                 
    2022     2021  
Current Portion:                
Notes and loans payable   $ 719,563     $ 127,615  
Total Current Portion     719,563       127,615  
Long term Portion:                
Notes and loans payable     2,782,784       780,845  
Total Long-term Portion     2,782,784       780,845  
    $ 3,502,347     $ 908,460  
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.23.2
ORGANIZATION AND DESCRIPTION OF BUSINESS (Details Narrative) - shares
Nov. 14, 2022
Nov. 14, 2021
Jun. 30, 2023
Sep. 08, 2021
Jul. 07, 2021
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]          
Number of share issued 1,000 1,000      
Holder ownership     86.00% 90.00%  
Custodian Ventures [Member]          
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]          
Preferred A-1 Stock, Shares Authorized         10,000,000
Chief Executive Officer [Member]          
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]          
Number of share issued 550 550      
Lillian Flores [Member]          
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]          
Number of share issued 450 450      
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Property, Plant and Equipment [Line Items]      
Cash $ 2,970,439 $ 1,227,654 $ 2,129,801
Operating lease liability   79,358  
Operating lease cost   373,745  
Operating Lease, Liability, Noncurrent 294,387 294,387
Increase Decrease In Operting Lease Assets   71,049  
Total asset of the leases   373,745  
Operating Lease 302,695 302,695
Amortization of the lease   71,049  
Reserve for returns $ 0 $ 0  
Machinery and Equipment [Member]      
Property, Plant and Equipment [Line Items]      
Estimated useful life   5 years  
Vehicles [Member]      
Property, Plant and Equipment [Line Items]      
Estimated useful life 5 years 5 years  
Leasehold Improvements [Member]      
Property, Plant and Equipment [Line Items]      
Estimated useful life 10 years 10 years  
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.23.2
RELATED PARTY RECEIVABLE (Details Narrative) - USD ($)
Jul. 07, 2021
Dec. 31, 2022
Dec. 31, 2021
Related Party Transactions [Abstract]      
Consideration paid Shares $ 500,000    
Notes Receivablerelated Party   $ 57,971 $ 10,596
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.23.2
FIXED ASSETS (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Property, Plant and Equipment [Line Items]      
Total Fixed Assets $ 621,426 $ 612,957 $ 378,749
Accumulated Depreciation (332,985) (314,151) (245,947)
Fixed Assets, Net 288,477 298,806 132,802
Leasehold Improvements [Member]      
Property, Plant and Equipment [Line Items]      
Total Fixed Assets 224,637 224,132
Machinery and Equipment [Member]      
Property, Plant and Equipment [Line Items]      
Total Fixed Assets 286,551 278,551 246,974
Vehicles [Member]      
Property, Plant and Equipment [Line Items]      
Total Fixed Assets $ 110,742 $ 110,274 $ 131,775
XML 41 R32.htm IDEA: XBRL DOCUMENT v3.23.2
PAYROLL LIABILITY – PENSION (Details Narrative) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Payroll Liability Pension      
Pension balances $ 345,140 $ 453,965 $ 616,579
XML 42 R33.htm IDEA: XBRL DOCUMENT v3.23.2
NOTE PAYABLE (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Short-Term Debt [Line Items]      
Total Current Portion $ 719,563 $ 719,563 $ 127,615
Total Long-term Portion 2,746,075 2,782,784 780,845
Notes Payable 3,465,638 3,502,347 908,460
Notes And Loans Payable [Member]      
Short-Term Debt [Line Items]      
Total Current Portion 719,563 719,563 127,615
Total Long-term Portion $ 2,746,075 $ 2,782,784 $ 780,845
XML 43 R34.htm IDEA: XBRL DOCUMENT v3.23.2
NOTES PAYABLE (Details Narrative) - USD ($)
1 Months Ended 6 Months Ended 12 Months Ended
Jul. 07, 2022
Dec. 31, 2021
Dec. 31, 2020
Jun. 30, 2020
Jan. 30, 2020
Jun. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Jun. 30, 2022
Short-Term Debt [Line Items]                  
Notes Payable   $ 908,460       $ 3,465,638 $ 3,502,347 $ 908,460  
Accrued Liabilities, Current         $ 91,635 49,035 $ 91,635
Master Security Company [Member]                  
Short-Term Debt [Line Items]                  
Principal amount         $ 150,000        
Term         21 months        
Interest rate         4.00%        
Periodic payment         $ 7,406        
Notes Payable   $ 7,729         0 7,729  
Secure Transportation Inc [Member]                  
Short-Term Debt [Line Items]                  
Interest rate   5.00%              
Periodic payment   $ 1,900              
Notes Payable   19,615         $ 0 $ 19,615  
Lillian Flores [Member]                  
Short-Term Debt [Line Items]                  
Principal amount $ 3,384,950                
Interest rate 3.11%   45.00%            
Notes Payable $ 2,697,960                
Initial Payment $ 686,990                
SBA Loan [Member]                  
Short-Term Debt [Line Items]                  
Principal amount       $ 1,080,000          
Expenses held in reserve       $ 312,339          
Term       10 years          
Interest rate is variable       prime rate plus 2.75%          
Interest rate           10.75% 9.00% 4.01%  
Notes Payable   888,845         $ 804,387 $ 888,845  
Notes Payable           $ 767,678 $ 785,988    
Debt Instrument, Interest Rate Terms       prime rate plus 2.75%          
Secure Transportation Inc [Member]                  
Short-Term Debt [Line Items]                  
Principal amount   $ 21,500           $ 21,500  
XML 44 R35.htm IDEA: XBRL DOCUMENT v3.23.2
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)
6 Months Ended 12 Months Ended
Nov. 14, 2022
Nov. 14, 2021
Jun. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Number of shares issued 1,000 1,000        
Shares Outstanding       93,417,302    
Reduction of Paid-in Capital       $ 579,000    
Equity description       his reduction was caused by an $89,999 impact of issuing new shares, a $10,000 impact form the cancelation of preferred shares and finally the $500,000 cost of the Company’s purchase of AGSS, formally Heath Revenue Assurance Holdings, Inc.    
Related party receivables         $ 105,000  
Owner draws (pre-merger)       $ 473,238 $ 62,824  
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest     $ 1,030,950      
Ameriguard Security Services [Member]            
Number of shares issued           90,000,000
Number of shares exchanged           1,000
Increase in common shares outstanding           89,999,000
Conversion of shares           675,000
XML 45 R36.htm IDEA: XBRL DOCUMENT v3.23.2
CONCENTRATION OF SALES (Details Narrative) - USD ($)
6 Months Ended 12 Months Ended 37 Months Ended 61 Months Ended 62 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Dec. 31, 2021
May 31, 2023
Sep. 30, 2027
Jun. 30, 2027
Jul. 31, 2026
Revenues $ 11,185,798 $ 11,867,882 $ 24,947,401 $ 22,442,513        
National Institute Of Health E P A [Member]                
Revenues         $ 2,904,000      
Subsequent Event [Member] | Social Security Administration N S C [Member]                
Revenues           $ 2,770,000    
Subsequent Event [Member] | Social Security Administration S S C [Member]                
Revenues             $ 1,511,000  
Subsequent Event [Member] | Social Security Administration W B D O C [Member]                
Revenues               $ 2,770,000
Revenue Benchmark [Member] | Product Concentration Risk [Member] | Guard Service [Member]                
Concentration Risk, Percentage   87.00% 87.00% 87.00%        
Guard Service [Member]                
Revenues $ 10,972,000 $ 11,709,000 $ 24,600,000 $ 22,100.000        
XML 46 R37.htm IDEA: XBRL DOCUMENT v3.23.2
LITIGATION AND CLAIMS (Details Narrative) - USD ($)
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Litigation And Claims    
Litigation settlement amount $ 23,000 $ 23,000
XML 47 R38.htm IDEA: XBRL DOCUMENT v3.23.2
INCOME TAXE (Details Narrative)
Dec. 31, 2022
USD ($)
Income Tax Disclosure [Abstract]  
Tax liability $ 0
XML 48 R39.htm IDEA: XBRL DOCUMENT v3.23.2
SUBSEQUENT EVENTS (Details Narrative) - Subsequent Event [Member]
1 Months Ended
Mar. 23, 2023
USD ($)
Subsequent Event [Line Items]  
Annual revenue reduced $ 5,122,000
Reduction in direct expenses $ 4,650,000
Subsequent Event, Description the board of directors approved the purchase of TransportUS, Inc. While the Company explored the purchase of TransportUS, Inc., owned by Lawrence Garcia, the board of directors has determined, following due diligence, that the financial statements of TransportUS, Inc. are not in a form that can be audited under US GAAP. We have therefore abandoned such undertaking for the foreseeable future.
XML 49 R40.htm IDEA: XBRL DOCUMENT v3.23.2
NOTES PAYABLE (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Dec. 31, 2021
Short-Term Debt [Line Items]      
Total Current Portion $ 719,563 $ 719,563 $ 127,615
Total Long-term Portion 2,746,075 2,782,784 780,845
Notes Payable 3,465,638 3,502,347 908,460
Notes And Loans Payable [Member]      
Short-Term Debt [Line Items]      
Total Current Portion 719,563 719,563 127,615
Total Long-term Portion $ 2,746,075 $ 2,782,784 $ 780,845
XML 50 R41.htm IDEA: XBRL DOCUMENT v3.23.2
OTHER INCOME (EXPENSE) (Details Narrative)
6 Months Ended
Jun. 30, 2023
USD ($)
Other Income and Expenses [Abstract]  
Other Operating Income (Expense), Net $ 473,000
XML 51 ameriguardsec_s1a3_htm.xml IDEA: XBRL DOCUMENT 0001514443 2023-01-01 2023-06-30 0001514443 dei:BusinessContactMember 2023-01-01 2023-06-30 0001514443 2022-12-31 0001514443 2021-12-31 0001514443 2022-01-01 2022-12-31 0001514443 2021-01-01 2021-12-31 0001514443 hraad:SecurityServicesMember 2022-01-01 2022-12-31 0001514443 hraad:SecurityServicesMember 2021-01-01 2021-12-31 0001514443 hraad:OtherRelatedIncomeMember 2022-01-01 2022-12-31 0001514443 hraad:OtherRelatedIncomeMember 2021-01-01 2021-12-31 0001514443 hraad:SalariesAndRelatedTaxesMember 2022-01-01 2022-12-31 0001514443 hraad:SalariesAndRelatedTaxesMember 2021-01-01 2021-12-31 0001514443 hraad:EmployeeBenefitsMember 2022-01-01 2022-12-31 0001514443 hraad:EmployeeBenefitsMember 2021-01-01 2021-12-31 0001514443 hraad:SubContractorPaymentsMember 2022-01-01 2022-12-31 0001514443 hraad:SubContractorPaymentsMember 2021-01-01 2021-12-31 0001514443 hraad:GuardTrainingMember 2022-01-01 2022-12-31 0001514443 hraad:GuardTrainingMember 2021-01-01 2021-12-31 0001514443 hraad:VehiclesAndEquipmentExpensesMember 2022-01-01 2022-12-31 0001514443 hraad:VehiclesAndEquipmentExpensesMember 2021-01-01 2021-12-31 0001514443 us-gaap:CommonStockMember 2020-12-31 0001514443 us-gaap:PreferredStockMember 2020-12-31 0001514443 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001514443 hraad:StockholdersEquityMember 2020-12-31 0001514443 2020-12-31 0001514443 us-gaap:CommonStockMember 2021-12-31 0001514443 us-gaap:PreferredStockMember 2021-12-31 0001514443 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001514443 hraad:StockholdersEquityMember 2021-12-31 0001514443 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001514443 us-gaap:PreferredStockMember 2021-01-01 2021-12-31 0001514443 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001514443 hraad:StockholdersEquityMember 2021-01-01 2021-12-31 0001514443 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0001514443 us-gaap:PreferredStockMember 2022-01-01 2022-12-31 0001514443 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0001514443 hraad:StockholdersEquityMember 2022-01-01 2022-12-31 0001514443 us-gaap:CommonStockMember 2022-12-31 0001514443 us-gaap:PreferredStockMember 2022-12-31 0001514443 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001514443 hraad:StockholdersEquityMember 2022-12-31 0001514443 2021-11-01 2021-11-14 0001514443 srt:ChiefExecutiveOfficerMember 2021-11-01 2021-11-14 0001514443 hraad:LillianFloresMember 2021-11-01 2021-11-14 0001514443 hraad:CustodianVenturesMember 2021-07-07 0001514443 2021-09-08 0001514443 2022-11-01 2022-11-14 0001514443 srt:ChiefExecutiveOfficerMember 2022-11-01 2022-11-14 0001514443 hraad:LillianFloresMember 2022-11-01 2022-11-14 0001514443 2023-06-30 0001514443 us-gaap:MachineryAndEquipmentMember 2022-12-31 0001514443 us-gaap:VehiclesMember 2022-12-31 0001514443 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001514443 us-gaap:VehiclesMember 2023-06-30 0001514443 us-gaap:LeaseholdImprovementsMember 2023-06-30 0001514443 2021-07-01 2021-07-07 0001514443 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001514443 us-gaap:MachineryAndEquipmentMember 2021-12-31 0001514443 us-gaap:VehiclesMember 2021-12-31 0001514443 us-gaap:MachineryAndEquipmentMember 2023-06-30 0001514443 hraad:SBALoanMember 2020-06-30 0001514443 hraad:SBALoanMember 2020-06-01 2020-06-30 0001514443 hraad:SBALoanMember 2022-01-01 2022-12-31 0001514443 hraad:SBALoanMember 2021-01-01 2021-12-31 0001514443 hraad:SBALoanMember 2022-12-31 0001514443 hraad:SBALoanMember 2021-12-31 0001514443 hraad:MasterSecurityCompanyMember 2020-01-30 0001514443 hraad:MasterSecurityCompanyMember 2020-01-01 2020-01-30 0001514443 hraad:MasterSecurityCompanyMember 2022-12-31 0001514443 hraad:MasterSecurityCompanyMember 2021-12-31 0001514443 hraad:SecureTransportationIncMember 2021-12-31 0001514443 hraad:SecureTransportationIncMember 2021-12-01 2021-12-31 0001514443 hraad:SecureTransportationIncMember 2022-12-31 0001514443 hraad:SecureTransportationIncMember 2021-12-31 0001514443 hraad:LillianFloresMember 2022-07-07 0001514443 hraad:LillianFloresMember 2020-12-01 2020-12-31 0001514443 hraad:LillianFloresMember 2022-07-01 2022-07-07 0001514443 hraad:SBALoanMember 2023-01-01 2023-06-30 0001514443 hraad:SBALoanMember 2023-06-30 0001514443 2022-06-30 0001514443 hraad:NotesAndLoansPayableMember 2022-12-31 0001514443 hraad:NotesAndLoansPayableMember 2021-12-31 0001514443 hraad:AmeriguardSecurityServicesMember 2020-01-01 2020-12-31 0001514443 hraad:GuardServiceMember 2022-01-01 2022-12-31 0001514443 hraad:GuardServiceMember 2021-01-01 2021-12-31 0001514443 hraad:GuardServiceMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-12-31 0001514443 hraad:GuardServiceMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2021-01-01 2021-12-31 0001514443 hraad:GuardServiceMember 2023-01-01 2023-06-30 0001514443 hraad:GuardServiceMember 2022-01-01 2022-06-30 0001514443 hraad:GuardServiceMember us-gaap:SalesRevenueNetMember us-gaap:ProductConcentrationRiskMember 2022-01-01 2022-06-30 0001514443 hraad:SocialSecurityAdministrationNSCMember us-gaap:SubsequentEventMember 2022-09-01 2027-09-30 0001514443 hraad:SocialSecurityAdministrationSSCMember us-gaap:SubsequentEventMember 2022-06-01 2027-06-30 0001514443 hraad:SocialSecurityAdministrationWBDOCMember us-gaap:SubsequentEventMember 2021-06-01 2026-07-31 0001514443 hraad:NationalInstituteOfHealthEPAMember 2020-05-01 2023-05-31 0001514443 us-gaap:SubsequentEventMember 2023-03-01 2023-03-23 0001514443 2022-01-01 2022-06-30 0001514443 hraad:SecurityServicesMember 2023-01-01 2023-06-30 0001514443 hraad:SecurityServicesMember 2022-01-01 2022-06-30 0001514443 hraad:OtherRelatedIncomeMember 2023-01-01 2023-06-30 0001514443 hraad:OtherRelatedIncomeMember 2022-01-01 2022-06-30 0001514443 hraad:SalariesAndRelatedTaxesMember 2023-01-01 2023-06-30 0001514443 hraad:SalariesAndRelatedTaxesMember 2022-01-01 2022-06-30 0001514443 hraad:EmployeeBenefitsMember 2023-01-01 2023-06-30 0001514443 hraad:EmployeeBenefitsMember 2022-01-01 2022-06-30 0001514443 hraad:SubContractorPaymentsMember 2023-01-01 2023-06-30 0001514443 hraad:SubContractorPaymentsMember 2022-01-01 2022-06-30 0001514443 hraad:GuardTrainingMember 2023-01-01 2023-06-30 0001514443 hraad:GuardTrainingMember 2022-01-01 2022-06-30 0001514443 hraad:VehiclesAndEquipmentExpensesMember 2023-01-01 2023-06-30 0001514443 hraad:VehiclesAndEquipmentExpensesMember 2022-01-01 2022-06-30 0001514443 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001514443 us-gaap:PreferredStockMember 2023-01-01 2023-06-30 0001514443 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001514443 hraad:StockholdersEquityMember 2023-01-01 2023-06-30 0001514443 us-gaap:CommonStockMember 2023-06-30 0001514443 us-gaap:PreferredStockMember 2023-06-30 0001514443 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001514443 hraad:StockholdersEquityMember 2023-06-30 0001514443 hraad:NotesAndLoansPayableMember 2023-06-30 iso4217:USD shares iso4217:USD shares pure 0001514443 true Amendment No.3 S-1/A AMERIGUARD SECURITY SERVICES, INC. NV 5470 W. Spruce Avenue Suite 102 Fresno CA (559) 271-5984 NEVADA AGENCY AND TRANSFER COMPANY 50 West Liberty Street Suite 880 Reno NV 8950 8950 (775) 322-0626 Non-accelerated Filer true false 1227654 2129801 1869268 2215197 110829 107884 3207751 4452882 298806 132802 302695 601501 132802 3809252 4585684 761515 418342 49035 737143 657741 453965 616579 719563 127615 2721221 1820277 2782784 780845 294387 5798392 2601122 0.001 0.001 94471302 94471302 94471302 94471302 158346 158346 -2147486 1816216 -1989140 1974562 3809252 4575684 24643096 22418328 304305 24185 24947401 22442513 15030738 13873241 3052774 2915322 3467391 3433959 202826 222298 194889 184176 21948618 20628996 2998783 1813517 1161982 365433 433424 295054 361314 318442 106382 112140 87119 111287 128544 77349 645268 294062 105826 59439 42927 52273 3072786 1685479 -74003 128038 344105 -344105 -418108 128038 10350 33923 -428458 94115 -0.0046 0.0010 93417302 93417302 2743302 69346 675000 10000 9976045 -7191705 2863685 -473238 -473238 89999000 89000 -10000 -579000 -500000 675000 -675000 94115 94115 93417302 158346 9397045 -7570828 1984562 -62824 -62824 -3384950 -3384950 -97470 -97470 -428458 -428458 93417302 158346 6012095 -8159580 -1989140 -428458 94115 345929 -23372 -2945 -32949 343172 33742 49035 79402 75693 -162614 77237 -79358 71049 258139 276739 -6043 -24552 -224132 -230175 -524552 21500 686990.00 180298 227097 62824 473238 -930112 -678835 -902148 -926648 2129801 3056449 1227653 2129801 10350 33923 105826 59439 3384950 302695 294387 <p id="xdx_804_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zEHMq2wUtwJ8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="b_006"></span>NOTE 1 – <span id="xdx_825_zBmkjAL0yHk2">ORGANIZATION AND DESCRIPTION OF BUSINESS</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">AmeriGuard Security Services, Inc. (the Company), was incorporated on November 14, 2002, with an S-Corp tax election. The corporation was incorporated with the issuance of <span id="xdx_90D_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211101__20211114_pdd" title="Number of share issued">1,000</span> shares of no-par value stock held by Lawrence Garcia, President and CEO with <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211101__20211114__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pdd" title="Number of share issued">550</span> shares and Lillian Flores, VP of Operations with <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20211101__20211114__srt--TitleOfIndividualAxis__custom--LillianFloresMember_pdd" title="Number of share issued">450</span> shares. The Company provides armed guard services as a federal contractor with licenses in 5 states and provides commercial guard services in California.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 7, 2021, the Company, entered into an agreement to gain 100% control of Health Revenue Assurance Holdings, Inc (HRAA) a public corporation, incorporated in Nevada, by the purchase of <span id="xdx_904_eus-gaap--PreferredStockSharesAuthorized_c20210707__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CustodianVenturesMember_pdd" title="Preferred A-1 Stock, Shares Authorized">10,000,000</span> shares of Preferred A-1 Stock from the seller, Custodian Ventures LLC. The purchase of HRAA allowed the Company to begin plans to consummate a reverse merger with HRAA becoming a wholly owned subsidiary of a public company. In March of 2022, a Certificate of Amendment was filed with the Nevada Secretary of State, changing the name of HRAA, to Ameriguard Security Services, Inc. (AGSS). Shortly thereafter, a stock name and ticker change report was filed with the SEC and the stock ticker of HRAA was changed to AGSS.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 9, 2022, the Company executed the reverse merger agreement and became the subsidiary of AGSS. From that point forward, the financial statement filings will be the consolidation of Ameriguard Security Services, Inc, a Nevada company with Ameriguard Security Services, Inc. a California company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s accounting year end is December 31.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Basis of Presentation </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">These financial statements are presented in United States dollars and have been prepared in accordance with United States generally accepted accounting principles.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Risks and Uncertainties</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The risks and uncertainties described below may not be the only ones we are or may face in the future. If any of the following do occur, our business, financial condition or results of operations could be materially adversely affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The company receives over <span id="xdx_904_ecustom--HolderOwnership_iI_dp_c20210908_zd1lPBGkNZLj" title="Holder ownership">90</span>% of its total revenue from four Federal contracts as described in Note 9 below. These contracts have specific terms, typically five years with the opportunity for extension, but there are no assurances they will be extended. Although we have had several extended in the past, there is no guarantee this will again happened in the future. However, there are significant direct expenses for each contract that also are removed from operations at the end of a contract. As a result, the revenue lost from a completed contract does not affect the bottom-line profits in an amount equal to the revenue lost. The actual net income impact depends on the contract.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The process required to acquire a government contract takes several months to complete prior to delivery of the proposal to the contracting agency. Due to the time span required to prepare a proposal and wining the contract is not guaranteed, the company maintains a department of individuals who monitor and write proposals for all government contracts that become open for bid on a continuing basis. It is important to the company that new contracts are acquired consistently to maintain and grow annual revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other risks to operations consist of State and Federal regulations, accelerating inflation, and overall business environment issues we cannot foresee.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1000 550 450 10000000 0.90 <p id="xdx_80C_eus-gaap--SignificantAccountingPoliciesTextBlock_zZy6HnaEIDg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2 – <span id="xdx_82B_zOxol13hMTrd">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--UseOfEstimates_zRecyqk8YDU5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_865_zIZtRitM9Ofk">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, along with the collectability of some receivables from customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_za8cGQoYtPne" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_zR3gSfbi6Edb">Cash and Cash Equivalents</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. On December 31, 2022, and December 31, 2021, the Company had cash and cash equivalents totaling $<span id="xdx_90B_eus-gaap--Cash_c20221231_pp0p0" title="Cash">1,227,654</span> and $<span id="xdx_90A_eus-gaap--Cash_c20211231_pp0p0" title="Cash">2,129,801</span> respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_849_eus-gaap--ReceivablesPolicyTextBlock_zWESyxeH5sg7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_znjXzBfVYbA9">Accounts Receivable</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We record accounts receivable at net realizable value. This value includes an appropriate allowance for estimated uncollectible accounts to reflect any loss anticipated on the accounts receivable balances and is charged to other bad debt expense. We calculate this allowance based on our history of write-offs, the level of past-due accounts based on the contractual terms of the receivables, and our relationships with, and the economic status of, our customers. With over ninety percent of year end accounts receivable balance from Federal contracts that require payment, and the uncollectable amount historically has been less than 1%. As of December 31, 2022, and 2021, an allowance for estimated uncollectible accounts was determined to be unnecessary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_ziK7Q4nFjCr6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_zIZ2MTxwH9wg">Property and Equipment</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment is retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses other depreciation methods (generally accelerated) for tax purposes where appropriate. The estimated useful life for Machinery and Equipment, and Vehicles is <span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zKkhmyynhbng" title="Estimated useful life"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zqGVLHBnwbaf" title="Estimated useful life">5</span></span> years, with Leasehold improvements useful life is <span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zawVsX2FNHz1" title="Estimated useful life">10</span> Years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_ecustom--OperatingLeasesPolicyTextBlock_zmpUbaiJJbOi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86D_zddzxFMuIBck">Operating Leases</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2016, FASB ASU No. 2016-02 established ASC Topic 842, Leases, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. Effective December 31, 2022, we have implemented ASU No. 2016-02 and booked the operating lease asset and the related liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have leased vehicles that are classified as operating leases per the guidelines. The Balance Sheet &amp; the Statement of Cash Flows reflects the implementation of this guideline. The Balance Sheet reflects the asset and liability of the operating leases. The Statement of Cash Flows reflects the implementation of this guideline as transactions that affected cash flow and non-cash financing activities. The change in the operating lease liability of ($<span id="xdx_90B_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_pp0p0_c20220101__20221231_zfuYNNtz3fy" title="Operating lease liability">79,358</span>) is the difference of the total liability of our lease ($<span id="xdx_900_eus-gaap--OperatingLeaseCost_pp0p0_c20220101__20221231_zyYXHAg0HEg1" title="Operating lease cost">373,745</span>) from the total liability balance of ($<span id="xdx_905_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20221231_zPWCuAE2SkDe" title="Operating Lease, Liability, Noncurrent">294,387</span>) as of December 31,2022. The ($<span id="xdx_90B_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_pp0p0_c20220101__20221231_zcpqxaLlxrbc" title="Operating lease liability">79,358</span>) change in the operating lease liability consists of the total lease payments made for the year. The change in operating lease asset of $<span id="xdx_90B_ecustom--IncreaseDecreaseInOpertingLeaseAssets_pp0p0_c20220101__20221231_zEvLnALpNnw6" title="Increase Decrease In Operting Lease Assets">71,049</span> is the net of the total asset of the leases ($<span id="xdx_906_ecustom--TotalAssetOfLeases_c20220101__20221231_zkkwljJIHQqi" title="Total asset of the leases">373,745</span>) and the remaining asset balance of $<span id="xdx_905_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20221231_zaQ9eycH7DM7" title="Operating Lease">302,695</span> as of December 31, 2022. The $<span id="xdx_902_eus-gaap--AmortizationOfLeasedAsset_c20220101__20221231_zcTYPgZjwCN5" title="Amortization of the lease">71,049</span> is the amortization of the lease for the year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zbdAP3XHXb59" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_zOkndvQr6HEk">Net Income/(Loss) per Share</span> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income/(loss) per common share is computed by dividing net income or loss by the weighted average common shares outstanding during the period as defined by Financial Accounting Standards, ASC Topic 260, “Earnings per Share”. Basic earnings/(loss) per common share (“EPS”) calculations are determined by dividing net income/(loss) by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.</span></p> <p id="xdx_841_eus-gaap--RevenueRecognitionPolicyTextBlock_zr0UYHuapOp4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_zz7QcfQznT2f">Revenue Recognition</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We recognize revenue when the Invoice for contracted services is issued as stipulated by the contract. Other services provided are recognized at the time the service is provided. Ninety eight percent of revenues are billed monthly and recognized in the month the services were provided. Refunds and returns, which are minimal, are recorded as a reduction of revenue. The Company has not recorded a reserve for returns on December 31, 2022, or 2021 since it does <span id="xdx_903_ecustom--ReserveForReturns_pp0p0_do_c20220101__20221231_z74gdi6s8I1l" title="Reserve for returns">no</span>t believe such returns will be material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zc0VMH0FQvGj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zbTGMBpEpIV9">Fair Value of Financial Instruments</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company applies the accounting guidance under Financial Accounting Standards Board (“FASB”) ASC 820-10, “Fair Value Measurements”, as well as certain related FASB staff positions. This guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The guidance also establishes a fair value hierarchy for measurements of fair value as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 - quoted market prices in active markets for identical assets or liabilities.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amount of the Company’s financial instruments approximates their fair value as of December 31, 2021 and December 31, 2022, due to the short-term nature of these instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84A_eus-gaap--UseOfEstimates_zRecyqk8YDU5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_865_zIZtRitM9Ofk">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, along with the collectability of some receivables from customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_za8cGQoYtPne" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86C_zR3gSfbi6Edb">Cash and Cash Equivalents</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. On December 31, 2022, and December 31, 2021, the Company had cash and cash equivalents totaling $<span id="xdx_90B_eus-gaap--Cash_c20221231_pp0p0" title="Cash">1,227,654</span> and $<span id="xdx_90A_eus-gaap--Cash_c20211231_pp0p0" title="Cash">2,129,801</span> respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 1227654 2129801 <p id="xdx_849_eus-gaap--ReceivablesPolicyTextBlock_zWESyxeH5sg7" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_867_znjXzBfVYbA9">Accounts Receivable</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We record accounts receivable at net realizable value. This value includes an appropriate allowance for estimated uncollectible accounts to reflect any loss anticipated on the accounts receivable balances and is charged to other bad debt expense. We calculate this allowance based on our history of write-offs, the level of past-due accounts based on the contractual terms of the receivables, and our relationships with, and the economic status of, our customers. With over ninety percent of year end accounts receivable balance from Federal contracts that require payment, and the uncollectable amount historically has been less than 1%. As of December 31, 2022, and 2021, an allowance for estimated uncollectible accounts was determined to be unnecessary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84F_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_ziK7Q4nFjCr6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_868_zIZ2MTxwH9wg">Property and Equipment</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment is retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses other depreciation methods (generally accelerated) for tax purposes where appropriate. The estimated useful life for Machinery and Equipment, and Vehicles is <span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zKkhmyynhbng" title="Estimated useful life"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zqGVLHBnwbaf" title="Estimated useful life">5</span></span> years, with Leasehold improvements useful life is <span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zawVsX2FNHz1" title="Estimated useful life">10</span> Years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> P5Y P5Y P10Y <p id="xdx_843_ecustom--OperatingLeasesPolicyTextBlock_zmpUbaiJJbOi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86D_zddzxFMuIBck">Operating Leases</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In February 2016, FASB ASU No. 2016-02 established ASC Topic 842, Leases, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. Effective December 31, 2022, we have implemented ASU No. 2016-02 and booked the operating lease asset and the related liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We have leased vehicles that are classified as operating leases per the guidelines. The Balance Sheet &amp; the Statement of Cash Flows reflects the implementation of this guideline. The Balance Sheet reflects the asset and liability of the operating leases. The Statement of Cash Flows reflects the implementation of this guideline as transactions that affected cash flow and non-cash financing activities. The change in the operating lease liability of ($<span id="xdx_90B_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_pp0p0_c20220101__20221231_zfuYNNtz3fy" title="Operating lease liability">79,358</span>) is the difference of the total liability of our lease ($<span id="xdx_900_eus-gaap--OperatingLeaseCost_pp0p0_c20220101__20221231_zyYXHAg0HEg1" title="Operating lease cost">373,745</span>) from the total liability balance of ($<span id="xdx_905_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_pp0p0_c20221231_zPWCuAE2SkDe" title="Operating Lease, Liability, Noncurrent">294,387</span>) as of December 31,2022. The ($<span id="xdx_90B_eus-gaap--IncreaseDecreaseInOperatingLeaseLiability_pp0p0_c20220101__20221231_zcpqxaLlxrbc" title="Operating lease liability">79,358</span>) change in the operating lease liability consists of the total lease payments made for the year. The change in operating lease asset of $<span id="xdx_90B_ecustom--IncreaseDecreaseInOpertingLeaseAssets_pp0p0_c20220101__20221231_zEvLnALpNnw6" title="Increase Decrease In Operting Lease Assets">71,049</span> is the net of the total asset of the leases ($<span id="xdx_906_ecustom--TotalAssetOfLeases_c20220101__20221231_zkkwljJIHQqi" title="Total asset of the leases">373,745</span>) and the remaining asset balance of $<span id="xdx_905_eus-gaap--OperatingLeaseRightOfUseAsset_iI_c20221231_zaQ9eycH7DM7" title="Operating Lease">302,695</span> as of December 31, 2022. The $<span id="xdx_902_eus-gaap--AmortizationOfLeasedAsset_c20220101__20221231_zcTYPgZjwCN5" title="Amortization of the lease">71,049</span> is the amortization of the lease for the year.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 79358 373745 294387 79358 71049 373745 302695 71049 <p id="xdx_84C_eus-gaap--EarningsPerSharePolicyTextBlock_zbdAP3XHXb59" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_86A_zOkndvQr6HEk">Net Income/(Loss) per Share</span> </span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net income/(loss) per common share is computed by dividing net income or loss by the weighted average common shares outstanding during the period as defined by Financial Accounting Standards, ASC Topic 260, “Earnings per Share”. Basic earnings/(loss) per common share (“EPS”) calculations are determined by dividing net income/(loss) by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.</span></p> <p id="xdx_841_eus-gaap--RevenueRecognitionPolicyTextBlock_zr0UYHuapOp4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_869_zz7QcfQznT2f">Revenue Recognition</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We recognize revenue when the Invoice for contracted services is issued as stipulated by the contract. Other services provided are recognized at the time the service is provided. Ninety eight percent of revenues are billed monthly and recognized in the month the services were provided. Refunds and returns, which are minimal, are recorded as a reduction of revenue. The Company has not recorded a reserve for returns on December 31, 2022, or 2021 since it does <span id="xdx_903_ecustom--ReserveForReturns_pp0p0_do_c20220101__20221231_z74gdi6s8I1l" title="Reserve for returns">no</span>t believe such returns will be material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 <p id="xdx_843_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zc0VMH0FQvGj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="text-decoration: underline"><span id="xdx_866_zbTGMBpEpIV9">Fair Value of Financial Instruments</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company applies the accounting guidance under Financial Accounting Standards Board (“FASB”) ASC 820-10, “Fair Value Measurements”, as well as certain related FASB staff positions. This guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The guidance also establishes a fair value hierarchy for measurements of fair value as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 - quoted market prices in active markets for identical assets or liabilities.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The carrying amount of the Company’s financial instruments approximates their fair value as of December 31, 2021 and December 31, 2022, due to the short-term nature of these instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_80D_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zked7kPFQ3Yh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3 –<span id="xdx_82F_zfkKa4rtfNJ2"> RELATED PARTY RECEIVABLE</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 7, 2021, the company has entered into an agreement to purchase 100% of the Preferred A-1 Stock of Health Revenue Assurance Holdings, Inc. a SEC registered company for $<span id="xdx_90C_ecustom--ConsiderationPaidShares_c20210701__20210707_pp0p0">500,000</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. <span>In March 2022, Health Revenue Assurance Holdings, Inc. name was changed to Ameriguard Security Services Inc. (AGSS). On December 9, 2022, we signed the definitive merger agreement initiating a reverse merger with AGSS, resulting in the Company becoming a 100% owned subsidiary of AGSS. Prior to the merger, the Company funded the operational expenses of AGSS and treated these expenses as related party expenses. These expenses we eliminated when the two companies were consolidated for the financial statement presentation. </span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The receivable balances on December 31, 2022, and 2021 were $<span id="xdx_90B_ecustom--NotesReceivablerelatedParty_iI_pp0p0_c20221231_zWEU4eN742jf" title="Notes Receivable related Party">57,971 </span></span><span>and $<span id="xdx_90A_ecustom--NotesReceivablerelatedParty_iI_pp0p0_c20211231_zZbLxDnOdQF1" title="Notes Receivable related Party">10,596</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span>respectively. Balances adjusted to zero as a result of consolidation.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p> 500000 57971 10596 <p id="xdx_805_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zmf1V8SSS3Af" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4 – <span id="xdx_825_z5chrPQcPBc4">FIXED ASSETS</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fixed assets consist of the following on December 31, 2022, and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zsBy2q79X0Uk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FIXED ASSETS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span id="xdx_8B0_zEbeV75OIyIj" style="display: none">Schedule of Fixed assets</span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2021</b></span></td> <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2020</b></span></td> <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Leasehold Improvements</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" style="width: 9%; text-align: right" title="Total Fixed Assets"><span style="font-family: Times New Roman, Times, Serif">224,132</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" style="width: 9%; text-align: right" title="Total Fixed Assets"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0485">-</span></span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Machinery and Equipment</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_pp0p0" style="text-align: right" title="Total Fixed Assets"><span style="font-family: Times New Roman, Times, Serif">278,551</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_pp0p0" style="text-align: right" title="Total Fixed Assets"><span style="font-family: Times New Roman, Times, Serif">246,974</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Vehicles</span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total Fixed Assets"><span style="font-family: Times New Roman, Times, Serif">110,274</span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total Fixed Assets"><span style="font-family: Times New Roman, Times, Serif">131,775</span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total Fixed Assets</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_c20221231_pp0p0" style="text-align: right" title="Total Fixed Assets"><span style="font-family: Times New Roman, Times, Serif">612,957</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_c20211231_pp0p0" style="text-align: right" title="Total Fixed Assets"><span style="font-family: Times New Roman, Times, Serif">378,749</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated Depreciation</span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20221231_zdPug3G0hdx3" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated Depreciation"><span style="font-family: Times New Roman, Times, Serif">(314,151</span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_982_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20211231_zpy79CcU7TJ7" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated Depreciation"><span style="font-family: Times New Roman, Times, Serif">(245,947</span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Fixed Assets, Net</span></td> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td> <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_c20221231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Fixed Assets, Net"><span style="font-family: Times New Roman, Times, Serif">298,806</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td> <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentNet_c20211231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Fixed Assets, Net"><span style="font-family: Times New Roman, Times, Serif">132,802</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_88F_eus-gaap--PropertyPlantAndEquipmentTextBlock_zsBy2q79X0Uk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FIXED ASSETS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span id="xdx_8B0_zEbeV75OIyIj" style="display: none">Schedule of Fixed assets</span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2021</b></span></td> <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; text-align: center"><span style="font-family: Times New Roman, Times, Serif"><b>2020</b></span></td> <td style="text-align: center; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"><b> </b></span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Leasehold Improvements</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" style="width: 9%; text-align: right" title="Total Fixed Assets"><span style="font-family: Times New Roman, Times, Serif">224,132</span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_pp0p0" style="width: 9%; text-align: right" title="Total Fixed Assets"><span style="font-family: Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0485">-</span></span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Machinery and Equipment</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_98A_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_pp0p0" style="text-align: right" title="Total Fixed Assets"><span style="font-family: Times New Roman, Times, Serif">278,551</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_pp0p0" style="text-align: right" title="Total Fixed Assets"><span style="font-family: Times New Roman, Times, Serif">246,974</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Vehicles</span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total Fixed Assets"><span style="font-family: Times New Roman, Times, Serif">110,274</span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total Fixed Assets"><span style="font-family: Times New Roman, Times, Serif">131,775</span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Total Fixed Assets</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_c20221231_pp0p0" style="text-align: right" title="Total Fixed Assets"><span style="font-family: Times New Roman, Times, Serif">612,957</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_c20211231_pp0p0" style="text-align: right" title="Total Fixed Assets"><span style="font-family: Times New Roman, Times, Serif">378,749</span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated Depreciation</span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_98A_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20221231_zdPug3G0hdx3" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated Depreciation"><span style="font-family: Times New Roman, Times, Serif">(314,151</span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_982_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20211231_zpy79CcU7TJ7" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated Depreciation"><span style="font-family: Times New Roman, Times, Serif">(245,947</span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">)</span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif">Fixed Assets, Net</span></td> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td> <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentNet_c20221231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Fixed Assets, Net"><span style="font-family: Times New Roman, Times, Serif">298,806</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td> <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentNet_c20211231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Fixed Assets, Net"><span style="font-family: Times New Roman, Times, Serif">132,802</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 224132 278551 246974 110274 131775 612957 378749 314151 245947 298806 132802 <p id="xdx_803_ecustom--PayrollLiabilityPensionTextBlock_zd08LtkkdfD" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 5 – <span id="xdx_822_z4JPM7hlMOIk">PAYROLL LIABILITY – PENSION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The company offers various pension plans to employee groups based on location of employment. Corporate office employees and guards have an option to participate in a 401K sponsored by the company with a matching program up to 5% of employee salary. Federal contracts have union agreements that define the pension calculation and due dates. It is the responsibility of the company to calculate the pension benefit amount each month and contribute the amount due to the plan designated. The pension balances due on December 31, 2022, and 2021 for all plans was $<span id="xdx_90C_ecustom--PensionBalances_iI_pp0p0_c20221231_zViFZ4GHGqy7" title="Pension balances">453,965</span> and $<span id="xdx_90D_ecustom--PensionBalances_iI_pp0p0_c20211231_z2Cm1ooE3xJa" title="Pension balances">616,579</span> respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 453965 616579 <p id="xdx_80F_eus-gaap--DebtDisclosureTextBlock_zR2KNgynGUNi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6 –<span id="xdx_82F_zgmwKZACWtka"> NOTES PAYABLE</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2020, AmeriGuard Security Services, Inc. received an SBA Loan through Fresno First Bank in the amount of $<span id="xdx_905_eus-gaap--DebtInstrumentFaceAmount_c20200630__us-gaap--DebtInstrumentAxis__custom--SBALoanMember_pp0p0" title="Principal amount">1,080,000</span> that was used to close out the Citibank loan in the amount of $<span id="xdx_904_ecustom--ExpensesHeldInReserve_c20200601__20200630__us-gaap--DebtInstrumentAxis__custom--SBALoanMember_pp0p0" title="Expenses held in reserve">312,339</span> with the remaining balance after expenses held in reserve. The SBA loan is a <span id="xdx_904_eus-gaap--DebtInstrumentTerm_dtY_c20200601__20200630__us-gaap--DebtInstrumentAxis__custom--SBALoanMember_zmt6NBCAcHJl" title="Term">10</span>-year loan with monthly principal and interest payments. Interest rate is variable at <span id="xdx_90C_ecustom--InterestRateIsVariable_c20200601__20200630__us-gaap--DebtInstrumentAxis__custom--SBALoanMember_zwZxM4kX832e" title="Interest rate is variable">prime rate plus 2.75%</span>, adjusted every calendar quarter. Interest rate on December 31, 2022, and 2021 was <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--SBALoanMember_zJnwZFRzjxDk" title="Interest rate">9</span>% and <span id="xdx_90A_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20210101__20211231__us-gaap--DebtInstrumentAxis__custom--SBALoanMember_z8Ls7IXHWHA2" title="Interest rate">4.01</span>% respectively. Balance remaining on the SBA loan was $<span id="xdx_90B_ecustom--NotePayable_iI_pp0p0_c20221231__us-gaap--DebtInstrumentAxis__custom--SBALoanMember_zisI2ePhYb5a" title="Notes Payable">804,387</span> and $<span id="xdx_902_ecustom--NotePayable_iI_pp0p0_c20211231__us-gaap--DebtInstrumentAxis__custom--SBALoanMember_zRuETZx12oP8" title="Notes Payable">888,845</span> as of December 31, 2022, and 2021 respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2020, the Company entered into a financing agreement with Master Security Company for the purchase of vehicles, guns, and guard equipment for the National Institute of Health USEPA contract which began May 2020. The principal financed was $<span id="xdx_901_eus-gaap--DebtInstrumentFaceAmount_c20200130__srt--CounterpartyNameAxis__custom--MasterSecurityCompanyMember_pp0p0" title="Principal amount">150,000</span>, with interest of <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20200101__20200130__srt--CounterpartyNameAxis__custom--MasterSecurityCompanyMember_z2vHqA54GH4e" title="Interest rate">4</span>% for a term of <span id="xdx_90B_eus-gaap--DebtInstrumentTerm_dtM_c20200101__20200130__srt--CounterpartyNameAxis__custom--MasterSecurityCompanyMember_zdXHKbl4wYof" title="Term">21</span> months. Resulting in a monthly principal and interest payment of $<span id="xdx_904_eus-gaap--DebtInstrumentPeriodicPayment_c20200101__20200130__srt--CounterpartyNameAxis__custom--MasterSecurityCompanyMember_pp0p0" title="Periodic payment">7,406</span>. Balance remaining in the amount of $<span id="xdx_90E_eus-gaap--NotesPayable_c20221231__srt--CounterpartyNameAxis__custom--MasterSecurityCompanyMember_pp0p0" title="Notes Payable">0</span> and $<span id="xdx_901_eus-gaap--NotesPayable_c20211231__srt--CounterpartyNameAxis__custom--MasterSecurityCompanyMember_pp0p0" title="Notes Payable">7,729</span> as of December 31, 2022, and 2021 respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2021, the Company entered into a financing agreement with Secure Transportation Inc. for the purchase of three used vehicles in the amount of $<span id="xdx_907_eus-gaap--DebtInstrumentFaceAmount_c20211231__us-gaap--DebtInstrumentAxis__custom--SecureTransportationIncMember_pp0p0" title="Principal amount">21,500</span>. Note requires 12 equal payments of $<span id="xdx_906_eus-gaap--DebtInstrumentPeriodicPayment_c20211201__20211231__srt--CounterpartyNameAxis__custom--SecureTransportationIncMember_pp0p0" title="Periodic payment">1,900</span> with a calculated interest rates of <span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20211201__20211231__srt--CounterpartyNameAxis__custom--SecureTransportationIncMember_z0P0HAC9eC1l" title="Interest rate">5</span>% with the first payment December 15, 2021. Balance remaining in the amount of $<span id="xdx_904_eus-gaap--NotesPayable_c20221231__srt--CounterpartyNameAxis__custom--SecureTransportationIncMember_pp0p0" title="Notes Payable">0</span> and $<span id="xdx_907_eus-gaap--NotesPayable_c20211231__srt--CounterpartyNameAxis__custom--SecureTransportationIncMember_pp0p0" title="Notes Payable">19,615</span> as of December 31, 2022, and 2021 respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 7, 2022, the Company entered into a buyout agreement with a shareholder Lillian Flores. The total buyout amount was $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_c20220707__srt--CounterpartyNameAxis__custom--LillianFloresMember_pp0p0">3,384,950 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>representing <span id="xdx_900_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20201201__20201231__srt--CounterpartyNameAxis__custom--LillianFloresMember_zHqWKaGaF7o8">45</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>% of the calculated business value as of December 31, 2020. Following the initial payment of $<span id="xdx_900_ecustom--InitialPayment_pp0p0_c20220701__20220707__srt--CounterpartyNameAxis__custom--LillianFloresMember_zP9HhvuzPAv1" title="Initial Payment">686,990</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>, the company agreed to make 4 equal installments of principal and interest of $739,508 each December 31, starting 2023. Interest is calculated at a fixed rate of <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateDuringPeriod_dp_c20220701__20220707__srt--CounterpartyNameAxis__custom--LillianFloresMember_zYzKiKxciDPg">3.110</span></span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>% compounded semi-annually. The company has accrued interest on December 31, 2022, of $<span id="xdx_904_eus-gaap--AccruedLiabilitiesCurrent_iI_c20221231_zkoqAYCxdyEj">49,035</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span>. Balance remaining in the amount of $<span id="xdx_905_eus-gaap--NotesPayable_c20220707__srt--CounterpartyNameAxis__custom--LillianFloresMember_pp0p0">2,697,960</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following schedule details the loans active as of December 31, 2022, and 2021:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_887_ecustom--ScheduleOfDetailsTheLoanActive_zj9n6bgJPPXe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NOTE PAYABLE (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt"> <span id="xdx_8B2_zMjYqfWdQiV" style="display: none">Schedule of the loan active</span></td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current Portion:</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; width: 76%; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Notes and loans payable</span></td> <td style="width: 1%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td> <td id="xdx_989_eus-gaap--NotesAndLoansPayableCurrent_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotesAndLoansPayableMember_pp0p0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Total Current Portion"><span style="font-family: Times New Roman, Times, Serif">719,563</span></td> <td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td> <td id="xdx_98E_eus-gaap--NotesAndLoansPayableCurrent_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotesAndLoansPayableMember_pp0p0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Total Current Portion"><span style="font-family: Times New Roman, Times, Serif">127,615</span></td> <td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total Current Portion</span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_98A_eus-gaap--NotesAndLoansPayableCurrent_c20221231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total Current Portion"><span style="font-family: Times New Roman, Times, Serif">719,563</span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_989_eus-gaap--NotesAndLoansPayableCurrent_c20211231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total Current Portion"><span style="font-family: Times New Roman, Times, Serif">127,615</span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Long term Portion:</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Notes and loans payable</span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_98D_eus-gaap--NotesAndLoansPayable_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotesAndLoansPayableMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total Long-term Portion"><span style="font-family: Times New Roman, Times, Serif">2,782,784</span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_98C_eus-gaap--NotesAndLoansPayable_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotesAndLoansPayableMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total Long-term Portion"><span style="font-family: Times New Roman, Times, Serif">780,845</span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total Long-term Portion</span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_98A_eus-gaap--NotesAndLoansPayable_c20221231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total Long-term Portion"><span style="font-family: Times New Roman, Times, Serif">2,782,784</span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_98B_eus-gaap--NotesAndLoansPayable_c20211231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total Long-term Portion"><span style="font-family: Times New Roman, Times, Serif">780,845</span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td> <td id="xdx_985_eus-gaap--NotesPayable_c20221231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Notes Payable"><span style="font-family: Times New Roman, Times, Serif">3,502,347</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td> <td id="xdx_984_eus-gaap--NotesPayable_c20211231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Notes Payable"><span style="font-family: Times New Roman, Times, Serif">908,460</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p> 1080000 312339 P10Y prime rate plus 2.75% 0.09 0.0401 804387 888845 150000 0.04 P21M 7406 0 7729 21500 1900 0.05 0 19615 3384950 0.45 686990 0.03110 49035 2697960 <table cellpadding="0" cellspacing="0" id="xdx_887_ecustom--ScheduleOfDetailsTheLoanActive_zj9n6bgJPPXe" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NOTE PAYABLE (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt"> <span id="xdx_8B2_zMjYqfWdQiV" style="display: none">Schedule of the loan active</span></td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: center; font-weight: bold; padding-bottom: 1pt; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td> <td style="text-align: center; padding-bottom: 1pt; font-weight: bold; vertical-align: bottom"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Current Portion:</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; width: 76%; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Notes and loans payable</span></td> <td style="width: 1%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td> <td id="xdx_989_eus-gaap--NotesAndLoansPayableCurrent_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotesAndLoansPayableMember_pp0p0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Total Current Portion"><span style="font-family: Times New Roman, Times, Serif">719,563</span></td> <td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td> <td id="xdx_98E_eus-gaap--NotesAndLoansPayableCurrent_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotesAndLoansPayableMember_pp0p0" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Total Current Portion"><span style="font-family: Times New Roman, Times, Serif">127,615</span></td> <td style="width: 1%; padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total Current Portion</span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_98A_eus-gaap--NotesAndLoansPayableCurrent_c20221231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total Current Portion"><span style="font-family: Times New Roman, Times, Serif">719,563</span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_989_eus-gaap--NotesAndLoansPayableCurrent_c20211231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total Current Portion"><span style="font-family: Times New Roman, Times, Serif">127,615</span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Long term Portion:</span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Notes and loans payable</span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_98D_eus-gaap--NotesAndLoansPayable_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotesAndLoansPayableMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total Long-term Portion"><span style="font-family: Times New Roman, Times, Serif">2,782,784</span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_98C_eus-gaap--NotesAndLoansPayable_c20211231__us-gaap--ShortTermDebtTypeAxis__custom--NotesAndLoansPayableMember_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total Long-term Portion"><span style="font-family: Times New Roman, Times, Serif">780,845</span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left; padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif">Total Long-term Portion</span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_98A_eus-gaap--NotesAndLoansPayable_c20221231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total Long-term Portion"><span style="font-family: Times New Roman, Times, Serif">2,782,784</span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 1pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td id="xdx_98B_eus-gaap--NotesAndLoansPayable_c20211231_pp0p0" style="border-bottom: Black 1pt solid; text-align: right" title="Total Long-term Portion"><span style="font-family: Times New Roman, Times, Serif">780,845</span></td> <td style="padding-bottom: 1pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td> <td id="xdx_985_eus-gaap--NotesPayable_c20221231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Notes Payable"><span style="font-family: Times New Roman, Times, Serif">3,502,347</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 2.5pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td> <td id="xdx_984_eus-gaap--NotesPayable_c20211231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Notes Payable"><span style="font-family: Times New Roman, Times, Serif">908,460</span></td> <td style="padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> </table> 719563 127615 719563 127615 2782784 780845 2782784 780845 3502347 908460 <p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_z107BXMTE6Ug" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7 – <span id="xdx_82F_zkfOtjNvK6ga">STOCKHOLDERS’ EQUITY</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 9, 2022, the Company executed a reverse merger agreement with AGSS resulting in significant adjustments to the equity section of both companies. The result of the merger was AGSS became the sole owner of the Company. Although the merger is dated December 9, 2022, for financial statement presentation purposes, we have presented the Equity Section as if the merger occurred in 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The first significant impact on stockholders’ equity was the issuance of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20200101__20201231__dei--LegalEntityAxis__custom--AmeriguardSecurityServicesMember_pdd" title="Number of shares issued">90,000,000</span> AGSS shares to the shareholders of Ameriguard Security Services, Inc (the Company) in exchange for <span id="xdx_905_ecustom--NumberOfSharesExchanged_c20200101__20201231__dei--LegalEntityAxis__custom--AmeriguardSecurityServicesMember_pdd" title="Number of shares exchanged">1000</span> shares of the Company, adding a net increase in common shares outstanding of <span id="xdx_90F_ecustom--IncreaseInCommonSharesOutstanding_c20200101__20201231__dei--LegalEntityAxis__custom--AmeriguardSecurityServicesMember_pdd" title="Increase in common shares outstanding">89,999,000</span>. Next was the cancelation and conversion of series <span id="xdx_90F_eus-gaap--ConversionOfStockSharesConverted1_c20200101__20201231__dei--LegalEntityAxis__custom--AmeriguardSecurityServicesMember_pdd" title="Conversion of shares">675,000</span> A-1 preferred shares held by AGSS on December 31, 2020. The final result in the total number of shares outstanding is <span id="xdx_906_eus-gaap--SharesOutstanding_c20221231_pdd" title="Shares Outstanding">93,417,302</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The next part of stockholder’s equity impacted was Additional Paid-in Capital. The impact was a reduction of Paid-in Capital of $<span id="xdx_90D_ecustom--ReductionOfPaidinCapital_c20220101__20221231_pp0p0" title="Reduction of Paid-in Capital">579,000</span>. T<span id="xdx_903_ecustom--EquityDescription_c20220101__20221231" title="Equity description">his reduction was caused by an $89,999 impact of issuing new shares, a $10,000 impact form the cancelation of preferred shares and finally the $500,000 cost of the Company’s purchase of AGSS, formally Heath Revenue Assurance Holdings, Inc.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There were two other transactions that impacted stockholders’ equity that occurred to the Company’s equity section relating to owner draws and the merger with a related company. As a part of the normal activity of the privately held Company, an S-Corp, shareholders were distributed funds accounted for as Owner Draws. The owner draw accounts were used primarily for taxes paid by the shareholders due to profits of the S-Corp being transferred to their personal returns along with some personal expenses and personal cash needs. For 2021, there was approximately $<span id="xdx_90A_ecustom--RelatedPartyReceivables_c20211231_pp0p0" title="Related party receivables">105,000</span> posted as Owner draw from historical balances of related party receivables. As part of the preparation for merger these inter-company balances were removed through the owner draw accounts. Total owner draw amounts were $<span id="xdx_903_ecustom--OwnerDrawsPremerger_c20220101__20221231_pp0p0" title="Owner draws (pre-merger)">473,238</span> and $<span id="xdx_905_ecustom--OwnerDrawsPremerger_c20210101__20211231_pp0p0" title="Owner draws (pre-merger)">62,824</span> for December 31, 2022, and 2021 respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 90000000 1000 89999000 675000 93417302 579000 his reduction was caused by an $89,999 impact of issuing new shares, a $10,000 impact form the cancelation of preferred shares and finally the $500,000 cost of the Company’s purchase of AGSS, formally Heath Revenue Assurance Holdings, Inc. 105000 473238 62824 <p id="xdx_801_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zPdM74ecccN9" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8 – <span id="xdx_82B_zSgvw18JUqh2">COMMITMENTS AND CONTINGENCIES</span> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The company has a multiple vehicle lease agreement with Enterprise Leasing. As of December 31, 2022, the company had 19 vehicles under lease. The lease agreement includes maintenance services along physical damage insurance. The term of the lease agreement varies based on the date vehicle were leased and the respective terms for each vehicle. The master lease is updated annually and requires annual internal financial reports and company tax return.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_80D_ecustom--ConcentrationOfSalesTextBlock_zQnejFyolCU2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9 – <span id="xdx_82E_zOxkUtaJKDea">CONCENTRATION OF SALES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The company generated approximately $<span id="xdx_901_eus-gaap--Revenues_c20220101__20221231__srt--ProductOrServiceAxis__custom--GuardServiceMember_pp0p0" title="Revenues">24,600,000</span> and $<span id="xdx_903_eus-gaap--Revenues_c20210101__20211231__srt--ProductOrServiceAxis__custom--GuardServiceMember_pp0p0" title="Revenues">22,100.000</span> in guard service revenue for the years 2022 and 2021 respectively. Of the total guard service revenue, approximately <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_dp_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--MajorCustomersAxis__custom--GuardServiceMember_zVpHqzI8EL9j" title="Concentration Risk, Percentage"><span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_dp_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--MajorCustomersAxis__custom--GuardServiceMember_zf5stErOz6le" title="Concentration Risk, Percentage">87</span></span>% was earned from four federal contracts operated by the company. The contracts and their respective terms are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.25in"> </td> <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">●</span></td> <td style="white-space: nowrap; width: 10%"><span style="font-size: 10pt">Social Security Administration, NSC</span></td> <td style="width: 2%"> </td> <td style="width: 0.25in; text-align: justify"><span style="font-size: 10pt">- </span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">September 2022 through September 2027</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Annual Revenue of approx. $3.145M</p></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"><span style="font-size: 10pt">●</span></td> <td style="white-space: nowrap"><span style="font-size: 10pt">Social security Administration, SSC</span></td> <td> </td> <td style="text-align: justify"><span style="font-size: 10pt">- </span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">June 2022 through June 2027</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Annual Revenue of approx. $4.932M</p></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"><span style="font-size: 10pt">●</span></td> <td style="white-space: nowrap"><span style="font-size: 10pt">Social Security Administration, WBDOC</span></td> <td> </td> <td style="text-align: justify"><span style="font-size: 10pt">- </span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">June 2021 through July 2026</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Annual Revenue of approx. $5.838M</p></td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"> </td> <td style="white-space: nowrap"> </td> <td> </td> <td style="text-align: justify"> </td> <td style="text-align: justify"> </td></tr> <tr style="vertical-align: top"> <td> </td> <td style="text-align: justify"><span style="font-size: 10pt;">●</span></td> <td style="white-space: nowrap"><span style="font-size: 10pt;">National Institute of Health- EPA</span></td> <td> </td> <td style="text-align: justify"><span style="font-size: 10pt;">- </span></td> <td> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">May 2020 through March 2023</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Annual Revenue of approx. $7.514M</p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 24600000 22100.000 0.87 0.87 <p id="xdx_80C_ecustom--LitigationAndClaimsTextBlock_zCsX9DSkTp9e" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10 – <span id="xdx_823_zRGWDkfEsDP5">LITIGATION AND CLAIMS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of December 31, 2022, there was one employment issue pending. The issue involves a terminated employee alleging discrimination and wrongful termination. A lawsuit has not been filed only a demand letter has been presented. Management has been working with the attorneys to find a reasonable settlement to this dispute without going to trial. After several months of discussion and negotiation it appears that the complaint will be settled for $<span id="xdx_903_eus-gaap--LitigationSettlementExpense_c20220101__20221231_pp0p0" title="Litigation settlement amount">23,000</span>. It is anticipated that an agreement may be reached by the end of March 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Per Attorney letters received there are no other pending cases or legal matters.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 23000 <p id="xdx_80E_eus-gaap--IncomeTaxDisclosureTextBlock_zHXwVUheoXP4" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 11 – <span id="xdx_827_zL79ZQZJiiI3">INCOME TAXE</span>S</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prior to the merger the Company had elected, with the consent of its stockholders, to be treated as an S Corporation under the Internal Revenue Code. In lieu of corporate income taxes, the stockholders of an S Corporation are taxed on their proportionate share of the Company’s income. As a result of the merger on December 9, 2022, the S Corporation status ends, and the consolidated 2022 tax return will be filed as a standard corporation. However, due to the losses incurred during the tax year ending 2022, there will be <span id="xdx_909_eus-gaap--TaxesPayableCurrent_iI_pp0p0_do_c20221231_ztsvRiC5pOp1" title="Tax liability">no</span> tax liability for 2022. Therefore, no provision for income taxes has been included in the accompanying financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0 <p id="xdx_80B_eus-gaap--SubsequentEventsTextBlock_zE3FlVm0PRsk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 12 – <span id="xdx_82F_zvmvMbIBvq0a">SUBSEQUENT EVENTS</span> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 22, 2023, The Company was notified by the Contracting Officer of National Institute of Health-EPA our contract with them was not continuing and they were invoking the 45 days cancelation clause in the contract. As a result, the company will transition the closure of the contract on or about April 30, 2023. This will reduce on our annual revenue in the amount of approximately $<span id="xdx_904_ecustom--AnnualRevenueReduced_c20230301__20230323__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_pp0p0" title="Annual revenue reduced">5,122,000 </span>in 2023, along with direct expenses that will be reduced by $<span id="xdx_908_ecustom--ReductionInDirectExpenses_c20230301__20230323__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_pp0p0" title="Reduction in direct expenses">4,650,000</span>.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span>On March 23, 2023, <span id="xdx_90C_eus-gaap--SubsequentEventDescription_c20230301__20230323__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember">the board of directors approved the purchase of TransportUS, Inc. While the Company explored the purchase of TransportUS, Inc., owned by Lawrence Garcia, the board of directors has determined, following due diligence, that the financial statements of TransportUS, Inc. are not in a form that can be audited under US GAAP. We have therefore abandoned such undertaking for the foreseeable future.</span></span></p> 5122000 4650000 the board of directors approved the purchase of TransportUS, Inc. While the Company explored the purchase of TransportUS, Inc., owned by Lawrence Garcia, the board of directors has determined, following due diligence, that the financial statements of TransportUS, Inc. are not in a form that can be audited under US GAAP. We have therefore abandoned such undertaking for the foreseeable future. 2990014 1227654 1408266 1869268 132045 110829 4530325 3207751 288477 298806 302695 302695 591172 601501 5121497 3809252 1172116 761515 91635 49035 732364 737143 345140 453965 719563 719563 3060818 2721221 2746075 2782784 294387 294387 6101280 5798393 0.001 94471302 158346 158346 -1138129 -2147486 -979783 -1989140 5121497 3809252 11068409 11751908 117389 115974 11185798 11867882 7675360 7205687 1566148 1496612 1331446 1703987 104041 111985 106785 99652 10783780 10617923 402018 1249959 836457 470077 192693 226741 249266 188226 58492 53870 108088 51108 60097 53852 430810 262573 97862 24628 18834 22188 2052600 1353263 -1650582 -103304 3302312 23982 642373 170935 2659939 -146953 1009357 -250257 1009357 -250257 0.0108 -0.0027 93417302 93417302 93417302 158346 6012095 -8159580 -1989140 1009357 1009357 93417302 158346 6012095 -7150223 -979783 1009357 -250257 -461002 121650 21215 9171 18834 47465 405822 329744 -42600 -108825 -102571 1807575 -106440 505 122226 8000 25535 21500 -8505 -126261 36709 45677 125316 -36709 -170993 1762360 -403693 1227654 2129801 2990014 1726108 97862 24628 302695 294387 <p id="xdx_801_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zZX4JIrvMZWk" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>NOTE 1 – <span id="xdx_82C_zWou8tjs83C4">ORGANIZATION AND DESCRIPTION OF BUSINESS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif;margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">AmeriGuard Security Services, Inc. (the Company), was incorporated on November 14, 2002, with an S-Corp tax election. The corporation was incorporated with the issuance of <span id="xdx_90B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221101__20221114_pdd">1,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of no-par value stock held by Lawrence Garcia, President and CEO with <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221101__20221114__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_pdd">550 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares and Lillian Flores, VP of Operations with <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20221101__20221114__srt--TitleOfIndividualAxis__custom--LillianFloresMember_zpKHagGtPgX">450 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares. The Company provides armed guard services as a federal contractor with licenses in 5 states and provides commercial guard services in California.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif;margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On July 7, 2021, the Company, entered into an agreement to gain 100% control of Health Revenue Assurance Holdings, Inc (HRAA) a public corporation, incorporated in Nevada, by the purchase of <span id="xdx_90C_eus-gaap--PreferredStockSharesAuthorized_iI_c20210707__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CustodianVenturesMember_z24psnuNUY7h">10,000,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">shares of Preferred A-1 Stock from the seller, Custodian Ventures LLC. The purchase of HRAA allowed the Company to begin plans to consummate a reverse merger with HRAA becoming a wholly owned subsidiary of a public company. In March of 2022, a Certificate of Amendment was filed with the Nevada Secretary of State, changing the name of HRAA, to Ameriguard Security Services, Inc. (AGSS). Shortly thereafter, a stock name and ticker change report were filed with the SEC and the stock ticker of HRAA was changed to AGSS.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On December 9, 2022, the Company executed the reverse merger agreement and became the subsidiary of AGSS. From that point forward, the financial statement filings will be the consolidation of Ameriguard Security Services, Inc, a Nevada company with Ameriguard Security Services, Inc. a California company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The Company’s accounting year end is December 31.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Basis of Presentation </i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">These financial statements are presented in United States dollars and have been prepared in accordance with United States generally accepted accounting principles.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><i>Risks and Uncertainties</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The risks and uncertainties described below may not be the only ones we are or may face in the future. If any of the following do occur, our business, financial condition or results of operations could be materially adversely affected.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif;margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The company receives over <span id="xdx_90D_ecustom--HolderOwnership_c20230630_pdd">86% </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of its total revenue from four Federal contracts as described in Note 9 below. These contracts have specific terms, typically five years with the opportunity for extension, but there are no assurances they will be extended. Although we have had several extended in the past, there is no guarantee this will again happened in the future. However, there are significant direct expenses for each contract that also are removed from operations at the end of a contract. As a result, the revenue lost from a completed contract does not affect the bottom-line profits in an amount equal to the revenue lost. The actual net income impact depends on the contract.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The process required to acquire a government contract takes several months to complete prior to delivery of the proposal to the contracting agency. Due to the time span required to prepare a proposal and winning the contract is not guaranteed, the company maintains a department of individuals who monitor and write proposals for all government contracts that become open for bid on a continuing basis. It is important to the company that new contracts are acquired consistently to maintain and grow annual revenue.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Other risks to operations consist of State and Federal regulations, staffing shortages, accelerating inflation, and overall business environment issues we cannot foresee.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> 1000 550 450 10000000 0.86 <p id="xdx_80D_eus-gaap--SignificantAccountingPoliciesTextBlock_zI53P5MwZtPb" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>NOTE 2 – <span id="xdx_822_z92tJVw2zAh">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p id="xdx_841_eus-gaap--UseOfEstimates_z78pNiHv9lg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_869_zofNl79yz2J9" style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt;">Use of Estimates</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, along with the collectability of some receivables from customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zCSexU6InrO3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_866_zjhRK7wq0Yr1" style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt;">Cash and Cash Equivalents</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif;margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. On June 30, 2023, and December 31, 2022, the Company had cash and cash equivalents totaling $<span id="xdx_90F_eus-gaap--Cash_iI_pp0p0_c20230630_z54KAry2ftk">2,970439 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90F_eus-gaap--Cash_iI_pp0p0_c20221231_zZDjZwVMtvOf">1,227,654 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p id="xdx_84B_eus-gaap--ReceivablesPolicyTextBlock_zKT3Nj4nGTGi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_86C_zca7GYHdDpqk" style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt;">Accounts Receivable</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We record accounts receivable at net realizable value. This value includes an appropriate allowance for estimated uncollectible accounts to reflect any loss anticipated on the accounts receivable balances and is charged to other bad debt expense. We calculate this allowance based on our history of write-offs, the level of past-due accounts based on the contractual terms of the receivables, and our relationships with, and the economic status of, our customers. With over 86% percent of year end accounts receivable balance from Federal contracts that require payment, and the uncollectable amount historically has been less than 1%. As of June 30, 2023, and December 31, 2022, an allowance for estimated uncollectible accounts was determined to be unnecessary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zwk53tpF1pBh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_865_zb8TMxMjPVqk" style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt;">Property and Equipment</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif;margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment is retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses other depreciation methods (generally accelerated) for tax purposes where appropriate. The estimated useful life for Machinery and Equipment, and Vehicles is <span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zqw07ZEj4jub">5 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years, with Leasehold improvements useful life is <span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zzH4QKzYbkCk">10 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p id="xdx_84D_ecustom--OperatingLeasesPolicyTextBlock_zqPCVREJLj4l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_863_zPqAGvz882Le" style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt;">Operating Leases</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In February 2016, FASB ASU No. 2016-02 established ASC Topic 842, Leases, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. Effective December 31, 2022, we have implemented ASU No. 2016-02 and booked the operating lease asset and the related liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zpRdAU2qpLtd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_861_zhzNR3qw0jI" style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt;">Net Income/(Loss) per Share</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Net income/(loss) per common share is computed by dividing net income or loss by the weighted average common shares outstanding during the period as defined by Financial Accounting Standards, ASC Topic 260, “Earnings per Share”. Basic earnings/(loss) per common share (“EPS”) calculations are determined by dividing net income/(loss) by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p id="xdx_840_eus-gaap--RevenueRecognitionPolicyTextBlock_zxTBWfDbLxI2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_866_zmY3plFNUVD1" style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt;">Revenue Recognition</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif;margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We recognize revenue when the Invoice for contracted services is issued as stipulated by the contract. Other services provided are recognized at the time the service is provided. Ninety eight percent of revenues are billed monthly and recognized in the month the services were provided. Refunds and returns, which are minimal, are recorded as a reduction of revenue. The Company has not recorded a reserve for returns on June 30, 2023, or 2022 since it does <span id="xdx_90B_ecustom--ReserveForReturns_pp0p0_do_c20230101__20230630_zBf9OGGmYYz8">no</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">t believe such returns will be material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zhG5pXMD5qAg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_863_zrogTL7KNjp6" style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt;">Fair Value of Financial Instruments</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The Company applies the accounting guidance under Financial Accounting Standards Board (“FASB”) ASC 820-10, “Fair Value Measurements”, as well as certain related FASB staff positions. This guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The guidance also establishes a fair value hierarchy for measurements of fair value as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Level 1 - quoted market prices in active markets for identical assets or liabilities.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The carrying amount of the Company’s financial instruments approximates their fair value as of June 30, 2023 and December 31, 2022, due to the short-term nature of these instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p id="xdx_841_eus-gaap--UseOfEstimates_z78pNiHv9lg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_869_zofNl79yz2J9" style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt;">Use of Estimates</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and revenues and expenses during the reported period. Actual results could differ from those estimates. Significant estimates include estimated useful lives and potential impairment of property and equipment, along with the collectability of some receivables from customers.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p id="xdx_84D_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zCSexU6InrO3" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_866_zjhRK7wq0Yr1" style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt;">Cash and Cash Equivalents</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif;margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. On June 30, 2023, and December 31, 2022, the Company had cash and cash equivalents totaling $<span id="xdx_90F_eus-gaap--Cash_iI_pp0p0_c20230630_z54KAry2ftk">2,970439 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90F_eus-gaap--Cash_iI_pp0p0_c20221231_zZDjZwVMtvOf">1,227,654 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> 2970439 1227654 <p id="xdx_84B_eus-gaap--ReceivablesPolicyTextBlock_zKT3Nj4nGTGi" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_86C_zca7GYHdDpqk" style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt;">Accounts Receivable</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We record accounts receivable at net realizable value. This value includes an appropriate allowance for estimated uncollectible accounts to reflect any loss anticipated on the accounts receivable balances and is charged to other bad debt expense. We calculate this allowance based on our history of write-offs, the level of past-due accounts based on the contractual terms of the receivables, and our relationships with, and the economic status of, our customers. With over 86% percent of year end accounts receivable balance from Federal contracts that require payment, and the uncollectable amount historically has been less than 1%. As of June 30, 2023, and December 31, 2022, an allowance for estimated uncollectible accounts was determined to be unnecessary.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p id="xdx_849_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zwk53tpF1pBh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_865_zb8TMxMjPVqk" style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt;">Property and Equipment</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif;margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Property and equipment are recorded at cost. Expenditures for major additions and improvements are capitalized and minor replacements, maintenance, and repairs are charged to expense as incurred. When property and equipment is retired or otherwise disposed of, the cost and accumulated depreciation are removed from the accounts and any resulting gain or loss is included in the results of operations for the respective period. Depreciation is provided over the estimated useful lives of the related assets using the straight-line method for financial statement purposes. The Company uses other depreciation methods (generally accelerated) for tax purposes where appropriate. The estimated useful life for Machinery and Equipment, and Vehicles is <span id="xdx_905_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zqw07ZEj4jub">5 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">years, with Leasehold improvements useful life is <span id="xdx_904_eus-gaap--PropertyPlantAndEquipmentUsefulLife_iI_dtY_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zzH4QKzYbkCk">10 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> P5Y P10Y <p id="xdx_84D_ecustom--OperatingLeasesPolicyTextBlock_zqPCVREJLj4l" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_863_zPqAGvz882Le" style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt;">Operating Leases</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In February 2016, FASB ASU No. 2016-02 established ASC Topic 842, Leases, which sets out the principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. Effective December 31, 2022, we have implemented ASU No. 2016-02 and booked the operating lease asset and the related liability.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zpRdAU2qpLtd" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_861_zhzNR3qw0jI" style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt;">Net Income/(Loss) per Share</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Net income/(loss) per common share is computed by dividing net income or loss by the weighted average common shares outstanding during the period as defined by Financial Accounting Standards, ASC Topic 260, “Earnings per Share”. Basic earnings/(loss) per common share (“EPS”) calculations are determined by dividing net income/(loss) by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per common share calculations are determined by dividing net income by the weighted average number of common shares and dilutive common share equivalents outstanding.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p id="xdx_840_eus-gaap--RevenueRecognitionPolicyTextBlock_zxTBWfDbLxI2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_866_zmY3plFNUVD1" style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt;">Revenue Recognition</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif;margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">We recognize revenue when the Invoice for contracted services is issued as stipulated by the contract. Other services provided are recognized at the time the service is provided. Ninety eight percent of revenues are billed monthly and recognized in the month the services were provided. Refunds and returns, which are minimal, are recorded as a reduction of revenue. The Company has not recorded a reserve for returns on June 30, 2023, or 2022 since it does <span id="xdx_90B_ecustom--ReserveForReturns_pp0p0_do_c20230101__20230630_zBf9OGGmYYz8">no</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">t believe such returns will be material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> 0 <p id="xdx_840_eus-gaap--FairValueOfFinancialInstrumentsPolicy_zhG5pXMD5qAg" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span id="xdx_863_zrogTL7KNjp6" style="text-decoration: underline; font-family: Times New Roman, Times, Serif; font-size: 10pt;">Fair Value of Financial Instruments</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The Company applies the accounting guidance under Financial Accounting Standards Board (“FASB”) ASC 820-10, “Fair Value Measurements”, as well as certain related FASB staff positions. This guidance defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact business and considers assumptions that marketplace participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of non-performance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The guidance also establishes a fair value hierarchy for measurements of fair value as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Level 1 - quoted market prices in active markets for identical assets or liabilities.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Level 2 - inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Level 3 - unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The carrying amount of the Company’s financial instruments approximates their fair value as of June 30, 2023 and December 31, 2022, due to the short-term nature of these instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p id="xdx_804_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zWLp4aUYIJXf" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>NOTE 3 – <span id="xdx_822_zHEhiRSDwAU3">RELATED PARTY RECEIVABLE</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif;margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On July 7, 2021, the company entered into an agreement to purchase 100% of the Preferred A-1 Stock of Health Revenue Assurance Holdings, Inc. a SEC registered company for $<span id="xdx_908_ecustom--ConsiderationPaidShares_pp0p0_c20210701__20210707_z9rgugWtPrPj">500,000</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. In March 2022, Health Revenue Assurance Holdings, Inc. name was changed to Ameriguard Security Services Inc. (AGSS). On December 9, 2022, we signed the definitive merger agreement initiating a reverse merger with AGSS, resulting in the Company becoming a 100% owned subsidiary of AGSS. Prior to the merger, the Company funded the operational expenses of AGSS and treated these expenses as related party expenses. These expenses we eliminated when the two companies were consolidated for the financial statement presentation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif;margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The receivable balances on June 30, 2023, and December 31, 2022, were $<span id="xdx_907_ecustom--NotesReceivablerelatedParty_iI_pp0p0_c20221231_zreKvVUNpqVg" title="Notes Receivablerelated Party">57,971</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Related party receivables are eliminated upon consolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> 500000 57971 <p id="xdx_80B_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zAX1PRqI6zR" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>NOTE 4 – <span id="xdx_823_zTht9NRd87pf">FIXED ASSETS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Fixed assets consist of the following on June 30, 2023, and December 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--PropertyPlantAndEquipmentTextBlock_zEYl4ti8qpzk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FIXED ASSETS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span id="xdx_8B2_zkD8pU5ykvL6" style="display: none">Schedule of fixed assets</span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"> </td> <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td> <td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td> <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td> <td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left">Leasehold Improvements</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zU4lYsWAVhO4" style="width: 9%; text-align: right" title="Total Fixed Assets">224,637</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zPmzmGXlfAcb" style="width: 9%; text-align: right" title="Total Fixed Assets">224,132</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Machinery and Equipment</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zu3TZB1GxC7k" style="text-align: right" title="Total Fixed Assets">286,551</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zhOdftCnynq3" style="text-align: right" title="Total Fixed Assets">278,551</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Vehicles</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zcAD8KsucZyh" style="border-bottom: Black 1pt solid; text-align: right" title="Total Fixed Assets">110,742</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zYWMAkIhgrY5" style="border-bottom: Black 1pt solid; text-align: right" title="Total Fixed Assets">110,274</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Total Fixed Assets</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20230630_zzwpmgrM1Yq7" style="text-align: right" title="Total Fixed Assets">621,426</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231_zJsPwaeNKvbl" style="text-align: right" title="Total Fixed Assets">612,957</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Accumulated Depreciation</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_98E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20230630_zcc1Ablg4Q95" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated Depreciation">(332,985</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_98C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20221231_zszZBcbFcMe" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated Depreciation">(314,151</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Fixed Assets, Net</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20230630_z99wmHFfyBwd" style="border-bottom: Black 2.5pt double; text-align: right" title="Fixed Assets, Net">288,477</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20221231_ziGe6KiJya53" style="border-bottom: Black 2.5pt double; text-align: right" title="Fixed Assets, Net">298,806</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" id="xdx_887_eus-gaap--PropertyPlantAndEquipmentTextBlock_zEYl4ti8qpzk" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - FIXED ASSETS (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span id="xdx_8B2_zkD8pU5ykvL6" style="display: none">Schedule of fixed assets</span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"> </td> <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td> <td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td> <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td> <td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 76%; text-align: left">Leasehold Improvements</td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zU4lYsWAVhO4" style="width: 9%; text-align: right" title="Total Fixed Assets">224,637</td> <td style="width: 1%; text-align: left"> </td> <td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td> <td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zPmzmGXlfAcb" style="width: 9%; text-align: right" title="Total Fixed Assets">224,132</td> <td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Machinery and Equipment</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zu3TZB1GxC7k" style="text-align: right" title="Total Fixed Assets">286,551</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_983_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--MachineryAndEquipmentMember_zhOdftCnynq3" style="text-align: right" title="Total Fixed Assets">278,551</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Vehicles</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20230630__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zcAD8KsucZyh" style="border-bottom: Black 1pt solid; text-align: right" title="Total Fixed Assets">110,742</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zYWMAkIhgrY5" style="border-bottom: Black 1pt solid; text-align: right" title="Total Fixed Assets">110,274</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Total Fixed Assets</td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20230630_zzwpmgrM1Yq7" style="text-align: right" title="Total Fixed Assets">621,426</td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentGross_iI_pp0p0_c20221231_zJsPwaeNKvbl" style="text-align: right" title="Total Fixed Assets">612,957</td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1pt">Accumulated Depreciation</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_98E_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20230630_zcc1Ablg4Q95" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated Depreciation">(332,985</td> <td style="padding-bottom: 1pt; text-align: left">)</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_98C_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_pp0p0_di_c20221231_zszZBcbFcMe" style="border-bottom: Black 1pt solid; text-align: right" title="Accumulated Depreciation">(314,151</td> <td style="padding-bottom: 1pt; text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 2.5pt">Fixed Assets, Net</td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20230630_z99wmHFfyBwd" style="border-bottom: Black 2.5pt double; text-align: right" title="Fixed Assets, Net">288,477</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentNet_iI_pp0p0_c20221231_ziGe6KiJya53" style="border-bottom: Black 2.5pt double; text-align: right" title="Fixed Assets, Net">298,806</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 224637 224132 286551 278551 110742 110274 621426 612957 332985 314151 288477 298806 <p id="xdx_800_ecustom--PayrollLiabilityPensionTextBlock_zRri7rLPghK2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>NOTE 5 – <span id="xdx_820_zmv1eUeUCxE8">PAYROLL LIABILITY – PENSION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif;margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The company offers various pension plans to employee groups based on location of employment. Corporate office employees and guards have an option to participate in a 401K sponsored by the company with a matching program up to 5% of employee salary. Federal contracts have union agreements that define the pension calculation and due dates. It is the responsibility of the company to calculate the pension benefit amount each month and contribute the amount due to the plan designated. The pension balances due on June 30, 2023, and December 31, 2022, for all plans were $<span id="xdx_902_ecustom--PensionBalances_c20230630_pp0p0">345,140 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90D_ecustom--PensionBalances_c20221231_pp0p0">453,965 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> 345140 453965 <p id="xdx_800_eus-gaap--DebtDisclosureTextBlock_zXNTxtvnaLma" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>NOTE 6 – <span id="xdx_823_znKp6Ei15Drg">NOTES PAYABLE</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif;margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">In June 2020, AmeriGuard Security Services, Inc. received an SBA Loan through Fresno First Bank in the amount of $<span id="xdx_906_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20200630__us-gaap--DebtInstrumentAxis__custom--SBALoanMember_zB8EQ97cAWK7">1,080,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">that was used to close out the Citibank loan in the amount of $<span id="xdx_903_ecustom--ExpensesHeldInReserve_pp0p0_c20200601__20200630__us-gaap--DebtInstrumentAxis__custom--SBALoanMember_zZMjyKIlIpW5">312,339 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">with the remaining balance after expenses held in reserve. The SBA loan is a <span id="xdx_90C_eus-gaap--DebtInstrumentTerm_dtY_c20200601__20200630__us-gaap--DebtInstrumentAxis__custom--SBALoanMember_zKWem0ItOpt9">10</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">-year loan with monthly principal and interest payments. Interest rate is variable at <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateTerms_c20200601__20200630__us-gaap--DebtInstrumentAxis__custom--SBALoanMember">prime rate plus 2.75%</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, adjusted every calendar quarter. Interest rate on June 30, 2023, and December 31, 2022, was <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20230101__20230630__us-gaap--DebtInstrumentAxis__custom--SBALoanMember_pdd">10.75% </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and <span id="xdx_905_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20220101__20221231__us-gaap--DebtInstrumentAxis__custom--SBALoanMember_pdd">9% </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">respectively. Balance remaining on the SBA loan was $<span id="xdx_90D_eus-gaap--NotesPayable_c20230630__us-gaap--DebtInstrumentAxis__custom--SBALoanMember_pp0p0">767,678 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_908_eus-gaap--NotesPayable_c20221231__us-gaap--DebtInstrumentAxis__custom--SBALoanMember_pp0p0">785,988 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">as of June 30, 2023, and December 31, 2022, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif;margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">On July 7, 2022, the Company entered into a buyout agreement with a shareholder Lillian Flores. The total buyout amount was $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pp0p0_c20220707__srt--CounterpartyNameAxis__custom--LillianFloresMember_zILya0VAKusk">3,384,950 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">representing <span id="xdx_908_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20201201__20201231__srt--CounterpartyNameAxis__custom--LillianFloresMember_zaWa26LRT9ud">45% </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">of the calculated business value as of December 31, 2020. Following the initial payment of $<span id="xdx_90D_ecustom--InitialPayment_pp0p0_c20220701__20220707__srt--CounterpartyNameAxis__custom--LillianFloresMember_zIMxBQccZoTk" title="Initial Payment">686,990</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, the company agreed to make 4 equal instalments of principal and interest of $739,508 each December 31, starting 2023. Interest is calculated at a fixed rate of <span id="xdx_901_eus-gaap--DebtInstrumentInterestRateDuringPeriod_c20220701__20220707__srt--CounterpartyNameAxis__custom--LillianFloresMember_pdd">3.110% </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">compounded semi-annually. The company has accrued interest on June 30, 2023, of $<span id="xdx_902_eus-gaap--AccruedLiabilitiesCurrent_c20220630_pp0p0">91,635</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. Balance remaining in the amount of $<span id="xdx_909_eus-gaap--NotesPayable_iI_pp0p0_c20220707__srt--CounterpartyNameAxis__custom--LillianFloresMember_zUPMWQ5NKwKd">2,697,960</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The following schedule details the loans active as of June 30, 2023, and December 31, 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--ScheduleOfDetailsTheLoanActive_zblye0o3I0ki" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NOTES PAYABLE (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span id="xdx_8BC_zYhxy7Y4ar56" style="display: none">Schedule of the loan active</span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"> </td> <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td> <td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td> <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td> <td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Current Portion:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; width: 76%; text-align: left; padding-bottom: 1pt">Notes and loans payable</td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_989_eus-gaap--NotesAndLoansPayableCurrent_iI_pp0p0_c20230630__us-gaap--ShortTermDebtTypeAxis__custom--NotesAndLoansPayableMember_zgn267FT2ySl" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Total Current Portion">719,563</td> <td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_986_eus-gaap--NotesAndLoansPayableCurrent_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotesAndLoansPayableMember_zkELwapjdg24" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Total Current Portion">719,563</td> <td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left; padding-bottom: 1pt">Total Current Portion</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_989_eus-gaap--NotesAndLoansPayableCurrent_iI_pp0p0_c20230630_ztP89C7gTey1" style="border-bottom: Black 1pt solid; text-align: right" title="Total Current Portion">719,563</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_985_eus-gaap--NotesAndLoansPayableCurrent_iI_pp0p0_c20221231_zf72MMcrDDIa" style="border-bottom: Black 1pt solid; text-align: right" title="Total Current Portion">719,563</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Long term Portion:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt">Notes and loans payable</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_982_eus-gaap--NotesAndLoansPayable_iI_pp0p0_c20230630__us-gaap--ShortTermDebtTypeAxis__custom--NotesAndLoansPayableMember_zNHOEErppxef" style="border-bottom: Black 1pt solid; text-align: right" title="Total Long-term Portion">2,746,075</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_983_eus-gaap--NotesAndLoansPayable_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotesAndLoansPayableMember_zTeMGZJTloF8" style="border-bottom: Black 1pt solid; text-align: right" title="Total Long-term Portion">2,782,784</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left; padding-bottom: 1pt">Total Long-term Portion</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_989_eus-gaap--NotesAndLoansPayable_iI_pp0p0_c20230630_zAMwl0N7s30d" style="border-bottom: Black 1pt solid; text-align: right" title="Total Long-term Portion">2,746,075</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_987_eus-gaap--NotesAndLoansPayable_iI_pp0p0_c20221231_zvzjTFagzwb7" style="border-bottom: Black 1pt solid; text-align: right" title="Total Long-term Portion">2,782,784</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_98E_eus-gaap--NotesPayable_iI_pp0p0_c20230630_zCa3yv0WRrAg" style="border-bottom: Black 2.5pt double; text-align: right" title="Notes Payable">3,465,638</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_988_eus-gaap--NotesPayable_iI_pp0p0_c20221231_z69StoWcQw08" style="border-bottom: Black 2.5pt double; text-align: right" title="Notes Payable">3,502,347</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> 1080000 312339 P10Y prime rate plus 2.75% 0.1075 0.09 767678 785988 3384950 0.45 686990 0.03110 91635 2697960 <table cellpadding="0" cellspacing="0" id="xdx_880_ecustom--ScheduleOfDetailsTheLoanActive_zblye0o3I0ki" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%" summary="xdx: Disclosure - NOTES PAYABLE (Details)"> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"><span id="xdx_8BC_zYhxy7Y4ar56" style="display: none">Schedule of the loan active</span></td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left"> </td> <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2023</td> <td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td> <td style="vertical-align: bottom; text-align: center; font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2022</td> <td style="vertical-align: bottom; text-align: center; padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Current Portion:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; width: 76%; text-align: left; padding-bottom: 1pt">Notes and loans payable</td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_989_eus-gaap--NotesAndLoansPayableCurrent_iI_pp0p0_c20230630__us-gaap--ShortTermDebtTypeAxis__custom--NotesAndLoansPayableMember_zgn267FT2ySl" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Total Current Portion">719,563</td> <td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td> <td style="width: 1%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td> <td id="xdx_986_eus-gaap--NotesAndLoansPayableCurrent_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotesAndLoansPayableMember_zkELwapjdg24" style="border-bottom: Black 1pt solid; width: 9%; text-align: right" title="Total Current Portion">719,563</td> <td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left; padding-bottom: 1pt">Total Current Portion</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_989_eus-gaap--NotesAndLoansPayableCurrent_iI_pp0p0_c20230630_ztP89C7gTey1" style="border-bottom: Black 1pt solid; text-align: right" title="Total Current Portion">719,563</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_985_eus-gaap--NotesAndLoansPayableCurrent_iI_pp0p0_c20221231_zf72MMcrDDIa" style="border-bottom: Black 1pt solid; text-align: right" title="Total Current Portion">719,563</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Long term Portion:</td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td> <td> </td> <td style="text-align: left"> </td> <td style="text-align: right"> </td> <td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1pt">Notes and loans payable</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_982_eus-gaap--NotesAndLoansPayable_iI_pp0p0_c20230630__us-gaap--ShortTermDebtTypeAxis__custom--NotesAndLoansPayableMember_zNHOEErppxef" style="border-bottom: Black 1pt solid; text-align: right" title="Total Long-term Portion">2,746,075</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_983_eus-gaap--NotesAndLoansPayable_iI_pp0p0_c20221231__us-gaap--ShortTermDebtTypeAxis__custom--NotesAndLoansPayableMember_zTeMGZJTloF8" style="border-bottom: Black 1pt solid; text-align: right" title="Total Long-term Portion">2,782,784</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left; padding-bottom: 1pt">Total Long-term Portion</td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_989_eus-gaap--NotesAndLoansPayable_iI_pp0p0_c20230630_zAMwl0N7s30d" style="border-bottom: Black 1pt solid; text-align: right" title="Total Long-term Portion">2,746,075</td> <td style="padding-bottom: 1pt; text-align: left"> </td> <td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td> <td id="xdx_987_eus-gaap--NotesAndLoansPayable_iI_pp0p0_c20221231_zvzjTFagzwb7" style="border-bottom: Black 1pt solid; text-align: right" title="Total Long-term Portion">2,782,784</td> <td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_98E_eus-gaap--NotesPayable_iI_pp0p0_c20230630_zCa3yv0WRrAg" style="border-bottom: Black 2.5pt double; text-align: right" title="Notes Payable">3,465,638</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td> <td id="xdx_988_eus-gaap--NotesPayable_iI_pp0p0_c20221231_z69StoWcQw08" style="border-bottom: Black 2.5pt double; text-align: right" title="Notes Payable">3,502,347</td> <td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> 719563 719563 719563 719563 2746075 2782784 2746075 2782784 3465638 3502347 <p id="xdx_802_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_ziRVjTP8x1Q8" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>NOTE 7 – <span id="xdx_823_zEYpOgPtZ8e3">STOCKHOLDERS’ EQUITY</span></b></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">From December 31, 2022, to June 30,2023 the only impact to equity was the Net Income for the period of $<span id="xdx_907_eus-gaap--ProfitLoss_pp0p0_c20230101__20230630_zVJClaDXwUai">1,030,950</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> 1030950 <p id="xdx_803_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zksK2jAjAHCe" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>NOTE 8 – <span id="xdx_82B_z9HDhL6kWjJ7">COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The company has a multiple vehicle lease agreement with Enterprise Leasing. As of June 30, 2023, the company had 19 vehicles under lease. The lease agreement includes maintenance services. The term of the lease agreement varies based on the date vehicle were leased and the respective terms for each vehicle. The master lease is updated annually and requires annual internal financial reports and company tax return.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p id="xdx_806_ecustom--ConcentrationOfSalesTextBlock_zT4oFaWEUIx6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>NOTE 9 – <span id="xdx_82A_zRmJNCojXN9i">CONCENTRATION OF SALES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif;margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">The company generated approximately $<span id="xdx_90E_eus-gaap--Revenues_c20230101__20230630__srt--ProductOrServiceAxis__custom--GuardServiceMember_pp0p0">10,972,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_90C_eus-gaap--Revenues_c20220101__20220630__srt--ProductOrServiceAxis__custom--GuardServiceMember_pp0p0">11,709,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">in guard service revenue for the six-month ending June 30, 2023 and 2022 respectively. Of the total guard service revenue, approximately <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_c20220101__20220630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember__srt--MajorCustomersAxis__custom--GuardServiceMember_pdd">87% </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">was earned from four federal contracts operated by the company. The contracts, their respective terms and approximate revenues are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; width: 30%; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Social Security Administration, NSC</span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">- </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">September 2022 through September 2027</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Six-month revenue - $<span id="xdx_902_eus-gaap--Revenues_pp0p0_c20220901__20270930__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--CounterpartyNameAxis__custom--SocialSecurityAdministrationNSCMember_zqXxsx2cYV06">2,770,000</span></span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Social security Administration, SSC</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">- </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">June 2022 through June 2027</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Six-month revenue - $<span id="xdx_902_eus-gaap--Revenues_pp0p0_c20220601__20270630__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--CounterpartyNameAxis__custom--SocialSecurityAdministrationSSCMember_zHzQjHyjl0H">1,511,000</span></span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Social Security Administration, WBDOC</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">- </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">June 2021 through July 2026</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Six-month revenue - $<span id="xdx_905_eus-gaap--Revenues_pp0p0_c20210601__20260731__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--CounterpartyNameAxis__custom--SocialSecurityAdministrationWBDOCMember_zFECknBDtq5k">2,770,000</span></span></p></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">National Institute of Health- EPA</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">- </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">May 2020 through May 2023</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">Six-month revenue - $<span id="xdx_90A_eus-gaap--Revenues_pp0p0_c20200501__20230531__srt--CounterpartyNameAxis__custom--NationalInstituteOfHealthEPAMember_zvV5jF70SIk3">2,904,000</span></span></p></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p> 10972000 11709000 0.87 2770000 1511000 2770000 2904000 <p id="xdx_804_eus-gaap--OtherIncomeAndOtherExpenseDisclosureTextBlock_z9VlT2GpQNSf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>NOTE 10 – <span id="xdx_827_zUuSGWKWYDqe">OTHER INCOME (EXPENSE)</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0;text-align: justify">The company received an Employee Retention Tax Credit of (ERTC) payment of $3,288,000 from the tax year 2021. The company also experienced a related expense of approximately $<span id="xdx_90A_eus-gaap--OtherOperatingIncomeExpenseNet_c20230101__20230630_zYS7w8njRXa6">473,000 </span>for professional services related to the ERTC filing.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> </p> 473000 <p id="xdx_80C_ecustom--LitigationAndClaimsTextBlock_zrF79hllxVP6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"><b>NOTE 11 – <span id="xdx_828_zBoNGESKx8Zh">LITIGATION AND CLAIMS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt;">As of December 31, 2022, there was one employment issue pending. The issue involves a terminated employee alleging discrimination and wrongful termination. A lawsuit has not been filed, only a demand letter has been presented. Management has been working with the attorneys to find a reasonable settlement to this dispute without going to trial. After several months of discussion and negotiation it appears that the complaint will be settled for $23,000. As of March 31, 2023, the final agreement was signed which pays out the $<span id="xdx_907_eus-gaap--LitigationSettlementExpense_c20230101__20230630_pp0p0">23,000 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">settlement in three monthly installments starting May 15, 2023, Per Attorney letters received there are no other pending cases or legal matters.</span></p> 23000 EXCEL 52 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 53 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 54 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 55 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 119 172 1 false 34 0 false 4 false false R1.htm 00000001 - Document - Cover Sheet http://healthrevenue.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - CONSOLIDATED BALANCE SHEET Sheet http://healthrevenue.com/role/ConsolidatedBalanceSheet CONSOLIDATED BALANCE SHEET Statements 2 false false R3.htm 00000003 - Statement - CONSOLIDATED BALANCE SHEET (Parenthetical) Sheet http://healthrevenue.com/role/ConsolidatedBalanceSheetParenthetical CONSOLIDATED BALANCE SHEET (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - CONSOLIDATED STATEMENT OF OPERATIONS Sheet http://healthrevenue.com/role/ConsolidatedStatementOfOperations CONSOLIDATED STATEMENT OF OPERATIONS Statements 4 false false R5.htm 00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) Sheet http://healthrevenue.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) Statements 5 false false R6.htm 00000006 - Statement - STATEMENT OF CASH FLOWS Sheet http://healthrevenue.com/role/StatementOfCashFlows STATEMENT OF CASH FLOWS Statements 6 false false R7.htm 00000007 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) Sheet http://healthrevenue.com/role/ConsolidatedBalanceSheets CONSOLIDATED BALANCE SHEETS (Unaudited) Statements 7 false false R8.htm 00000008 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Sheet http://healthrevenue.com/role/ConsolidatedBalanceSheetsParenthetical CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) Statements 8 false false R9.htm 00000009 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Sheet http://healthrevenue.com/role/ConsolidatedStatementsOfOperations CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) Statements 9 false false R10.htm 00000010 - Statement - CONSPIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Unaudited) Sheet http://healthrevenue.com/role/ConspidatedStatementsOfStockholdersDeficit CONSPIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Unaudited) Statements 10 false false R11.htm 00000011 - Statement - STATEMENTS OF CASH FLOWS (Unaudited) Sheet http://healthrevenue.com/role/StatementsOfCashFlows STATEMENTS OF CASH FLOWS (Unaudited) Statements 11 false false R12.htm 00000012 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS Sheet http://healthrevenue.com/role/OrganizationAndDescriptionOfBusiness ORGANIZATION AND DESCRIPTION OF BUSINESS Notes 12 false false R13.htm 00000013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://healthrevenue.com/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 13 false false R14.htm 00000014 - Disclosure - RELATED PARTY RECEIVABLE Sheet http://healthrevenue.com/role/RelatedPartyReceivable RELATED PARTY RECEIVABLE Notes 14 false false R15.htm 00000015 - Disclosure - FIXED ASSETS Sheet http://healthrevenue.com/role/FixedAssets FIXED ASSETS Notes 15 false false R16.htm 00000016 - Disclosure - PAYROLL LIABILITY ??? PENSION Sheet http://healthrevenue.com/role/PayrollLiabilityPension PAYROLL LIABILITY ??? PENSION Notes 16 false false R17.htm 00000017 - Disclosure - NOTES PAYABLE Notes http://healthrevenue.com/role/NotesPayable NOTES PAYABLE Notes 17 false false R18.htm 00000018 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://healthrevenue.com/role/StockholdersEquity STOCKHOLDERS??? EQUITY Notes 18 false false R19.htm 00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://healthrevenue.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 19 false false R20.htm 00000020 - Disclosure - CONCENTRATION OF SALES Sheet http://healthrevenue.com/role/ConcentrationOfSales CONCENTRATION OF SALES Notes 20 false false R21.htm 00000021 - Disclosure - LITIGATION AND CLAIMS Sheet http://healthrevenue.com/role/LitigationAndClaims LITIGATION AND CLAIMS Notes 21 false false R22.htm 00000022 - Disclosure - INCOME TAXE Sheet http://healthrevenue.com/role/IncomeTaxe INCOME TAXE Notes 22 false false R23.htm 00000023 - Disclosure - SUBSEQUENT EVENTS Sheet http://healthrevenue.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 23 false false R24.htm 00000024 - Disclosure - OTHER INCOME (EXPENSE) Sheet http://healthrevenue.com/role/OtherIncomeExpense OTHER INCOME (EXPENSE) Notes 24 false false R25.htm 00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 25 false false R26.htm 00000026 - Disclosure - FIXED ASSETS (Tables) Sheet http://healthrevenue.com/role/FixedAssetsTables FIXED ASSETS (Tables) Tables http://healthrevenue.com/role/FixedAssets 26 false false R27.htm 00000027 - Disclosure - NOTES PAYABLE (Tables) Notes http://healthrevenue.com/role/NotesPayableTables NOTES PAYABLE (Tables) Tables http://healthrevenue.com/role/NotesPayable 27 false false R28.htm 00000028 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details Narrative) Sheet http://healthrevenue.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative ORGANIZATION AND DESCRIPTION OF BUSINESS (Details Narrative) Details http://healthrevenue.com/role/OrganizationAndDescriptionOfBusiness 28 false false R29.htm 00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesPolicies 29 false false R30.htm 00000030 - Disclosure - RELATED PARTY RECEIVABLE (Details Narrative) Sheet http://healthrevenue.com/role/RelatedPartyReceivableDetailsNarrative RELATED PARTY RECEIVABLE (Details Narrative) Details http://healthrevenue.com/role/RelatedPartyReceivable 30 false false R31.htm 00000031 - Disclosure - FIXED ASSETS (Details) Sheet http://healthrevenue.com/role/FixedAssetsDetails FIXED ASSETS (Details) Details http://healthrevenue.com/role/FixedAssetsTables 31 false false R32.htm 00000032 - Disclosure - PAYROLL LIABILITY ??? PENSION (Details Narrative) Sheet http://healthrevenue.com/role/PayrollLiabilityPensionDetailsNarrative PAYROLL LIABILITY ??? PENSION (Details Narrative) Details http://healthrevenue.com/role/PayrollLiabilityPension 32 false false R33.htm 00000033 - Disclosure - NOTE PAYABLE (Details) Sheet http://healthrevenue.com/role/NotePayableDetails NOTE PAYABLE (Details) Details 33 false false R34.htm 00000034 - Disclosure - NOTES PAYABLE (Details Narrative) Notes http://healthrevenue.com/role/NotesPayableDetailsNarrative NOTES PAYABLE (Details Narrative) Details http://healthrevenue.com/role/NotesPayableTables 34 false false R35.htm 00000035 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative) Sheet http://healthrevenue.com/role/StockholdersEquityDetailsNarrative STOCKHOLDERS??? EQUITY (Details Narrative) Details http://healthrevenue.com/role/StockholdersEquity 35 false false R36.htm 00000036 - Disclosure - CONCENTRATION OF SALES (Details Narrative) Sheet http://healthrevenue.com/role/ConcentrationOfSalesDetailsNarrative CONCENTRATION OF SALES (Details Narrative) Details http://healthrevenue.com/role/ConcentrationOfSales 36 false false R37.htm 00000037 - Disclosure - LITIGATION AND CLAIMS (Details Narrative) Sheet http://healthrevenue.com/role/LitigationAndClaimsDetailsNarrative LITIGATION AND CLAIMS (Details Narrative) Details http://healthrevenue.com/role/LitigationAndClaims 37 false false R38.htm 00000038 - Disclosure - INCOME TAXE (Details Narrative) Sheet http://healthrevenue.com/role/IncomeTaxeDetailsNarrative INCOME TAXE (Details Narrative) Details http://healthrevenue.com/role/IncomeTaxe 38 false false R39.htm 00000039 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://healthrevenue.com/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://healthrevenue.com/role/SubsequentEvents 39 false false R40.htm 00000040 - Disclosure - NOTES PAYABLE (Details) Notes http://healthrevenue.com/role/NotesPayableDetails NOTES PAYABLE (Details) Details http://healthrevenue.com/role/NotesPayableTables 40 false false R41.htm 00000041 - Disclosure - OTHER INCOME (EXPENSE) (Details Narrative) Sheet http://healthrevenue.com/role/OtherIncomeExpenseDetailsNarrative OTHER INCOME (EXPENSE) (Details Narrative) Details http://healthrevenue.com/role/OtherIncomeExpense 41 false false All Reports Book All Reports ameriguardsec_s1a3.htm ameriguardsec_ex107.htm ameriguardsec_ex23-1.htm hraad-20230630.xsd hraad-20230630_cal.xml hraad-20230630_def.xml hraad-20230630_lab.xml hraad-20230630_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 57 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ameriguardsec_s1a3.htm": { "axisCustom": 0, "axisStandard": 14, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 440, "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 119, "dts": { "calculationLink": { "local": [ "hraad-20230630_cal.xml" ] }, "definitionLink": { "local": [ "hraad-20230630_def.xml" ] }, "inline": { "local": [ "ameriguardsec_s1a3.htm" ] }, "labelLink": { "local": [ "hraad-20230630_lab.xml" ] }, "presentationLink": { "local": [ "hraad-20230630_pre.xml" ] }, "schema": { "local": [ "hraad-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 321, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 29, "http://healthrevenue.com/20230630": 12, "http://xbrl.sec.gov/dei/2023": 2, "total": 43 }, "keyCustom": 53, "keyStandard": 119, "memberCustom": 20, "memberStandard": 11, "nsprefix": "hraad", "nsuri": "http://healthrevenue.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://healthrevenue.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000010 - Statement - CONSPIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Unaudited)", "menuCat": "Statements", "order": "10", "role": "http://healthrevenue.com/role/ConspidatedStatementsOfStockholdersDeficit", "shortName": "CONSPIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "AsOf2023-06-30_us-gaap_CommonStockMember", "decimals": "0", "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000011 - Statement - STATEMENTS OF CASH FLOWS (Unaudited)", "menuCat": "Statements", "order": "11", "role": "http://healthrevenue.com/role/StatementsOfCashFlows", "shortName": "STATEMENTS OF CASH FLOWS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS", "menuCat": "Notes", "order": "12", "role": "http://healthrevenue.com/role/OrganizationAndDescriptionOfBusiness", "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "13", "role": "http://healthrevenue.com/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - RELATED PARTY RECEIVABLE", "menuCat": "Notes", "order": "14", "role": "http://healthrevenue.com/role/RelatedPartyReceivable", "shortName": "RELATED PARTY RECEIVABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - FIXED ASSETS", "menuCat": "Notes", "order": "15", "role": "http://healthrevenue.com/role/FixedAssets", "shortName": "FIXED ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "hraad:PayrollLiabilityPensionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - PAYROLL LIABILITY \u2013 PENSION", "menuCat": "Notes", "order": "16", "role": "http://healthrevenue.com/role/PayrollLiabilityPension", "shortName": "PAYROLL LIABILITY \u2013 PENSION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "hraad:PayrollLiabilityPensionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - NOTES PAYABLE", "menuCat": "Notes", "order": "17", "role": "http://healthrevenue.com/role/NotesPayable", "shortName": "NOTES PAYABLE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "menuCat": "Notes", "order": "18", "role": "http://healthrevenue.com/role/StockholdersEquity", "shortName": "STOCKHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - COMMITMENTS AND CONTINGENCIES", "menuCat": "Notes", "order": "19", "role": "http://healthrevenue.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - CONSOLIDATED BALANCE SHEET", "menuCat": "Statements", "order": "2", "role": "http://healthrevenue.com/role/ConsolidatedBalanceSheet", "shortName": "CONSOLIDATED BALANCE SHEET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "hraad:ConcentrationOfSalesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - CONCENTRATION OF SALES", "menuCat": "Notes", "order": "20", "role": "http://healthrevenue.com/role/ConcentrationOfSales", "shortName": "CONCENTRATION OF SALES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "hraad:ConcentrationOfSalesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "hraad:LitigationAndClaimsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - LITIGATION AND CLAIMS", "menuCat": "Notes", "order": "21", "role": "http://healthrevenue.com/role/LitigationAndClaims", "shortName": "LITIGATION AND CLAIMS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "hraad:LitigationAndClaimsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2022-01-012022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - INCOME TAXE", "menuCat": "Notes", "order": "22", "role": "http://healthrevenue.com/role/IncomeTaxe", "shortName": "INCOME TAXE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2022-01-012022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2022-01-012022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "23", "role": "http://healthrevenue.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2022-01-012022-12-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - OTHER INCOME (EXPENSE)", "menuCat": "Notes", "order": "24", "role": "http://healthrevenue.com/role/OtherIncomeExpense", "shortName": "OTHER INCOME (EXPENSE)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "25", "role": "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:UseOfEstimates", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - FIXED ASSETS (Tables)", "menuCat": "Tables", "order": "26", "role": "http://healthrevenue.com/role/FixedAssetsTables", "shortName": "FIXED ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "hraad:ScheduleOfDetailsTheLoanActive", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - NOTES PAYABLE (Tables)", "menuCat": "Tables", "order": "27", "role": "http://healthrevenue.com/role/NotesPayableTables", "shortName": "NOTES PAYABLE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": null, "first": true, "lang": "en-US", "name": "hraad:ScheduleOfDetailsTheLoanActive", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2022-11-012022-11-14", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - ORGANIZATION AND DESCRIPTION OF BUSINESS (Details Narrative)", "menuCat": "Details", "order": "28", "role": "http://healthrevenue.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative", "shortName": "ORGANIZATION AND DESCRIPTION OF BUSINESS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "AsOf2023-06-30", "decimals": "INF", "lang": null, "name": "hraad:HolderOwnership", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "menuCat": "Details", "order": "29", "role": "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Cash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - CONSOLIDATED BALANCE SHEET (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://healthrevenue.com/role/ConsolidatedBalanceSheetParenthetical", "shortName": "CONSOLIDATED BALANCE SHEET (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockSharesOutstanding", "us-gaap:CommonStockSharesOutstanding", "span", "span", "span", "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2021-07-012021-07-07", "decimals": "0", "first": true, "lang": null, "name": "hraad:ConsiderationPaidShares", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - RELATED PARTY RECEIVABLE (Details Narrative)", "menuCat": "Details", "order": "30", "role": "http://healthrevenue.com/role/RelatedPartyReceivableDetailsNarrative", "shortName": "RELATED PARTY RECEIVABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2021-07-012021-07-07", "decimals": "0", "first": true, "lang": null, "name": "hraad:ConsiderationPaidShares", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - FIXED ASSETS (Details)", "menuCat": "Details", "order": "31", "role": "http://healthrevenue.com/role/FixedAssetsDetails", "shortName": "FIXED ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "span", "p", "hraad:PayrollLiabilityPensionTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "hraad:PensionBalances", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - PAYROLL LIABILITY \u2013 PENSION (Details Narrative)", "menuCat": "Details", "order": "32", "role": "http://healthrevenue.com/role/PayrollLiabilityPensionDetailsNarrative", "shortName": "PAYROLL LIABILITY \u2013 PENSION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "hraad:PayrollLiabilityPensionTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "hraad:PensionBalances", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "hraad:ScheduleOfDetailsTheLoanActive", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesAndLoansPayableCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - NOTE PAYABLE (Details)", "menuCat": "Details", "order": "33", "role": "http://healthrevenue.com/role/NotePayableDetails", "shortName": "NOTE PAYABLE (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R34": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "hraad:ScheduleOfDetailsTheLoanActive", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "AsOf2021-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesPayable", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - NOTES PAYABLE (Details Narrative)", "menuCat": "Details", "order": "34", "role": "http://healthrevenue.com/role/NotesPayableDetailsNarrative", "shortName": "NOTES PAYABLE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "AsOf2022-06-30", "decimals": "0", "lang": null, "name": "us-gaap:AccruedLiabilitiesCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2022-11-012022-11-14", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "menuCat": "Details", "order": "35", "role": "http://healthrevenue.com/role/StockholdersEquityDetailsNarrative", "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2022-01-012022-12-31", "decimals": "0", "lang": null, "name": "hraad:ReductionOfPaidinCapital", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - CONCENTRATION OF SALES (Details Narrative)", "menuCat": "Details", "order": "36", "role": "http://healthrevenue.com/role/ConcentrationOfSalesDetailsNarrative", "shortName": "CONCENTRATION OF SALES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "td", "tr", "table", "hraad:ConcentrationOfSalesTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2020-05-012023-05-31_custom_NationalInstituteOfHealthEPAMember", "decimals": "0", "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "p", "hraad:LitigationAndClaimsTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LitigationSettlementExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - LITIGATION AND CLAIMS (Details Narrative)", "menuCat": "Details", "order": "37", "role": "http://healthrevenue.com/role/LitigationAndClaimsDetailsNarrative", "shortName": "LITIGATION AND CLAIMS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "hraad:LitigationAndClaimsTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LitigationSettlementExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TaxesPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - INCOME TAXE (Details Narrative)", "menuCat": "Details", "order": "38", "role": "http://healthrevenue.com/role/IncomeTaxeDetailsNarrative", "shortName": "INCOME TAXE (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "AsOf2022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:TaxesPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-03-012023-03-23_us-gaap_SubsequentEventMember", "decimals": "0", "first": true, "lang": null, "name": "hraad:AnnualRevenueReduced", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "menuCat": "Details", "order": "39", "role": "http://healthrevenue.com/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-03-012023-03-23_us-gaap_SubsequentEventMember", "decimals": "0", "first": true, "lang": null, "name": "hraad:AnnualRevenueReduced", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2022-01-012022-12-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - CONSOLIDATED STATEMENT OF OPERATIONS", "menuCat": "Statements", "order": "4", "role": "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "shortName": "CONSOLIDATED STATEMENT OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2022-01-012022-12-31", "decimals": "INF", "lang": null, "name": "hraad:NetIncomelossPerCommonShareBasicAndDiluted", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "hraad:ScheduleOfDetailsTheLoanActive", "us-gaap:DebtDisclosureTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NotesAndLoansPayableCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - NOTES PAYABLE (Details)", "menuCat": "Details", "order": "40", "role": "http://healthrevenue.com/role/NotesPayableDetails", "shortName": "NOTES PAYABLE (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R41": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherOperatingIncomeExpenseNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - OTHER INCOME (EXPENSE) (Details Narrative)", "menuCat": "Details", "order": "41", "role": "http://healthrevenue.com/role/OtherIncomeExpenseDetailsNarrative", "shortName": "OTHER INCOME (EXPENSE) (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:OtherOperatingIncomeExpenseNet", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)", "menuCat": "Statements", "order": "5", "role": "http://healthrevenue.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "shortName": "CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "AsOf2020-12-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - STATEMENT OF CASH FLOWS", "menuCat": "Statements", "order": "6", "role": "http://healthrevenue.com/role/StatementOfCashFlows", "shortName": "STATEMENT OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2022-01-012022-12-31", "decimals": "0", "lang": null, "name": "us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000007 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited)", "menuCat": "Statements", "order": "7", "role": "http://healthrevenue.com/role/ConsolidatedBalanceSheets", "shortName": "CONSOLIDATED BALANCE SHEETS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "AsOf2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "AsOf2022-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000008 - Statement - CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "menuCat": "Statements", "order": "8", "role": "http://healthrevenue.com/role/ConsolidatedBalanceSheetsParenthetical", "shortName": "CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R9": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000009 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "menuCat": "Statements", "order": "9", "role": "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations", "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "ameriguardsec_s1a3.htm", "contextRef": "From2023-01-01to2023-06-30", "decimals": "0", "lang": null, "name": "us-gaap:CostOfGoodsAndServicesSold", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } } }, "segmentCount": 34, "tag": { "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types." } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_BusinessContactMember": { "auth_ref": [ "r438", "r439" ], "lang": { "en-us": { "role": { "documentation": "Business contact for the entity", "label": "Business Contact [Member]" } } }, "localname": "BusinessContactMember", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "domainItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of contact personnel", "label": "Contact Personnel Name" } } }, "localname": "ContactPersonnelName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page." } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r436", "r438", "r439" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r437" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r428" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityAddressesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Entity Addresses [Line Items]" } } }, "localname": "EntityAddressesLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityAddressesTable": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Container of address information for the entity", "label": "Entity Addresses [Table]" } } }, "localname": "EntityAddressesTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r431" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r444" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r439" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r427" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r438" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r433" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r426" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r430" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r429" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r434" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r435" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r443" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://healthrevenue.com/role/Cover" ], "xbrltype": "booleanItemType" }, "hraad_AccountsPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Accounts payable" } } }, "localname": "AccountsPayable", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "hraad_AmeriguardSecurityServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ameriguard Security Services [Member]" } } }, "localname": "AmeriguardSecurityServicesMember", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "hraad_AnnualRevenueReduced": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Annual revenue reduced" } } }, "localname": "AnnualRevenueReduced", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "hraad_BuildingImprovements": { "auth_ref": [], "calculation": { "http://healthrevenue.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "BuildingImprovements", "negatedLabel": "Building improvements" } } }, "localname": "BuildingImprovements", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows", "http://healthrevenue.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hraad_CellularServices": { "auth_ref": [], "calculation": { "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Cellular services" } } }, "localname": "CellularServices", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "hraad_ConcentrationOfSalesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CONCENTRATION OF SALES" } } }, "localname": "ConcentrationOfSalesTextBlock", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConcentrationOfSales" ], "xbrltype": "textBlockItemType" }, "hraad_ConsiderationPaidShares": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Consideration paid Shares" } } }, "localname": "ConsiderationPaidShares", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/RelatedPartyReceivableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "hraad_CustodianVenturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Custodian Ventures [Member]" } } }, "localname": "CustodianVenturesMember", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" ], "xbrltype": "domainItemType" }, "hraad_DisclosureConcentrationOfSalesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Concentration Of Sales" } } }, "localname": "DisclosureConcentrationOfSalesAbstract", "nsuri": "http://healthrevenue.com/20230630", "xbrltype": "stringItemType" }, "hraad_DisclosureLitigationAndClaimsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation And Claims" } } }, "localname": "DisclosureLitigationAndClaimsAbstract", "nsuri": "http://healthrevenue.com/20230630", "xbrltype": "stringItemType" }, "hraad_DisclosurePayrollLiabilityPensionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payroll Liability Pension" } } }, "localname": "DisclosurePayrollLiabilityPensionAbstract", "nsuri": "http://healthrevenue.com/20230630", "xbrltype": "stringItemType" }, "hraad_EmployeeBenefitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Employee Benefits [Member]" } } }, "localname": "EmployeeBenefitsMember", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "hraad_EquityDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity description" } } }, "localname": "EquityDescription", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "hraad_EquityMerger": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Equity Merger" } } }, "localname": "EquityMerger", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "hraad_EquityMergerShares": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Merger, Shares" } } }, "localname": "EquityMergerShares", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "hraad_ExpensesHeldInReserve": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Expenses held in reserve" } } }, "localname": "ExpensesHeldInReserve", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "hraad_GeneralLiabilityInsurance": { "auth_ref": [], "calculation": { "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "General liability insurance" } } }, "localname": "GeneralLiabilityInsurance", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "hraad_GuardServiceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Guard Service [Member]" } } }, "localname": "GuardServiceMember", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConcentrationOfSalesDetailsNarrative" ], "xbrltype": "domainItemType" }, "hraad_GuardTrainingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Guard Training [Member]" } } }, "localname": "GuardTrainingMember", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "hraad_HolderOwnership": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Holder ownership" } } }, "localname": "HolderOwnership", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" ], "xbrltype": "percentItemType" }, "hraad_IncreaseDecreaseInOpertingLeaseAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Increase Decrease In Operting Lease Assets" } } }, "localname": "IncreaseDecreaseInOpertingLeaseAssets", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "hraad_IncreaseDecreaseInPayrollLiabilityPension": { "auth_ref": [], "calculation": { "http://healthrevenue.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Payroll liability - Pension" } } }, "localname": "IncreaseDecreaseInPayrollLiabilityPension", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows", "http://healthrevenue.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hraad_IncreaseInCommonSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase in common shares outstanding" } } }, "localname": "IncreaseInCommonSharesOutstanding", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "hraad_InitialPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Initial Payment" } } }, "localname": "InitialPayment", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "hraad_InterestRateIsVariable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Interest rate is variable" } } }, "localname": "InterestRateIsVariable", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "hraad_LillianFloresMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Lillian Flores [Member]" } } }, "localname": "LillianFloresMember", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/NotesPayableDetailsNarrative", "http://healthrevenue.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" ], "xbrltype": "domainItemType" }, "hraad_LitigationAndClaimsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LITIGATION AND CLAIMS" } } }, "localname": "LitigationAndClaimsTextBlock", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/LitigationAndClaims" ], "xbrltype": "textBlockItemType" }, "hraad_LoanInterest": { "auth_ref": [], "calculation": { "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations": { "order": 8.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Loan interest" } } }, "localname": "LoanInterest", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "hraad_LoanPrinciplePayments": { "auth_ref": [], "calculation": { "http://healthrevenue.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "LoanPrinciplePayments", "negatedLabel": "Loan principle payments" } } }, "localname": "LoanPrinciplePayments", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows", "http://healthrevenue.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hraad_MasterSecurityCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Master Security Company [Member]" } } }, "localname": "MasterSecurityCompanyMember", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "hraad_NationalInstituteOfHealthEPAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "National Institute Of Health E P A [Member]" } } }, "localname": "NationalInstituteOfHealthEPAMember", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConcentrationOfSalesDetailsNarrative" ], "xbrltype": "domainItemType" }, "hraad_NetAdjustmentsEquity": { "auth_ref": [], "calculation": { "http://healthrevenue.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "NetAdjustmentsEquity", "negatedLabel": "Net adjustments, Equity" } } }, "localname": "NetAdjustmentsEquity", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hraad_NetIncomelossPerCommonShareBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income/(loss) per Common Share - Basic and Diluted" } } }, "localname": "NetIncomelossPerCommonShareBasicAndDiluted", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "perShareItemType" }, "hraad_NotePayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "NotePayable", "verboseLabel": "Notes Payable" } } }, "localname": "NotePayable", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "hraad_NotesAndLoansPayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes And Loans Payable [Member]" } } }, "localname": "NotesAndLoansPayableMember", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/NotePayableDetails", "http://healthrevenue.com/role/NotesPayableDetails" ], "xbrltype": "domainItemType" }, "hraad_NotesReceivablerelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Notes Receivablerelated Party" } } }, "localname": "NotesReceivablerelatedParty", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/RelatedPartyReceivableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "hraad_NumberOfSharesExchanged": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Number of shares exchanged" } } }, "localname": "NumberOfSharesExchanged", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "hraad_OperatingLeaseAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Operating lease asset" } } }, "localname": "OperatingLeaseAsset", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hraad_OperatingLeasesLeaseLiability": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Operating leases - lease liability" } } }, "localname": "OperatingLeasesLeaseLiability", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows", "http://healthrevenue.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hraad_OperatingLeasesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Leases" } } }, "localname": "OperatingLeasesPolicyTextBlock", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "hraad_OperatingLeasesRightOfUseAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Operating leases - right of use asset" } } }, "localname": "OperatingLeasesRightOfUseAsset", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows", "http://healthrevenue.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hraad_OtherRelatedIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Related Income [Member]" } } }, "localname": "OtherRelatedIncomeMember", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "hraad_OwnerDistributions": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "OwnerDistributions", "negatedLabel": "Owner distributions" } } }, "localname": "OwnerDistributions", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hraad_OwnerDraws": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Owner draws (pre-merger)" } } }, "localname": "OwnerDraws", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "hraad_OwnerDrawsPremerger": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "OwnerDrawsPremerger", "verboseLabel": "Owner draws (pre-merger)" } } }, "localname": "OwnerDrawsPremerger", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "hraad_PaymentForShareholderBuyout": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "PaymentForShareholderBuyout", "negatedLabel": "Payment for Shareholder buyout" } } }, "localname": "PaymentForShareholderBuyout", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hraad_PaymentsToAcquirePurchaseOfFixedAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "PaymentsToAcquirePurchaseOfFixedAssets", "negatedLabel": "Purchase of fixed assets" } } }, "localname": "PaymentsToAcquirePurchaseOfFixedAssets", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hraad_PayrollLiabilityPension": { "auth_ref": [], "calculation": { "http://healthrevenue.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "label": "Payroll liability - Pension (note 5)" } } }, "localname": "PayrollLiabilityPension", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet", "http://healthrevenue.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "hraad_PayrollLiabilityPensionTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "PAYROLL LIABILITY \u2013 PENSION" } } }, "localname": "PayrollLiabilityPensionTextBlock", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/PayrollLiabilityPension" ], "xbrltype": "textBlockItemType" }, "hraad_PensionBalances": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Pension balances" } } }, "localname": "PensionBalances", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/PayrollLiabilityPensionDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "hraad_ReductionInDirectExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Reduction in direct expenses" } } }, "localname": "ReductionInDirectExpenses", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "hraad_ReductionOfPaidinCapital": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Reduction of Paid-in Capital" } } }, "localname": "ReductionOfPaidinCapital", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "hraad_RelatedPartyReceivable": { "auth_ref": [], "calculation": { "http://healthrevenue.com/role/ConsolidatedBalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "RelatedPartyReceivable", "verboseLabel": "Related Party Receivable (note 3)" } } }, "localname": "RelatedPartyReceivable", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "hraad_RelatedPartyReceivableNote3": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Related Party Receivable (note 3)" } } }, "localname": "RelatedPartyReceivableNote3", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "hraad_RelatedPartyReceivables": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Related party receivables" } } }, "localname": "RelatedPartyReceivables", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "hraad_ReserveForReturns": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Reserve for returns" } } }, "localname": "ReserveForReturns", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "hraad_RetainedDeficitOfMergerWithRelatedEntity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Retained Deficit of merger with related entity" } } }, "localname": "RetainedDeficitOfMergerWithRelatedEntity", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "hraad_SBALoanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SBA Loan [Member]" } } }, "localname": "SBALoanMember", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "hraad_SalariesAndRelatedTaxesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Salaries And Related Taxes [Member]" } } }, "localname": "SalariesAndRelatedTaxesMember", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "hraad_ScheduleOfDetailsTheLoanActive": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Schedule of the loan active" } } }, "localname": "ScheduleOfDetailsTheLoanActive", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/NotesPayableTables" ], "xbrltype": "textBlockItemType" }, "hraad_SecureTransportationIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Secure Transportation Inc [Member]" } } }, "localname": "SecureTransportationIncMember", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "hraad_SecureTransportationVehicleLoan": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Secure Transportation vehicle loan" } } }, "localname": "SecureTransportationVehicleLoan", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hraad_SecurityServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Security Services [Member]" } } }, "localname": "SecurityServicesMember", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "hraad_ShareholderBuyout": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "Shareholder buyout" } } }, "localname": "ShareholderBuyout", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "hraad_ShareholderLoan": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Shareholder Loan" } } }, "localname": "ShareholderLoan", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "hraad_SocialSecurityAdministrationNSCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Social Security Administration N S C [Member]" } } }, "localname": "SocialSecurityAdministrationNSCMember", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConcentrationOfSalesDetailsNarrative" ], "xbrltype": "domainItemType" }, "hraad_SocialSecurityAdministrationSSCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Social Security Administration S S C [Member]" } } }, "localname": "SocialSecurityAdministrationSSCMember", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConcentrationOfSalesDetailsNarrative" ], "xbrltype": "domainItemType" }, "hraad_SocialSecurityAdministrationWBDOCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Social Security Administration W B D O C [Member]" } } }, "localname": "SocialSecurityAdministrationWBDOCMember", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConcentrationOfSalesDetailsNarrative" ], "xbrltype": "domainItemType" }, "hraad_StockholdersEquityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Member]" } } }, "localname": "StockholdersEquityMember", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://healthrevenue.com/role/ConspidatedStatementsOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "hraad_SubContractorPaymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Sub Contractor Payments [Member]" } } }, "localname": "SubContractorPaymentsMember", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "hraad_TotalAssetOfLeases": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "label": "Total asset of the leases" } } }, "localname": "TotalAssetOfLeases", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "hraad_TotalCurrentLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "TotalCurrentLiabilities", "totalLabel": "Total Current Liabilities" } } }, "localname": "TotalCurrentLiabilities", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "hraad_TotalLiabilitiesAndStockholdersEquity": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "label": "TotalLiabilitiesAndStockholdersEquity", "totalLabel": "Total Liabilities and Stockholders\u2019 Equity" } } }, "localname": "TotalLiabilitiesAndStockholdersEquity", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "hraad_VehicleExpense": { "auth_ref": [], "calculation": { "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "label": "Vehicle expense" } } }, "localname": "VehicleExpense", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "hraad_VehiclesAndEquipmentExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Vehicles And Equipment Expenses [Member]" } } }, "localname": "VehiclesAndEquipmentExpensesMember", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "hraad_WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Common Shares Outstanding - Basic and Diluted" } } }, "localname": "WeightedAverageNumberOfCommonSharesOutstandingBasicAndDiluted", "nsuri": "http://healthrevenue.com/20230630", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations" ], "xbrltype": "sharesItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r458" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://healthrevenue.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r120", "r121", "r179", "r203", "r266", "r394", "r396" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://healthrevenue.com/role/ConcentrationOfSalesDetailsNarrative", "http://healthrevenue.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r158", "r408", "r470", "r478", "r479" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://healthrevenue.com/role/ConcentrationOfSalesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r158", "r408", "r470", "r478", "r479" ], "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://healthrevenue.com/role/ConcentrationOfSalesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r156", "r271", "r301", "r302", "r303", "r304", "r305", "r306", "r391", "r407", "r413", "r448", "r466", "r467", "r470", "r478" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://healthrevenue.com/role/ConcentrationOfSalesDetailsNarrative", "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r156", "r271", "r301", "r302", "r303", "r304", "r305", "r306", "r391", "r407", "r413", "r448", "r466", "r467", "r470", "r478" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://healthrevenue.com/role/ConcentrationOfSalesDetailsNarrative", "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r120", "r121", "r179", "r203", "r266", "r395", "r396" ], "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://healthrevenue.com/role/ConcentrationOfSalesDetailsNarrative", "http://healthrevenue.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r458", "r473" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://healthrevenue.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://healthrevenue.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r8", "r412" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "verboseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r159", "r160" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts receivable, net (note 1)" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet", "http://healthrevenue.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r12" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Interest Due (note 6)", "verboseLabel": "Accrued Liabilities, Current" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet", "http://healthrevenue.com/role/ConsolidatedBalanceSheets", "http://healthrevenue.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedPayrollTaxesCurrent": { "auth_ref": [ "r12" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Payroll" } } }, "localname": "AccruedPayrollTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet", "http://healthrevenue.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r32", "r99", "r294" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedLabel": "Accumulated Depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/FixedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r216", "r217", "r218", "r322", "r455", "r456", "r457", "r471", "r484" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://healthrevenue.com/role/ConspidatedStatementsOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustment to reconcile net loss from operations:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows", "http://healthrevenue.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AmortizationOfLeasedAsset": { "auth_ref": [ "r80", "r81" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The expense charged against earnings for the periodic recognition of capitalized leases. This element may apply to energy companies that lease mineral producing properties and to other enterprises that capitalize property, plant, or equipment obtained through capital leases.", "label": "Amortization of the lease" } } }, "localname": "AmortizationOfLeasedAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r75", "r100", "r118", "r144", "r150", "r154", "r161", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r232", "r236", "r248", "r288", "r345", "r412", "r424", "r468", "r469", "r475" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Default Label]", "totalLabel": "Total Assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet", "http://healthrevenue.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet", "http://healthrevenue.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r95", "r101", "r118", "r161", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r232", "r236", "r248", "r412", "r468", "r469", "r475" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet", "http://healthrevenue.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet", "http://healthrevenue.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r118", "r161", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r232", "r236", "r248", "r468", "r469", "r475" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Total Non-Current Assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet", "http://healthrevenue.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r44", "r63", "r64" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "ORGANIZATION AND DESCRIPTION OF BUSINESS" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/OrganizationAndDescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_Cash": { "auth_ref": [ "r83", "r289", "r323", "r340", "r412", "r424", "r449" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash [Default Label]", "verboseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r17", "r97", "r392" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet", "http://healthrevenue.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r17", "r60", "r114" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash at End of Period", "periodStartLabel": "Cash at Beginning of Period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r17", "r60", "r114" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash at End of Period", "periodStartLabel": "Cash at Beginning of Period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r0", "r60" ], "calculation": { "http://healthrevenue.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net Increase (Decrease) in Cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows", "http://healthrevenue.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental disclosure of non-cash financing activities:" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows", "http://healthrevenue.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r68", "r164", "r165", "r389", "r465" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r414", "r415", "r416", "r418", "r419", "r420", "r421", "r455", "r456", "r471", "r480", "r484" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://healthrevenue.com/role/ConspidatedStatementsOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheetParenthetical", "http://healthrevenue.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r48" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheetParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r5", "r48", "r332", "r351", "r484", "r485" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheetParenthetical", "http://healthrevenue.com/role/ConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r48", "r290", "r412" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $.001 par value, 94,471,302 shares issued and outstanding at December 31, 2022 and 2021 (Note 7)", "verboseLabel": "Common stock, $.001 par value, 94,471,302 shares issued and outstanding at June 30, 2023 and 2022" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet", "http://healthrevenue.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r25", "r27", "r37", "r38", "r158", "r388" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConcentrationOfSalesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r25", "r27", "r37", "r38", "r158", "r312", "r388" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConcentrationOfSalesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r25", "r27", "r37", "r38", "r158", "r388", "r446" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConcentrationOfSalesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r25", "r27", "r37", "r38", "r158" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConcentrationOfSalesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r25", "r27", "r37", "r38", "r158", "r388" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConcentrationOfSalesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ConversionOfStockAmountConverted1": { "auth_ref": [ "r20", "r21", "r22" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Cancelation and conversion of preferred stock" } } }, "localname": "ConversionOfStockAmountConverted1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r20", "r21", "r22" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Cancelation and conversion of preferred stock, Shares", "verboseLabel": "Conversion of shares" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://healthrevenue.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CostOfGoodsAndServicesSold": { "auth_ref": [ "r55", "r271" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.", "label": "Total Cost of Services" } } }, "localname": "CostOfGoodsAndServicesSold", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfGoodsAndServicesSoldAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cost of Services" } } }, "localname": "CostOfGoodsAndServicesSoldAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtDisclosureTextBlock": { "auth_ref": [ "r69", "r116", "r175", "r181", "r182", "r183", "r184", "r185", "r186", "r191", "r198", "r199", "r200" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.", "label": "NOTES PAYABLE" } } }, "localname": "DebtDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/NotesPayable" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r7", "r45", "r46", "r76", "r77", "r122", "r176", "r177", "r178", "r179", "r180", "r182", "r187", "r188", "r189", "r190", "r192", "r193", "r194", "r195", "r196", "r197", "r256", "r402", "r403", "r404", "r405", "r406", "r453" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r39", "r40", "r176", "r256", "r403", "r404" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Principal amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateDuringPeriod": { "auth_ref": [ "r14", "r39", "r194" ], "lang": { "en-us": { "role": { "documentation": "The average effective interest rate during the reporting period.", "label": "Interest rate" } } }, "localname": "DebtInstrumentInterestRateDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentInterestRateTerms": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets.", "label": "Debt Instrument, Interest Rate Terms" } } }, "localname": "DebtInstrumentInterestRateTerms", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r15", "r122", "r176", "r177", "r178", "r179", "r180", "r182", "r187", "r188", "r189", "r190", "r192", "r193", "r194", "r195", "r196", "r197", "r256", "r402", "r403", "r404", "r405", "r406", "r453" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentPeriodicPayment": { "auth_ref": [ "r15", "r43" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the required periodic payments including both interest and principal payments.", "label": "Periodic payment" } } }, "localname": "DebtInstrumentPeriodicPayment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]" } } }, "localname": "DeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r2", "r31" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations": { "order": 9.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r2", "r31" ], "calculation": { "http://healthrevenue.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r108", "r128", "r129", "r130", "r131", "r132", "r137", "r139", "r140", "r141", "r142", "r246", "r247", "r284", "r298", "r398" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r23", "r24" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Net Income/(Loss) per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r5", "r92", "r104", "r105", "r106", "r123", "r124", "r125", "r127", "r133", "r135", "r143", "r162", "r163", "r214", "r216", "r217", "r218", "r224", "r225", "r238", "r239", "r240", "r241", "r242", "r243", "r245", "r249", "r250", "r251", "r252", "r253", "r254", "r260", "r307", "r308", "r309", "r322", "r374" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://healthrevenue.com/role/ConspidatedStatementsOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r4", "r6" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r56", "r356" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations": { "order": 7.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r54", "r118", "r144", "r149", "r153", "r155", "r161", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r248", "r400", "r468" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "totalLabel": "Gross Margin" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet": { "auth_ref": [], "calculation": { "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, nonoperating income (expense) and income (loss) from equity method investments, before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of interest income (expense).", "label": "Net Income/(loss) before Income Taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeInterestExpenseInterestIncomeIncomeTaxesExtraordinaryItemsNoncontrollingInterestsNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r119", "r219", "r221", "r222", "r223", "r226", "r228", "r229", "r230", "r316" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "INCOME TAXE" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/IncomeTaxe" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r82", "r91", "r134", "r135", "r147", "r220", "r227", "r300" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r19" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Interest Paid" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows", "http://healthrevenue.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r1" ], "calculation": { "http://healthrevenue.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "verboseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows", "http://healthrevenue.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r1" ], "calculation": { "http://healthrevenue.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows", "http://healthrevenue.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": { "auth_ref": [ "r1" ], "calculation": { "http://healthrevenue.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.", "label": "Increase (Decrease) in Accrued Interest Receivable, Net", "negatedLabel": "Accrued Interest" } } }, "localname": "IncreaseDecreaseInAccruedInterestReceivableNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows", "http://healthrevenue.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r1" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase (Decrease) in Employee Related Liabilities", "verboseLabel": "Accrued Payroll" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in Operating Assets and Liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r447", "r452" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "verboseLabel": "Operating lease liability" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingLiabilities": { "auth_ref": [ "r1" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities that result from activities that generate operating income.", "label": "Operating lease liability" } } }, "localname": "IncreaseDecreaseInOperatingLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidInsurance": { "auth_ref": [ "r1" ], "calculation": { "http://healthrevenue.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of consideration paid in advance for insurance that provides economic benefits in future periods.", "label": "Increase (Decrease) in Prepaid Insurance", "negatedLabel": "Prepaid insurance" } } }, "localname": "IncreaseDecreaseInPrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows", "http://healthrevenue.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r109", "r112", "r113" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Income Taxes Paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows", "http://healthrevenue.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/FixedAssetsDetails", "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r11", "r118", "r161", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r233", "r236", "r237", "r248", "r331", "r399", "r424", "r468", "r475", "r476" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities [Default Label]", "totalLabel": "Total Liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities" } } }, "localname": "LiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet", "http://healthrevenue.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r52", "r78", "r292", "r412", "r454", "r463", "r472" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r13", "r96", "r118", "r161", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r233", "r236", "r237", "r248", "r412", "r468", "r475", "r476" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet", "http://healthrevenue.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Long Term Liabilities" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet", "http://healthrevenue.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationSettlementExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.", "label": "Litigation settlement amount" } } }, "localname": "LitigationSettlementExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/LitigationAndClaimsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_MachineryAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.", "label": "Machinery and Equipment [Member]" } } }, "localname": "MachineryAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/FixedAssetsDetails", "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MarketingAndAdvertisingExpense": { "auth_ref": [ "r56" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations": { "order": 6.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising.", "label": "Advertising and marketing" } } }, "localname": "MarketingAndAdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r111" ], "calculation": { "http://healthrevenue.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net Cash Provided by Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows", "http://healthrevenue.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash (Used)/Provided from Financing Activities", "verboseLabel": "Cash Provided/(Used) from Financing Activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows", "http://healthrevenue.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r111" ], "calculation": { "http://healthrevenue.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net Cash Used by Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows", "http://healthrevenue.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows (Used)/Provided from Investing Activities", "verboseLabel": "Cash Flows Used/(Provided) from Investing Activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows", "http://healthrevenue.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r60", "r61", "r62" ], "calculation": { "http://healthrevenue.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net Cash (Used)/provided in Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows", "http://healthrevenue.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flows from Operating Activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows", "http://healthrevenue.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r53", "r62", "r79", "r94", "r102", "r103", "r106", "r118", "r126", "r128", "r129", "r130", "r131", "r134", "r135", "r138", "r144", "r149", "r153", "r155", "r161", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r247", "r248", "r297", "r353", "r372", "r373", "r400", "r422", "r468" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://healthrevenue.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net (Loss) for year ended December 31, 2022", "terseLabel": "Net Income for the period", "totalLabel": "Net Income/(loss)", "verboseLabel": "Net Income/(Loss)" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://healthrevenue.com/role/ConspidatedStatementsOfStockholdersDeficit", "http://healthrevenue.com/role/StatementOfCashFlows", "http://healthrevenue.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesAndLoansPayable": { "auth_ref": [ "r7", "r77", "r477" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of all notes and loans payable (with maturities initially due after one year or beyond the operating cycle if longer).", "label": "Long term portion of notes payable (note 6)", "verboseLabel": "Total Long-term Portion" } } }, "localname": "NotesAndLoansPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet", "http://healthrevenue.com/role/ConsolidatedBalanceSheets", "http://healthrevenue.com/role/NotePayableDetails", "http://healthrevenue.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesAndLoansPayableCurrent": { "auth_ref": [ "r10" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of all long-term notes and loans payable due within one year or the operating cycle if longer.", "label": "Total Current Portion" } } }, "localname": "NotesAndLoansPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/NotePayableDetails", "http://healthrevenue.com/role/NotesPayableDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayable": { "auth_ref": [ "r7", "r77", "r477" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.", "label": "Notes Payable" } } }, "localname": "NotesPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/NotePayableDetails", "http://healthrevenue.com/role/NotesPayableDetails", "http://healthrevenue.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableCurrent": { "auth_ref": [ "r10" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedBalanceSheets": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.", "label": "Current portion of notes payable (note 6)" } } }, "localname": "NotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet", "http://healthrevenue.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses [Default Label]", "totalLabel": "Total Operating Expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r144", "r149", "r153", "r155", "r400" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Net Income/(Loss) from Operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r259", "r411" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r258" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "verboseLabel": "Operating Lease" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet", "http://healthrevenue.com/role/ConsolidatedBalanceSheets", "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r257" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet", "http://healthrevenue.com/role/ConsolidatedBalanceSheets", "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Non-Current Assets" } } }, "localname": "OtherAssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet", "http://healthrevenue.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_OtherIncome": { "auth_ref": [ "r299", "r354", "r382", "r383", "r384" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue and income classified as other.", "label": "Other Income" } } }, "localname": "OtherIncome", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income and Expenses [Abstract]" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": { "auth_ref": [ "r72", "r74" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.", "label": "OTHER INCOME (EXPENSE)" } } }, "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/OtherIncomeExpense" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherLiabilities": { "auth_ref": [ "r42", "r287", "r327", "r328", "r424", "r481" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other.", "label": "Other Liabilities", "totalLabel": "Total Liabilities" } } }, "localname": "OtherLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingExpense": { "auth_ref": [ "r57" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OtherNonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to nonoperating activities, classified as other.", "label": "Other Nonoperating Expense", "negatedLabel": "Other (Expense)" } } }, "localname": "OtherNonoperatingExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r57" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "totalLabel": "Total Other Income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income (Expenses)" } } }, "localname": "OtherNonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other Operating Income (Expense), Net" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/OtherIncomeExpenseDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r59" ], "calculation": { "http://healthrevenue.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [ "r414", "r415", "r418", "r419", "r420", "r421", "r480", "r484" ], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://healthrevenue.com/role/ConspidatedStatementsOfStockholdersDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r47", "r332" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred A-1 Stock, Shares Authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r393", "r401", "r464" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet", "http://healthrevenue.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": { "auth_ref": [ "r58" ], "calculation": { "http://healthrevenue.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.", "label": "Sales of Vehicle" } } }, "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductConcentrationRiskMember": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.", "label": "Product Concentration Risk [Member]" } } }, "localname": "ProductConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConcentrationOfSalesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProfessionalFees": { "auth_ref": [ "r422", "r482", "r483" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer.", "label": "Professional services" } } }, "localname": "ProfessionalFees", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r94", "r102", "r103", "r110", "r118", "r126", "r134", "r135", "r144", "r149", "r153", "r155", "r161", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r231", "r234", "r235", "r247", "r248", "r285", "r296", "r321", "r353", "r372", "r373", "r400", "r409", "r410", "r423", "r450", "r468" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/FixedAssetsDetails", "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r66", "r86", "r89", "r90" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "FIXED ASSETS" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/FixedAssets" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r67", "r98", "r295" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Total Fixed Assets" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/FixedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/FixedAssetsDetails", "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r3", "r286", "r295", "r412" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Fixed assets, net depreciation (note 4)", "verboseLabel": "Fixed Assets, Net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet", "http://healthrevenue.com/role/ConsolidatedBalanceSheets", "http://healthrevenue.com/role/FixedAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r3", "r86", "r89", "r293" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule of fixed assets" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/FixedAssetsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r67" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/FixedAssetsDetails", "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Estimated useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r459", "r460", "r461", "r462" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Accounts Receivable" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r215", "r264", "r265", "r326", "r327", "r328", "r329", "r330", "r350", "r352", "r381" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r215", "r264", "r265", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r326", "r327", "r328", "r329", "r330", "r350", "r352", "r381", "r474" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r261", "r262", "r263", "r265", "r267", "r317", "r318", "r319", "r357", "r358", "r359", "r378", "r380" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTY RECEIVABLE" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/RelatedPartyReceivable" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r49", "r71", "r291", "r310", "r311", "r315", "r333", "r412" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Retained earnings/(deficit)", "verboseLabel": "Retained (deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet", "http://healthrevenue.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "auth_ref": [ "r355", "r390", "r397" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.", "label": "Revenue Recognition" } } }, "localname": "RevenueRecognitionPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r107", "r118", "r145", "r146", "r148", "r151", "r152", "r156", "r157", "r158", "r161", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r248", "r285", "r468" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Total Revenue", "verboseLabel": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConcentrationOfSalesDetailsNarrative", "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_SalariesAndWages": { "auth_ref": [ "r451" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for salary and wage arising from service rendered by nonofficer employee. Excludes allocated cost, labor-related nonsalary expense, and direct and overhead labor cost included in cost of good and service sold.", "label": "Salaries, payroll taxes and benefits" } } }, "localname": "SalariesAndWages", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r158", "r445" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConcentrationOfSalesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable": { "auth_ref": [ "r33", "r73" ], "lang": { "en-us": { "role": { "documentation": "Schedule, table or text reflecting arrangements that are not equity-based payments, or pension and other postretirement benefits, with individual employees. The arrangements (for example, profit sharing, deferred bonuses or certain split-dollar life insurance arrangements) are generally based on employment contracts between the entity and one or more selected officers or key employees, and which contain a promise by the employer to pay certain amounts at designated future dates, sometimes including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period and the carrying amount as of the balance sheet date of the related liability.", "label": "Schedule of Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits, by Title of Individual and by Type of Deferred Compensation [Table]" } } }, "localname": "ScheduleOfDeferredCompensationArrangementWithIndividualExcludingShareBasedPaymentsAndPostretirementBenefitsByTitleOfIndividualAndByTypeOfDeferredCompensationTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/FixedAssetsDetails", "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShortTermDebtTable": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.", "label": "Schedule of Short-Term Debt [Table]" } } }, "localname": "ScheduleOfShortTermDebtTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/NotePayableDetails", "http://healthrevenue.com/role/NotesPayableDetails", "http://healthrevenue.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares Outstanding", "periodEndLabel": "Ending balance, Shares", "periodStartLabel": "Beginning balance, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://healthrevenue.com/role/ConspidatedStatementsOfStockholdersDeficit", "http://healthrevenue.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermDebtLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Short-Term Debt [Line Items]" } } }, "localname": "ShortTermDebtLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/NotePayableDetails", "http://healthrevenue.com/role/NotesPayableDetails", "http://healthrevenue.com/role/NotesPayableDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeAxis": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "Information by type of short-term debt arrangement.", "label": "Short-Term Debt, Type [Axis]" } } }, "localname": "ShortTermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/NotePayableDetails", "http://healthrevenue.com/role/NotesPayableDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShortTermDebtTypeDomain": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "localname": "ShortTermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/NotePayableDetails", "http://healthrevenue.com/role/NotesPayableDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r63", "r115" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r5", "r16", "r92", "r104", "r105", "r106", "r123", "r124", "r125", "r127", "r133", "r135", "r143", "r162", "r163", "r214", "r216", "r217", "r218", "r224", "r225", "r238", "r239", "r240", "r241", "r242", "r243", "r245", "r249", "r250", "r251", "r252", "r253", "r254", "r260", "r307", "r308", "r309", "r322", "r374" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://healthrevenue.com/role/ConspidatedStatementsOfStockholdersDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r123", "r124", "r125", "r143", "r271", "r313", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r332", "r335", "r336", "r337", "r338", "r339", "r341", "r342", "r343", "r344", "r346", "r347", "r348", "r349", "r350", "r352", "r355", "r356", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r374", "r417" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConcentrationOfSalesDetailsNarrative", "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://healthrevenue.com/role/ConspidatedStatementsOfStockholdersDeficit", "http://healthrevenue.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r123", "r124", "r125", "r143", "r271", "r313", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r332", "r335", "r336", "r337", "r338", "r339", "r341", "r342", "r343", "r344", "r346", "r347", "r348", "r349", "r350", "r352", "r355", "r356", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r370", "r371", "r374", "r417" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConcentrationOfSalesDetailsNarrative", "http://healthrevenue.com/role/ConsolidatedStatementOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations", "http://healthrevenue.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit", "http://healthrevenue.com/role/ConspidatedStatementsOfStockholdersDeficit", "http://healthrevenue.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r5", "r47", "r48", "r71", "r314", "r374", "r385" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Number of share issued", "verboseLabel": "Number of shares issued" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/OrganizationAndDescriptionOfBusinessDetailsNarrative", "http://healthrevenue.com/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r48", "r50", "r51", "r65", "r334", "r351", "r375", "r376", "r412", "r424", "r454", "r463", "r472", "r484" ], "calculation": { "http://healthrevenue.com/role/ConsolidatedBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "Equity, Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total Stockholders\u2019 Equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet", "http://healthrevenue.com/role/ConsolidatedBalanceSheets", "http://healthrevenue.com/role/ConspidatedStatementsOfStockholdersDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedBalanceSheet", "http://healthrevenue.com/role/ConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r34", "r35", "r36", "r92", "r93", "r105", "r123", "r124", "r125", "r127", "r133", "r162", "r163", "r214", "r216", "r217", "r218", "r224", "r225", "r238", "r239", "r240", "r241", "r242", "r243", "r245", "r249", "r250", "r254", "r260", "r308", "r309", "r320", "r334", "r351", "r375", "r376", "r386", "r423", "r454", "r463", "r472", "r484" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r70", "r117", "r201", "r202", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r244", "r377", "r379", "r387" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventDescription": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Describes the event or transaction that occurred between the balance sheet date and the date the financial statements are issued or available to be issued.", "label": "Subsequent Event, Description" } } }, "localname": "SubsequentEventDescription", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [ "r255", "r269" ], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r255", "r269" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConcentrationOfSalesDetailsNarrative", "http://healthrevenue.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r255", "r269" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r255", "r269" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConcentrationOfSalesDetailsNarrative", "http://healthrevenue.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r255", "r269" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConcentrationOfSalesDetailsNarrative", "http://healthrevenue.com/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r268", "r270" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/StatementOfCashFlows", "http://healthrevenue.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TaxesPayableCurrent": { "auth_ref": [ "r10" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Tax liability" } } }, "localname": "TaxesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/IncomeTaxeDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r28", "r29", "r30", "r84", "r85", "r87", "r88" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VehiclesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment used primarily for road transportation.", "label": "Vehicles [Member]" } } }, "localname": "VehiclesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/FixedAssetsDetails", "http://healthrevenue.com/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r136", "r141" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://healthrevenue.com/role/ConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 4 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19,20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(c))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(i)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org//740/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(15))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(16))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column A))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column B))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column C))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column D))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column E))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column F))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org//1943274/2147483070/710-10-25-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r425": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r426": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r427": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r428": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r429": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Subparagraph": "(c)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r431": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r432": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r433": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r434": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r435": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r436": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r437": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r438": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r439": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r44": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org//205/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r441": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r442": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r443": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r444": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r465": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(k)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org//360/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "610", "URI": "https://asc.fasb.org//610/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "10", "Topic": "710", "URI": "https://asc.fasb.org//1943274/2147483043/710-10-30-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "720", "URI": "https://asc.fasb.org//720/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "840", "URI": "https://asc.fasb.org//1943274/2147481192/840-30-45-3", "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 58 0001829126-23-005654-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001829126-23-005654-xbrl.zip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end

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